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1 The epidemiology of HIV
The human immunodeficiency virus (HIV) was first discovered in 1983. In 2009, it was 
estimated that 33.3 (31.4 -35.3) million individuals are infected with HIV worldwide. 
In that year 1.8 (1.6-2.1) million people died from HIV. Although the virus continues 
to spread, the number of new infections has fallen from an estimated 3.2 (3.0 -3.5) 
million in 1997 to 2.6 (2.3 – 2.8) million in 2009. [1] There are several explanations 
for this decrease. First, the use of antiretrovirals has slowed down the epidemic by 
suppressing viral replication and thereby the HIV RNA load [2]. This RNA load is a 
key factor in determining transmissibility of HIV [3]. Second, sexual risk behaviour 
has decreased in most countries [1]. Third, HIV prevalence follows an ‘S’ curve, 
like any infectious disease where it start slowly and gradually. In the final phase of 
the epidemic, people are either no longer infectious (due to effective treatment) or 
deaths outnumber new cases, so that the total number alive and infected passes its 
peak and begin to decline or reach a plateau. [4]
The majority of new HIV infections continue to occur in sub-Saharan Africa. 
Here, an estimated 1.8 (1.6 -2.0) million people were newly infected in 2009 and 
22.5 million (20.9 -24.2) people were living with HIV in this region (figure 1). 
In Europe, the HIV-1 epidemic is much smaller, with an estimated 130,000 
(110,000-160,000) newly infected in Western and Central Europe in 2009. This 
results in 820,000 (720,000-910,000) individuals living with HIV-1 and a prevalence 
of 0.2% in this region. [1]
Global prevalence of HIV, 2009
Figure 1. Adapted from www.unaids.org [1].
92 Phases of HIV-1 disease progression
The HIV infection can be broken into three distinct stages: primary infection, chronic 
infection, and acquired immunodeficiency syndrome (AIDS) [5].
The primary (or acute) infection starts after HIV enters the body. The high 
replication of the virus initiates an immune response by producing HIV antibodies 
and cytotoxic lymphocytes. This stage of infection lasts for 10-16 weeks and is often 
accompanied by a flu-like illness. It is characterized by high viral loads [6] which is 
the key determinant in explaining transmission of HIV [7]. Many studies observed 
that recently infected patients account for a disproportionally high number of new 
infections [8-10]. After the acute stage of HIV infection the patient progresses to 
the chronic stage which lasts for an average of eight years [11]. The initial immune 
response leads to a large down-regulation of amount of HIV plasma RNA in the blood. 
However, the virus is not completely eliminated from the body and viral replication 
and CD4 decrease is continued at a low level. Because of the low level of plasma 
HIV-RNA in this stage, the infectiousness of persons in this stage is much lower than 
of those in the acute stage [12]. If patients remain untreated and CD4 cell numbers 
have declined below a critical level, the infection leads to the phase of AIDS, where 
fatal opportunistic infections and cancers can develop. In the AIDS stage, the viral 
load increases to high levels which again coincide with a high infectiousness [12]. 
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Figure 2. Schematic overview of the HIV replication cycle (adapted from Wikipedia).
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3 Antiretrovirals
Currently, six classes of antiretrovirals have been developed and approved for 
clinical use: nucleos(t)ide reverse transcriptase inhibitor (NRTI), non-nucleoside 
reverse transcriptase inhibitor (NNRTI), protease inhibitors (PI), fusion inhibitors, 
entry inhibitors, and integrase inhibitors. Each class inhibits HIV-1 at a different stage 
in its replication cycle (figure 2). 
The NRTIs compose the first class of antiretroviral drugs developed. This 
class contains 7 drugs that have been Food and Drug Administration (FDA) approved 
(lamivudine, abacavir, zidovudine, stavudine, didanosine, emtricitabine, tenofovir, 
and zalcitabine) [13]. The chemical structure of this class of drugs resembles the 
natural nucleoside [14]. For example, zidovudine contains an azido group in place 
of the hydroxyl group at the 3’ position of the deoxyribose ring (figure 3). Presence 
of this azido group prevents formation of phosphodiester linkages needed for DNA 
replication, causing chain termination and thereby suppressing replication of the 
virus. 
      
            
Figure 3. Structural formula of the natural nucleoside thymidine and the therapeutic analogue of a) 
thymidine and b) zidovudine (adapted from Wikipedia).
The PI drug class was the second class of antiretroviral drugs developed. It 
consists of 10 drugs approved for use in the treatment of HIV-1 (saquinavir, ritonavir, 
indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir, 
and darunavir) [13]. PI drugs prevent viral replication by inhibiting the activity of the 
protease enzyme, which is required for cleavage of the HIV precursor polyproteins 
into proteins that are essential for viral assembly and subsequent activity [14]. The 
majority of currently available PIs are coadministered with low-dosed ritonavir as 
a pharmaco-enhancer that significantly increases PI level in plasma (saquinavir, 
inidnavir, amprenavir, and lopinavir) [15]. Boosting the PI results in a reduced 
pill burden and the higher plasma levels make it difficult for the virus to develop 
resistance as more mutations are required to escape the higher plasma levels [16-
 B  A 
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19].
In the NNRTI drug class, 5 drugs have been FDA approved (delavirdine, 
efavirenz, etravirine, nevirapine, and rilpivirine) [13]. These compounds bind to the 
reverse transcriptase enzyme. This binding results in an enzyme which is incapable 
of interacting properly with the viral RNA to produce viral DNA [14].
The most recently developed drug classes are the fusion-, entry- and 
integrase inhibitors. As fusion inhibitor, the drug enfuvirtide has been developed. 
This binds to the HIV gp41 molecule and thereby inhibits fusion of the viral and the 
cell membranes [14]. The entry inhibitor maraviroc is a CCR5 coreceptor antagonist. 
It binds to the CCR5 receptor on the host cell membrane, and thereby prevents the 
interaction and binding of the HIV-1 gp120 and CCR5. This binding is necessary for 
the membrane fusion of the viral and the cell membranes [20]. The HIV integrase 
inhibitor raltegravir was approved by the FDA in 2007 [13]. By blocking the action of 
the integrase enzyme, the viral genome cannot be inserted into the DNA of the host 
cell [21].
Currently, HIV-1 treatment consists of a combination of 3 or more 
antiretrovirals, so-called highly active anti-retroviral therapy (HAART). The use of 
HAART has strongly reduced morbidity and mortality among patients infected with 
HIV [22]. Treatment has further improved by the introduction of regimens that are 
less toxic, have better efficacy (e.g. boosted PIs), and reduced pill burden. Treatment 
guidelines now recommend to start therapy with 2 NRTIs (tenofovir/emtricitabine or 
abacavir/lamivudine) and a third agent from another drug class (efavirenz, boosted 
atazanavir, boosted darunavir, or raltegravir). Furthermore, patients should start 
treatment when having a CD4 cell counts of <350 cells/mm3 or <500 cells/mm3, 
according to the European [23] and American treatment guideline [24], respectively. 
The importance of early treatment has been shown by its reduction in mortality [25-
27] and the reduction of transmission of HIV [28-33].  
For patients living in North America and Western Europe, treatment was 
highly accessible from the moment the first antiretroviral drugs became available. 
However, very few people living in the developing world had access to HIV treatment 
from the introduction of antiretrovirals until the beginning of the 21st century. In 2001, 
generic drugs were produced resulting in a large reduction in price. The next step 
was the initiation of the 3 by 5 target (3 million people in low- and middle-income 
countries on antiretrovirals by 2005) of the WHO. However the largest impact on 
expanding treatment on global scale was initiated by the President’s Emergency 
Plan For AIDS Relief (PEPFAR) which was a commitment of $15 billion over five 
years (2003-2008) aimed to provide antiretroviral treatment to 2 million HIV-infected 
people in resource-limited settings. In 2008, PEPFAR was renewed, revised and 
expanded to $48 billion through 2013.
Due to this large effort to improve the access to treatment, the number of 
patients on treatment increased from 400,000 in 2003 to a 1.3 million in 2005. This 
number even further increased to an estimated 5.2 million people in 2009. However, 
though now more people are receiving antiretroviral therapy in all regions of the world 
than at any previous time in the epidemic, many people eligible for treatment still do 
not have access to treatment. This lack of access is highest in Eastern Europe and 
Central Asia, sub-Saharan Africa, and Central and South America, with 82%, 63%, 
and 58%, respectively. [1]    
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Figure 4. Cloud of quasispecies.
4 HIV drug resistance
4.1 Mechanism of HIV drug resistance
The HIV virus is characterized by its high genetic diversity. First, this high diversity 
is a result of the high levels of virus production and turnover. Second, HIV has a 
very high rate of nucleotide sequence evolution which in turn is due to the high 
error rate of the viral reverse transcriptase. This leads to the generation of many 
variants of HIV in a single infected patient. The swarm of genetic viral variants is 
called ‘quasispecies’. [34] Viruses with mutations that result in a fitness advantage 
will outgrow other variants and become the dominant viral population among the 
quasispecies. 
4.2 Acquired HIV drug resistance
In treated patients, drug resistance associated mutations can be acquired when virus 
suppression is not completely achieved and replication of the virus can continue at 
low levels (figure 4). The genetic barrier, defined as the number of viral mutations 
required to escape from the selective pressure of the drug, is an important factor for 
the development of drug resistance [35-37]. Boosted PIs have a high genetic barrier 
as they require multiple (3-5) mutations to overcome the drug pressure [19, 35, 37]. 
Conversely, all other drugs have a low genetic barrier as a single mutation is sufficient 
for viral breakthrough [35, 37-38]. Many mutations selected by the use of one drug 
also cause cross-resistance to other drugs of the same drug class, complicating 
further treatment options. Often, viruses with major resistance mutations have 
reduced replication rates. This can be compensated by compensatory mutations 
that emerge after the major mutations. They do not reduce drug susceptibility, but 
improve the replication of the virus. 
4.3 Transmitted HIV drug resistance
Viruses with resistance mutations can be transmitted to other individuals. Because a 
wild-type is rarely co-transmitted together with the drug-resistant HIV, the quasispecies 
have no ‘memory’ of the wild-type [39]. There are 3 possible evolutionary pathways 
for this transmitted drug-resistant variants described. First, when there is a profound 
effect on the replication rate of the virus, the resistant variant may revert back to 
wild-type. Second, atypical variants (a novel amino acid that is neither the wild-type 
amino acid nor an intermediate towards wild-type) may be observed when it results 
in higher replication rate than the original transmitted resistant variant. Finally, the 
resistant variant can persist. Mutations that induce only a limited decrease in the 
Resistance 
anti-
retrovirals 
Wild-type 
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replication rate tend to persist. Furthermore, in the treated failing patients, multiple 
compensatory mutations may appear after the initial selection of resistance mutations 
that lower the replicative capacity. After transmission to a new host, evolution may 
be expected to occur in a stepwise manner. However, if all possible nucleotide 
changes would initially decrease the replicative capacity, reversion to wild-type will 
be blocked. [40] 
4.4 Detection of HIV drug resistance
Resistance can be detected both with phenotypic and genotypic assays. The 
phenotypic assay measures the ability of an HIV-1 variant to grow in vitro in the 
presence of an antiretroviral drug in comparison with the wild-type variant. Genotypic 
assays identify drug-resistant mutations by sequencing the virus. The cost of a 
genotypic assay is 50% or less of the price of the phenotypic test. Furthermore, the 
genotypic assay is performed in only one to two weeks, while for a phenotypic assay 
up to four weeks may be needed. Therefore, the genotypic test is the preferred 
test in clinical practice and is recommended by the European HIV Drug Resistance 
Guidelines Panel [41] and the International AIDS Society-USA Panel [24].  However, 
genotypic testing is challenging due to the complexity of interpreting the many 
different drug-resistant mutations and translating these mutations into treatment 
response. Several interpretation systems have been developed, which provide rules 
to help physicians interpret genotypic HIV drug resistance results.
When a resistant virus reverts back to wild-type, the initial resistant variant 
may persist in resting memory cell cells, which can have a very long half life. When 
such an individual starts treatment, the replication of the wild-type virus will be 
blocked and the resistance-variants will re-emerge quickly. The current clinically-used 
genotypic test is population sequencing. This technique fails to identify drug-resistant 
minority variants that are present in <20% of the virus population infecting a patient 
[42-43]. These minority variants have been detected in almost 14% of antiretroviral 
naïve HIV-infected individuals [44]. The presence of minorities, particularly involving 
NNRTI resistance, is associated with an increased risk of virological failure to first-
line therapy [44]. Therefore, the level of resistance is underestimated using the 
population sequencing assay. 
4.5 Patterns of transmitted drug resistance over time
Due to the increased risk for virologic failure when patients start therapy [45], 
transmitted drug resistance is an important public health concern. Therefore, 
surveillance of transmitted drug resistance is necessary. Transmitted drug resistance 
was first detected in patients resistant to the NRTIs zidovudine or stavudine [46-47]. 
These drugs were initially prescribed to HIV patients in North America and Western 
Europe as mono- or dual-therapy. This mono- and dual-therapy of zidovudine and 
stavudine led to a rapid development of thymidine analogue mutations (TAMs) 
[48-49]. Subsequently a rapid increase was observed in the prevalence of NRTI 
transmitted drug resistance mutations (TDRM), and specifically the TAMs in North 
America and Western Europe [50-52]. After 1996 HAART was introduced, which is 
virologically more active [53-54] and is associated with a substantially lower risk of 
resistance. Among the most common mutations in treated patients is the M184V [55]. 
The M184V mutation can be selected by the drugs emtricitabine and lamivudine, 
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which are both currently popular in first-line regimens [24, 56-59]. This mutation has 
a strong effect on replication capacity and if transmitted, reverts back to wild-type 
rapidly (68% after 6 months of HIV infection [60]).
5 Objective of this thesis
This thesis focuses on three topics. First, we investigated the epidemiology of HIV-1 
TDRM. Second, we studied different sides of the interpretation of HIV drug resistant 
mutations. Finally, we performed cost-effectiveness analyses on baseline genotypic 
testing. The next paragraphs discuss the topics for the different chapters.
Epidemiology of HIV transmitted drug resistance
Substantial differences in TDRM to particular drug classes can be expected over time 
in different parts of the world due to the differences in drug use as described before. 
To our knowledge no review has been published summarizing the published articles 
on TDRM. Therefore, we conducted a review describing available data on HIV-1 
transmitted drug resistance mutations, with a major emphasis on the time trends of 
drug resistance prevalence in the different regions across the world (chapter 2). We 
identified relevant literature by searching in PubMed through September 2009.
A limitation of this review was the use of many different algorithms in the 
included studies to interpret, which makes it more difficult to compare the studies. 
In the WATCH study, we collected and analyzed data of currently available studies 
on TDRM from across the world using a single algorithm to score drug resistance 
(chapter 3). Using this approach, we were able to give insights in different profiles 
of TDRM over time between continents. However, in this study we could not rule 
out the occurrence of convenience sampling (i.e. an over-representation of patients 
suspected to carry a drug-resistant virus), due to the different sampling strategies 
used among the included studies. 
In the European SPREAD study, we were able to uniformly sample newly 
diagnosed patients in a representative way. The SPREAD programme combines the 
efforts of virologists, clinicians, and public health institutes to study the epidemiology 
of transmission of drug resistant HIV. The programme started in September 2002 and 
now includes data until December 2007, enrolling 4,317 patients from 27 countries. 
In chapter 4, we present the analyses performed on the data including the newest 
data collected in this programme. In Europe, we expect differences in TDRM to the 
particular drug classes over time also due to changes in use of treatment over time in 
Europe, as described before. Therefore, the objective in this study was to determine 
the trends in transmitted drug resistance in newly diagnosed HIV-1 infected patients 
over time in Europe.
The SPREAD study also resulted in the study described in chapter 5. Here, 
we further explored the prevalence of TDRM in the three main HIV transmission 
groups: men who have sex with men, heterosexual patients, and injection drug users. 
The prevalence of HIV resistance-associated mutations are expected to be different 
among different routes of transmission. Men having sex with men (MSM) mostly 
originate from western countries where antiretroviral drugs have been available for 
many years. In contrast, heterosexual patients mostly originate from Sub-Saharan 
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Africa where large scale antiretrovirals have only been available recently. Injection 
drug users infected with HIV are mostly found in Central and East European countries 
where the coverage of antiretrovirals in HIV patients in need of treatment has been 
low in many countries [61]. These differences in drug use between the transmission 
groups are reflected in several studies showing a higher likelihood in MSM patients 
to be infected with a resistant virus compared to other patients [62-64]. Furthermore, 
due to differences in the use of these drug classes over time, TDRM to specific 
drug classes are expected to have evolved differently over time. Yet, there are no 
European-wide studies performed analysing time trend of the prevalence of TDRM 
in the different transmission groups.  In chapter 5, we present the time trends in the 
prevalence of TDRM in the different transmission groups for the main drug classes 
in Europe. 
Although travel and migration played a key role in the early spread of HIV, it is 
not known to what extent travel currently explains transmission of HIV. We therefore 
performed phylogenetic analyses on the patient data of the SPREAD programme to 
estimate the proportion of individuals newly diagnosed with HIV that was infected 
within their own country (chapter 6). 
The interpretations of HIV-1 drug resistant mutations
The estimation of the prevalence of transmitted drug resistance using genotypic 
testing has some limitations. Two of these limitations are discussed in chapters 7 and 
8. In chapter 7, we focus on the difficulties of the interpretation of mutations towards 
therapy response. Several algorithms for the interpretation of HIV-1 genotypic drug 
resistance information have been designed [65]. These interpretation systems 
provide rules to help physicians interpret the drug mutations. The purpose of our 
study was to compare the different interpretation systems that have been developed. 
The three most commonly used interpretations systems, ANRS, Stanford HIVdb, 
and Rega have been validated in different studies [66-68]. To compare the systems, 
it is important to include virological response data in correlation with the prediction of 
interpretation systems. We performed a comparison between the systems in patients 
with virological failure (transmitted and acquired resistance) using three different 
virological outcome time points.
Another limitation of genotypic testing is the possibility of overestimating 
the prevalence of TDRM due to the presence of low-level polymorphisms. These 
polymorphisms are naturally occurring amino acid substitutions at positions associated 
with antiretroviral drug resistance. We examined how these polymorphisms influence 
the classification method developed by the WHO used for global surveillance of 
TDRM in resource-limited countries. This is presented in chapter 8.
Cost-effectiveness of baseline genotypic testing
The use of genotypic testing has been proven. However, the cost-effectiveness 
analyses that have been published were all performed before the year 2001 [69-
71]. Because of changes in TDRM, decrease in rates of opportunistic infections and 
mortality, and changes in health care costs, we investigated the cost-effectiveness 
of baseline genotypic testing (chapter 9). 
The results of this thesis are summarized and discussed in chapter 10. 
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ABSTRACT
Background: A substantial number of studies have been performed across the 
world to determine transmitted drug resistance. Large variations between different 
parts of the world can be expected because of differences in availability over time of 
treatment. Time trend analyses are often not possible, because of small numbers of 
included patients. In this review, we present the available data on the transmission 
of drug resistant HIV with a major emphasis on the time trends of drug resistance 
prevalences.
 
Methods: We identified relevant literature by searching in PubMed through Sept. 
2009. Studies were grouped, according to the year of data-collection, into the 
following time periods: <2001, 2001-2003, >2003.
Results: We selected a total of 215 studies which included 43,170 patients. The 
following prevalences of transmission of drug resistant HIV were found in rank 
order: North America (12.9%), Europe (10.9%), Latin America (6.3%), Africa (4.7%) 
and Asia (4.2%). Changes over time in particular drug classes were found in all 
parts of the world. Nucleoside reverse transcriptase inhibitor (NRTI) resistance 
was declining over time in North America (p-value: 0.03), Europe (p-value: <0.001) 
and Latin America (p-value: <0.001). The decline in NRTI resistance reflects the 
improvement of treatment regimens in resource-rich settings. In contrast NRTI 
resistance prevalence was increasing in Asia (p-value: 0.047) and Africa (p-value: 
<0.001). This can be explained by the antiretrovirals becoming more available during 
recent years in these continents.
Conclusions: Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance 
was rising over time in North America (p-value: <0.001), Europe (p-value: <0.001), 
Latin America (p-value: <0.001), and Asia (p-value: 0.01). This paper gives a complete 
overview of the epidemiology of resistance of antiretroviral drug in drug-naïve 
patients worldwide. The time trends that were observed seem to reflect changes in 
describing prescriptions over time. Changes include the more wide-spread of anti-
retroviral drugs in developing countries and the development of therapies from low-
active mono-therapies to highly active anti-retroviral regimens in the industrialized 
countries.
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INTRODUCTION
The use of highly active antiretroviral therapy has substantially improved survival 
among patients infected with HIV-1. But the success of antiretroviral treatment can 
be limited by the emergence of HIV drug resistance which in turn can be transmitted 
to newly infected individuals. Transmission of drug resistance is associated with an 
increased risk for virological failure 12 months after start of treatment [1].
A large number of studies reported on transmitted drug resistance across 
the world. These studies report a prevalence of transmitted drug resistance that 
ranges between 0 to 25% [2-4]. The prevalence is lowest in resource-limited settings 
[5]. But the prevalence in resource-limited countries may have increased in recent 
years as access to antiretroviral drugs has been expanding.
Substantial differences in resistance to particular classes of antiretroviral 
drugs may exist over time between different parts of the world. For example, use of 
nevirapine in Africa to prevent mother-to-child transmission could have increased 
the prevalence of transmitted resistance to non-nucleoside reverse transcriptase 
inhibitors (NNRTI) in Africa [6]. Similarly, in resource-rich settings zidovudine was 
given as mono-therapy before 1996 resulting in transmitted nucleoside reverse 
transcriptase inhibitor (NRTI) drug resistance [7-8]. In recent years, other classes 
of antiretrovirals have become popular which could have changed the epidemic of 
transmission of drug resistance. 
We conducted a systematic review of literature to compare temporal changes 
in the prevalence of transmission of drug resistant HIV-1 across different continents.
 
Selection of studies on transmitted drug resistance
PubMed was used to identify studies written in English on the epidemiology of 
transmission of drug resistant HIV-1, until Sept 1st 2009 (key words “HIV” and 
“resistance” or “HIV” and “transmission”). Primary research studies that investigated 
the prevalence of HIV drug resistance in antiretroviral naïve HIV-1 infected persons 
were eligible for inclusion. 
Transmitted drug resistance was reported in 215 papers including 43,170 
patients (table 1). Most studies came from Europe (82 studies/ 25,446 patients), 
followed by Africa (47/ 3,096), North America (36/ 8,718), Latin America (26/ 3,218), 
Asia (23/ 2,507), and Australia (1/ 185). The characteristics of included patients 
varied among the continents. The proportion of risk groups per continent in the 
included studies followed the regional mode of HIV-1 transmission across the world. 
For example, in North America and Europe, patients were predominantly infected 
through men having sex with men (MSM) (41% and 47%, respectively), whereas in 
other continents this did not exceed 20%, as described in literature [9]. 
Definition of transmission of drug resistance
We compiled transmitted drug-resistance as reported in the studies. Resistance to 
NRTI, NNRTI, and protease inhibitors (PI) was defined as the presence of at least 
one drug resistance associated mutation to that particular drugs class. Multiclass 
resistance was defined as the presence of resistance-associated mutations to at 
least two different classes of antiretroviral drugs. The list used to define transmitted 
drug resistance was extracted from the studies.
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Statistical analysis
Time trends were analyzed by grouping the studies according to the year of data-
collection: before 2001, 2001-2003, and 2004 or later. We used these cut-offs so that 
we could include time periods with comparable numbers of patients. Taking different 
time periods did not result in different trends over time (data not shown). Studies 
reporting the epidemiology of transmission of resistance over a range of years were 
grouped according to the average of the years. 
Sixteen studies did not report the year of data collection. The average 
difference between year of data collection and year of publication was 4 years. We 
therefore calculated the missing data-collection years, by subtracting 4 years from 
the year of publication. Exclusion of these studies or subtraction of 0, 2, or 6 years 
from the year of publication did not change the results (data not shown).
Prevalence estimates are presented with 95% confidence intervals 
calculated according to the Wilson score interval. Poisson regression analysis was 
used to calculate the time trends analyses for each continent. 
Epidemiology of transmission of drug resistance
Europe
The studies were predominantly performed in Western-Europe (n=75). A smaller 
number of studies (n=7) came from Central Europe and the former Soviet-Union. 
Studies from the former Soviet-Union are of particular interest as this part of the 
world has the strongest growing epidemic world-wide due to an explosive outbreak 
of HIV-1 infections among intravenous drug users [10-12]. 
The prevalence of transmission of drug resistance across Europe was 
10.9% (95% confidence interval 10.6-11.3%) (figure 1). Transmission of drug 
resistance most frequently involved NRTIs with a prevalence of 7.4% (7.1-7.7%). 
The prevalence of resistance to NNRTIs was with a prevalence of 3.4% (3.2-3.6%) 
slightly higher than the prevalence of 2.9% (2.7-3.2%) found for protease inhibitors. 
Transmission of drug resistance declined over time in Europe (figure 2). 
The prevalence was around 11.5% before 2003 and reduced to 7.7% after that 
year (p<0.001). A closer examination of the classes showed that this decrease was 
ascribed to the decline in resistance to NRTI (from 8.0 to 4.3%) and protease inhibitors 
(from 3.3 to 1.4%) (both p-values: <0.001). Resistance to NNRTIs increased from 
2.9% to a small peak in 2001-2002 of 4.4%, after which it decreased again to 3.2% 
(p-value: 0.004). 
Two European studies that reported on the epidemiology of transmitted 
drug resistance over time confirm our results. First, the pan-European SPREAD 
programme also reported a decrease in the prevalence of transmitted NRTI 
resistance and an increase in the prevalence of transmitted NNRTI resistance over 
time (2002-2006). These changes were however not statistically significant which 
could be ascribed to a smaller sample size in the SPREAD programme [13]. The 
second study confirming the decline in transmitted drug resistance over time was 
performed in the United Kingdom. This study reported a small increase in NRTI 
resistance, with some evidence of a levelling off from 1996 to 2003. This British 
study also reported an increase in transmission of NNRTI resistance [14].
25
Figure 1. Prevalence of 
transmitted drug resis-
tance to any of the drug 
classes (Any), NRTI 
(nucleoside reverse 
transcriptase inhibitor), 
NNRTI (non-nucleoside 
reverse transcriptase in-
hibitor) and PI (protease 
inhibitor) in Africa, Asia, 
Europe, North Ameri-
ca, and Latin America.
North America
Europe and North America have the longest access to antiretrovirals across the 
world. There were, however, several differences between the two continents. 
In North America, the prevalence of transmission of drug resistance was higher 
with a proportion of 12.9% (12.2-13.7%). Similar to Europe, transmission of drug 
resistance was for the largest part ascribed to NRTIs; prevalence 7.4% (6.8-8.0%). 
But transmission of NNRTI resistance was in North America with a proportion of 
5.7% (5.2-6.2%) higher than the prevalence of 3.4% found in Europe. Similar to 
Europe, resistance to protease inhibitors was also uncommon in North America with 
a prevalence of 3.2% (2.8-3.6%) as compared to 2.9% in Europe.
Contrary to Europe, the prevalence of resistance showed an increase over 
time from 11.6% (10.7-12.7%) in studies performed before 2001 to 14.3% (12.8-
16.1%) in studies performed after 2003 (p-value: 0.003) (Fig. 2). This increase in 
overall transmitted resistance was ascribed to the increase in NNRTI resistance 
(from 4.1% to 8.3%, p-value: <0.001), whereas the NRTI resistance was decreasing 
from 8.0% to 6.4% (p-value: 0.032). 
Studies that included longitudinal data confirm the time trends we observed. 
A study performed in San Francisco showed a decrease in transmitted NRTI 
resistance from 21% in 1996-1997 to 3.3% in 1998-1999 and a subsequent increase 
to 6.2% in 2000-2001 [8].
The decline in NRTI resistance in resource-rich settings reflects the 
improvement of treatment regimens. Before 1996, antiretroviral therapy consisted 
of mono-therapy or dual-therapy of NRTI’s, which lead to the appearance of drug-
resistant HIV-1 in many patients [15-16]. After 1996, HAART was introduced, which 
is virologically more active and is associated with a substantially lower risk of 
resistance. As a consequence, NRTI resistance was initially high and then decreased 
in recent years. 
The increase of NNRTI resistance in Europe and North America coincides 
with the more frequent use of this drugs class in the developed world in the previous 
years. NNRTIs were approved in 1996 and clinical trials in 1999 indicated that 
virologic outcomes during treatment with this drugs class were better compared with 
those of PI-based treatment [17]. 
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Latin America
Large Latin American countries as Argentina and Brazil have sponsored a policy of 
universal access to antiretroviral drugs since the 1990s. Interestingly, transmission 
of drug resistance was reported in 6.3% (5.5-7.3%) of HIV-1 patients from Latin 
American studies suggesting that universal access did not result in high levels of 
resistance.
Studies from Latin America reported a low prevalence of transmission of 
drug resistance to the different drug classes, with 3.8% (3.2-4.6%) for NRTI, 1.6% 
(1.2-2.1%) for NNRTI and 2.4% (2.0-2.8%) for protease inhibitors. The time trends 
for resistance to particular classes followed the same trend as in Europe and North 
America. Resistance to NRTIs decreased over time (6.6% to 2.8%, p-value: <0.001). 
The prevalence of transmission of NNRTIs increased from 0.6% to 2.7% (p<0.001). 
Figure 2. Prevalence over time of transmitted 
drug resistance to any of the drug classes 
(Any), NRTI (nucleoside reverse transcriptase 
inhibitor), NNRTI (non-nucleoside reverse 
transcriptase inhibitor) and PI (protease 
inhibitor) in Africa, Asia, Europe, North 
America, and Latin America.
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Resistance to protease inhibitors increased but remained limited (from 1.6% to 2.7%, 
p-value: 0.01).
Transmitted drug resistance to protease inhibitors was uncommon in all parts 
of the world (less than 3.2%). This may be explained by the high genetic threshold for 
resistance to boosted protease inhibitors. Moreover, protease inhibitors are not used 
in treatment of all patients as they are frequently reserved for second line therapy.  
 
Africa
Transmission of drug resistance was variable in Africa and 30 out of 47 studies reported 
a prevalence <5%. The combined prevalence of transmission of drug resistance in 
studies from Africa was low with a proportion of 4.7% (4.0-5.5%). However, many 
parts of Africa do still not have access to antiretrovirals. Epidemiological studies 
on transmitted resistance will not be performed in these areas as resistance is 
unlikely. Therefore, the transmitted resistance prevalence that we calculated from 
the available studies performed in Africa is an overestimation of the real prevalence 
in this continent. 
Importantly, transmission of drug resistant HIV increased over time. The 
prevalence was 2.8% (1.7-4.5%) before 2001 and almost doubled to 5.3% (4.0-
6.9%) after 2003. This increase was, however, not statistically significant (p=0.06). 
The increase can be explained by the increase in NRTI drug resistance over time 
from 0.6% before 2001 to 3.0% after 2003 (p-value: <0.001). The prevalence of 
PI resistance was low (0.9%; CI: 0.6-1.3%) and NNRTI prevalence showed a non-
significant increase from 1.7% to 2.5%.  
In Africa, different patterns of resistance to particular antiretroviral drug 
classes were seen as in other parts of the world. Contrary to the Americas and 
Europe, the prevalence of NRTI resistance was increasing over time. This increase 
can be explained by the antiretrovirals becoming more widely available during recent 
years (e.g. due to the efforts of the Global Fund and PEPFAR -President’s Emergency 
Plan for AIDS Relief). Due to the increased use of HAART (which includes NRTIs 
as the backbone), resistant mutations have developed, and as a consequence 
transmitted NRTI resistance in Africa has been rising. 
A high proportion of NNRTI-resistance was initially observed and is 
decreasing over time. This high contribution reflects the prophylactic use of a single 
dose of NNRTI-monotherapy for prevention of mother-to-child-transmission [6, 18]. 
Due to the low genetic threshold for resistance to NNRTIs, viral resistance could be 
induced [19]. Currently, the WHO recommends combinations of different antiretroviral 
drugs (including NRTIs) to prevent vertical transmission, instead of using the simplest 
regimen of single-dose nevirapine [20]. Furthermore, universal access of HAART 
has been scaled up in developing countries [21-22]. As a consequence, transmitted 
NRTI resistance has increased and the contribution of NNRTI resistance to the total 
resistance has decreased. 
Asia
We found a lack of data on transmission of drug resistant in Asia. Data from Asia 
should therefore be interpreted with caution. Only a low number of studies (and 
patients) could be extracted from literature. Consequently, time trend analyses 
showed less significant results. For example, the overall resistance prevalence of 
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4.2% (3.4-5.4%) was stable over time (p-values: 0.496).  However, NRTI and NNRTI 
resistance were slightly increasing from 1.3% to 3.5% (p-value: 0.047) and 0.6% 
to 2.2% (p-value: 0.01), respectively. Transmitted resistance to protease inhibitors 
declined over time from 1.3% to 0.4% (p-value: 0.02). 
Oceania
Only one study was included from Australia in this review. This study reported a high 
prevalence of 23.2% (17.7-29.8%). No further analyses were performed with this 
data.
DISCUSSION
In this review, we examined all literature available on HIV-1 transmitted drug 
resistance epidemiology. Reviewing all literature on this subject allowed us to 
calculate the change over time in the prevalence of transmission of drug resistant 
HIV-1 for the different drug classes in each continent.
The prevalence of transmitted resistance ranged between 0% e.g. [23-26] 
and 27% [8]. This means that most HIV infections are with a virus that is susceptible 
to antiretrovirals. There were, however, clear differences across the world. The 
highest prevalence of transmitted resistance was found in North America (12.9%) 
and Europe (10.9%) in which antiretroviral drugs are available for prolonged periods 
of time. Lower proportions of transmitted resistance were found in Latin America 
(6.3%), Africa (4.7%), and in Asia (4.2%). 
Time trends observed in this study may be caused by true differences in 
temporal changes in treatment regimens between continents, or by others sources 
of variability. An important factor may be the inclusion of recent or chronic infected 
patients, a distinction sometimes made in studies performed in resource-rich 
countries. Resistance in recently infected patients has been reported to be higher 
than resistance in patients infected >1 year [27]. This can be explained by several 
factors. First, the difference partly reflects the variation of resistance prevalence 
among different HIV risk groups. The majority of the recently infected patients are 
MSM [28]. Transmitted drug resistance is often much higher in MSM HIV infected 
patients compared to the heterosexual risk group, because most HIV patients who 
acquired HIV through heterosexual contact are more likely to come from regions 
with limited access to antiretroviral drugs [13, 29]. In addition, the lower prevalence 
of transmitted drug resistance in chronic patients can be explained by the outgrowth 
of the wild type or the reversion of the transmitted drug resistance mutations. 
Remarkably, some resistance viruses remain present in patients, despite the negative 
effect on replication capacity, due to the appearance of compensatory mutations and 
the reduced replication capacity of the required intermediate viruses [30]. In this 
review, the effect of differences between studies in including recently or chronically 
infected patients on the time trends is probably limited, as most differences in studies 
were seen between continents and not over time.
Another source of variation in resistance prevalence between studies may be 
the use of different methods to define drug resistance. The majority of the studies we 
included have defined resistance either with the IAS-USA or the Stanford genotypic 
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resistance interpretation algorithm. However, the use of different algorithms to score 
resistance may not have a large impact. This is supported by a previous study 
reporting that scoring resistance using the IAS-USA mutation list of 2006 [31], or the 
Stanford HIVdb (version 4.3.0, 2007) or the Shafer list of 2007 [32] was associated 
with comparable levels of transmitted drug resistance in 8272 genotypic resistance 
tests of drug-naïve patients conducted during 1997-2005 [33]. 
This review is limited by the data that could be extracted from published 
reports.  Convenience sampling (i.e. an over-representation of patients suspected 
to carry a drug resistant virus) may have an impact on the prevalence estimates. 
Although we cannot rule out that convenience sampling occurred, the vast majority of 
included studies used well-defined sampling strategies to identify relevant patients. 
Heterogeneity is another bias that can occur within reviews. Heterogeneity 
applies to differences in the strategy used to sample patients and in research 
methodology. We reduced the heterogeneity by taking into account the year of data-
collection and performing analyses per continent.  
The studies that were collected used population sequence analysis. This 
method fails to detect minor populations of drug-resistant quasi-species [34]. As 
resistance variants in the absence of drug-selection pressure in the antiretroviral 
naïve host may be present in minority viral variants population-sequence analysis 
will underestimate the prevalence of drug resistant HIV-1. 
Despite these shortcomings, this review is the first, to our knowledge, to 
summarize all the published articles on transmitted drug resistance.
CONCLUSION
In this paper, we gave an overview of the epidemiology of resistance to antiretroviral 
drug in drug-naïve patients worldwide. The resistance profiles of the three 
antiretroviral drug classes seem to be different among continents and reflect changes 
in prescribing behaviour of antiretroviral drugs. Although the prevalence of resistance 
to antiretroviral drugs decreases, resistance can become a larger problem in third 
world continents, where antiretroviral drug therapy is becoming more widespread. 
Continuous global surveillance is needed to monitor the circulating HIV-strains and 
ensure that the development of treatment is adjusted to the drug resistance evolution.
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ABSTRACT
Background: Transmission of HIV-1 drug resistance occurs in all regions of the 
world with access to treatment. We collected epidemiological studies on resistance 
and analyzed their data in a standardized way, which allowed us to determine and 
compare prevalences across the world. 
Methods: Relevant studies were identified in Medline and conference reports. 
Authors were approached to share protease and reverse transcriptase sequences 
and clinical and demographic data. The sequences were analyzed for major drug 
resistance associated mutations included in the IAS-USA mutation figures (Fall 
2006).
Results: We included 6244 antiretroviral naïve patients from 44 countries. The 
prevalence of patients harbouring at least one resistance associated mutation was 
10.1% (95% CI: 9.4%-10.9%). This prevalence was higher in the Northern hemisphere 
(14.2% in Asia, 13.6% in North America, and 10.2% in Europe) than in the Southern 
hemisphere (approximately 7% in Latin America and Africa). The high prevalence in 
Asia was ascribed to a monophyletic cluster of A62V in Kazakhstan. The prevalence 
of resistance to the nucleoside reverse transcriptase inhibitors (NRTI) drug class 
was the highest (between 3.6% in Latin America and 12.6% in Asia). Multi-class-
resistance was limited (<2%). Compared to Europe, the non-nucleoside reverse 
transcriptase inhibitors (NNRTI) (odds ratio: 2.3; 95% CI: 1.5-3.7) and protease 
inhibitors (1.8; 1.1-2.9) transmitted resistance were higher in North America. In Asia, 
resistance prevalence was higher for NRTI (4.5; 2.0-9.8) and lower for NNRTI (0.06; 
0.01-0.24) and protease inhibitors (0.3; 0.1-0.6), compared to Europe. No statistical 
significant results were found in other continents. 
Conclusions: The resistance profiles of the antiretroviral drug classes differ slightly 
between continents. Transmitted resistance was found in all continents stressing the 
need of continuous global surveillance of transmitted resistance.  
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INTRODUCTION
In the last decades there has been a substantial progress in the treatment of HIV-
infected patients due to the introduction of a large number of antiretroviral drugs. Use 
of antiretroviral drugs has dramatically reduced mortality among patients living with 
HIV in Europe and North America [1-2]. In recent years comparable effectiveness of 
antiretroviral drugs has been reported in resource-poor settings [3].
Resistance, however, may limit the success of antiretroviral drug treatment. 
Resistance occurs frequently in patients with virological failure and may decrease 
both the magnitude and the duration of the response to treatment [4]. Transmission 
of resistant viruses between individuals has been observed [5], which can result in a 
less favourable response to therapy and limited therapeutic options [6-9].
A substantial number of reports are available on transmitted drug resistance. 
These studies reported a wide variation in the prevalence of transmitted drug 
resistance ranging between 0 to 25% [5, 10-11]. Unsurprisingly, a part of this 
variation in prevalence may be ascribed to differential treatment availability between 
continents. But the variation between different parts of the world is difficult to 
characterise due to the use of different algorithms to interpret transmitted resistance 
profiles that have changed over time [10, 12].
In this paper we will discuss the results of the WATCH study (World-wide 
Analysis of resistance Transmission over time of Chronically and acute infected 
HIV patients). WATCH collected and analysed data of currently available studies on 
transmission of HIV-drug resistance from across the world. Importantly, WATCH used 
a single algorithm to score drug resistance. Using this approach, we give insight to 
different profiles of transmitted resistance over time and in differences in prevalence 
and characteristics of genotypic profiles and viral subtypes between continents. 
METHODS
Identification of relevant studies
To identify studies on transmission of drug resistant HIV, literature was searched 
in PubMed. For this purpose the search terms “HIV OR RESISTANCE” and “HIV 
OR TRANSMISSION” were used. Also, relevant conference reports were reviewed. 
The included studies had to include HIV-1 seropositive persons, who were never 
exposed to antiretroviral drugs, and were at least 18 years. Also, sequences should 
be available for both the reverse transcriptase (RT) and the protease (PR) gene. 
For the collection of the data, authors of the compiled articles that met the inclusion 
criteria were contacted and asked to share HIV-1 pol sequences and additional 
demographic and clinical data. Part of the data sets has been published elsewhere 
[13-53].
Patients were considered to be recently infected if they had a negative 
HIV-1 ELISA test result or a negative, incomplete or indeterminate Western Blot, 
with subsequent documented HIV-1 seroconversion within 1 year before the drug-
resistance analysis was performed. If no reliable information about the duration 
of infection was available, newly diagnosed cases were classified as having an 
unknown duration of infection.
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Genotypic resistance analysis
Population nucleotide sequence analysis was performed by local laboratories. We 
used Clustal X (version 1.81) [54]  for the alignment of the sequences. Resistance-
related mutations were defined according to the International AIDS Society (IAS, Fall 
2006) [55] mutation list. The revertants at codon 215, which are listed as footnotes in 
the IAS figures and are considered to be indicators of transmitted resistance, were 
included in the analysis as well. The classes of drugs included were nucleoside 
reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase 
inhibitors (NNRTI) and proteases inhibitors (PI). Other classes of antiretroviral 
drugs were not considered, as resistance to these drugs in treated patients is 
not widespread. Multiclass resistance was defined as the presence of resistance 
mutations to at least two different drug classes. 
Sequence quality verification
All sequences encompassed at least codons 30-90 of the protease gene and 
codons 41-219 of the reverse transcriptase gene. Sequences containing a stop 
codon (mixtures excluded) at a resistance-related position and individual resistance-
related codons with ambiguities consisting of >2 bases per nucleotide position or of 
>2 ambiguities per codon were excluded from the analysis. Furthermore, codons 
with <3 nucleotides were recorded as missing.
HIV-subtype classification
HIV-subtypes were assessed by the construction of phylogenetic trees using the 
neighbour-joining method. We included subtype reference from the Los Alamos 
Sequence Database (www.hiv.lanl.gov). The Kimura 2-parameter distance 
estimation method was used to generate pairwise distance matrices with a transition 
to transversion ratio of 2.0. The consistency of the phylogenetic clustering was 
tested by bootstrap analysis with 1000 replicates. Bootstrap values above 70 
were considered to be sufficient for subtype assignment. Trees were based on pol 
sequences and were constructed for each centre [56]. 
Statistical analysis
The 95% confidence interval was calculated according to the Wilson interval. 
Categorical data were compared with the χ2 test and continuous data by the Mann-
Whitney U test. The comparison of the frequencies was analysed by the χ2 test. 
Trend analysis was performed using the heterogeneity and trend in proportions tests 
[57], stratifying the calendar years into 3 intervals: 1996-2000, 2001-2002, and 2003-
2007. For the trend analysis, only patients with a recent infection were included, 
as chronically infected patients could have been infected for many years before 
diagnosis. Analyses were done on a continent-level, where Israel was considered 
as being part of Europe. Finally, the comparison for the different drug classes was 
analysed using logistic regression with Europe as the reference group. 
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RESULTS
Study population
Data were collected between 1996 and 2007. We collected data from 7482 persons 
in 41 countries. A total of 1238 individuals were excluded. Of these 1238 patients, 87
patients were aged under 18 years and 12 individuals had a HIV sequence containing 
a stopcodon at a resistance-related position. The HIV sequence isolated from 1139 
individuals did not meet the quality control criteria (predominantly because only 
the protease region was available). A large part of the excluded individuals came 
from Africa (37%) and Latin America (23%), where sequence analysis of reverse 
transcriptase was often not performed.
Most included individuals came from Europe (3362, 54%): Austria (total 
number of patients: 84), Belgium (125), Cyprus (2), Czech Republic (43), Denmark 
(130), Finland (8), France (24), Germany (653), Greece (33), Israel (96), Italy (491), 
Luxembourg (155), Netherlands (23), Norway (21), Poland (35), Portugal (103), 
Serbia (10), Slovenia (38), Spain (228), Sweden (152), Switzerland (244), United 
Kingdom (664). But a substantial percentage was derived from other continents, 
North America: Canada (445), Mexico (44), USA (408); Latin America: Argentina 
(216), Brazil (548), Chile (37); Asia: China (29), India (118), Japan (76), Kazakhstan 
(85), South Korea (46), Vietnam (147); Africa: Burkina Faso (101), Cameroon (73), 
Cote d’Ivoire (135), DR Congo (18), Gabon (13), Mozambique (40), Nigeria (78), 
Rwanda (97), Senegal (56), South Africa (72). 
Table 1 summarizes the characteristics of the 6244 persons that were 
included. Individuals were predominantly male (except in Africa). The continents had 
a dissimilar risk group distribution. In Europe and North America, most individuals 
were men who have sex with men (MSM) (45%). Conversely, in other parts of the 
world, the majority of patients had reported to be infected through heterosexual 
contact. Asia had the highest proportion (32%) of individuals who acquired HIV 
through intravenous drug use. 
Subtype B was most common in North America (91%), Latin America (70%) 
and Europe (68%). In Asia and Africa, HIV subtype A was the most prevalent (52% 
and 58%, respectively). Subtype C was found in data from all continents (ranging 
between 4% of the sequences collected in North America to 23% in Asia).
 The mean HIV-RNA load was around 4.75 log copies/ml. In North America, 
however, a somewhat lower RNA load was found, and in Africa a somewhat higher 
RNA load was found. The median CD4 cell count was quite similar in Europe, North 
America, and Latin America (around 325 cells/mm3). In Africa the median CD4 cell 
count was substantially lower (215 cells/mm3), which could indicate that patients 
included from this continent are in an advanced stage of disease.
Resistance analysis
A proportion of 10.1% (95% confidence interval 9.4-10.9%) was infected with 
HIV containing at least one drug resistance associated mutation (Figure 1A). The 
highest overall resistance for the different drug classes was observed for the NRTIs 
(6.8%; 6.5-7.9%), followed by NNRTIs (3.1%; 2.8-3.7%), and PIs (2.6%; 2.3-3.2%). 
Importantly, multi-drug resistance was relatively rare (1.9%; 1.7-2.4%). In this study
population, 1436 patients had evidence of a recent HIV infection enabling calculation 
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Figure 1. (a) Frequency of HIV resistance within drug classes. (b) Frequency of any resistance within 
continents. (c) Frequency of resistance within the drug classes and continents. (d) Trend of any HIV 
resistance from 1996-2007. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; PI, protease inhibitor; MDR, multi drug resistance.
of the incidence of transmitted resistance of 9.3% (7.8-10.9%).          
Table 2 shows the frequency of transmitted drug resistance mutations 
(TDRM). The most frequently NRTI-resistance associated mutations were T215 
revertants (23.6%), M41L (22.3%), and M184V (12.7%). Mutations associated with
the thymidine analogues (TAMs) were present in 48.5% of all sequences with signs 
of transmitted resistance. For NNRTIs, the most common mutations were K103N 
(16.6%), Y181C (6.8%), and V108I (4.6%). Finally, the most common PI-related 
mutations were L90M (11.1%), V82A (6.0%), and M46I (5.7%). 
 Figure 1 (b and c) show the overall prevalence of HIV TDRM for the different 
continents. Surprisingly, the highest prevalence of resistance was found in Asia 
(14.2%; 11.4-17.5%). This substantial prevalence was ascribed to Kazakhstan, 
where 48 of 85 patients harboured viruses with the NRTI-resistance related A62V 
amino acid substitution. This A62V mutation was not observed very frequent in other 
continents. Without this A62V mutation, the TDRM prevalence in Asia was 4.2% 
(2.4-5.9%).
In Africa, a relatively low prevalence of 6.8% (5.2-8.9%) was found. As in 
the other continents, the majority of the resistance mutations were at an NRTI-
resistance-position. But the distribution of the particular mutations was different in
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Africa; TAMs such as M41L and T215 variants were less common. Conversely, 
M184V was found more frequently. The prevalence of TDRM in Latin America 
was the same as the estimate for Africa; 6.8% (5.0-9.1%). The highest prevalence 
estimates for TDRM were found in the industrialized countries. North America had 
the highest TDRM prevalence at 13.6% (11.5-16.1%). In North America, the highest 
TDRM prevalence was seen for NNRTI and PI drug classes. The TAMs and M184IV 
mutations were more present in this population compared to the other continents. 
Europe showed a resistance prevalence of 10.2% (9.2-11.3%). Here T215 revertants 
were frequently present compared to the other continents.
Comparison of mutational patterns
Comparing the relative proportion of resistance to the different drug classes showed 
that Asia differed significantly from Europe in NRTI resistance, with an odds ratio
(OR) of 3.7 (95% confidence interval (CI) 1.7-8.0) (figure 2). NNRTI- and protease-
inhibitor associated resistance was more common in North America (OR 2.9; 95% 
Table 2.  Resistance mutations profiles.
Total In all 
patients
In patients 
with 
TDRM
Africa
n=687
Asia
n=501
Europe
n=3362
North 
America
n=853
Latin 
America
n=844
Mutationa n prevalence, %
NRTI
     M41L 141 2.3 22.3 1.0 0.4 2.3 4.3 1.9
     K65R 1 0.0 0.2 0.0 0.0 0.0 0.0 0.0
     D67N 67 1.1 10.6 0.9 0.2 1.2 2.1 0.1
     K70RE 40 0.6 6.3 0.0 0.2 0.7 1.4 0.1
     M184V 80 1.3 12.7 1.5 0.4 1.2 2.6 0.8
     L210W 51 0.8 8.1 0.4 0.0 0.8 2.0 0.4
     T215FY 48 0.8 7.6 0.4 0.2 0.9 1.4 0.6
     T215revertants 149 2.4 23.6 0.4 0.6 3.2 3.3 1.1
     K219EQ 57 0.9 9.0 1.0 1.0 1.0 1.3 0.0
     TAMsb 306 5.0 48.5 2.8 2.0 5.8 7.2 2.4
     => 2 TAMsb 147 2.4 23.3 0.7 0.2 2.7 5.0 0.9
     TAM +M184V 344 5.6 54.5 3.6 2.4 6.4 8.0 2.8
Multi-NRTI
      A62V 66 1.1 10.5 0.0 9.6 0.3 0.6 0.4
      V75I 7 0.1 1.1 0.0 0.0 0.1 0.4 0.0
      F77L 11 0.2 1.7 0.1 0.4 0.2 0.1 0.0
      Q151M 4 0.1 0.6 0.0 0.0 0.1 0.1 0.1
NNRTI
      K103N 105 1.7 16.6 1.5 0.0 1.6 3.8 1.4
      V108I 29 0.5 4.6 0.1 0.4 0.5 0.9 0.2
      V181C 43 0.7 6.8 1.3 0.0 0.5 1.5 0.6
PI
      L33F 22 0.4 3.5 0.3 0.4 0.4 0.7 0.0
      M46I/L 57 0.9 9.0 0.3 0.4 1.0 1.3 1.1
      V82AFSTL 49 0.8 7.8 0.1 0.0 0.9 1.6 0.4
      L90M 70 1.1 11.1 0.1 0.6 0.9 3.6 0.4
a In addition to these mutations, the following mutations were also studied: Y115F, M184I, F116Y, L100I, 
V106A/M V181I, Y188L/C/H, G190A/S, P225H, P236L, D30N, V32I, I47AV, G48V, I50LV, I54ML, L76V, 
I84V, N88S; b M41L + D67N + K70R + L210W + 215A/C/D/E/F/N/S/V/Y+ K219E + K219Q; TDRM, 
transmitted drug resistance mutations; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; and TAM, thymidine analogue mutation.
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CI 1.9-4.4; and OR 1.8; 95% CI 1.1-2.7, respectively). Conversely, compared to 
Europe, lower prevalence of NNRTI and protease resistance associated mutations 
were found in Asia (OR 0.1; 95% CI 0.02-0.3; OR 0.3; 95% CI 0.1-0.6). In theory,
the dissimilar outcomes could have been explained by differences in the calendar
years in which the sequences were collected. For example, sequences from the mid-
1990s could contain relatively more TAMs due to usage of zidovudine monotherapy. 
We therefore adjusted our analysis for calendar year. In figure 2, the adjusted odd 
ratios are shown as white squares and do not differ much from the black (unadjusted) 
squares. Therefore the calendar year did not have an impact on the statistical 
significance of our results. 
Trend analysis
For patients with a recent infection the incidence varied significantly (p=0.012) 
among time periods. The incidence of at ‘least 1 resistance’ mutation, decreased 
from 1996-1999 to 2000-2001 from 11.5% to 7.4%, increased to 13.6% in 2002-2003 
and decreased again to 6.8% in 2004-2007 (figure 1D). Because of the fluctuation in 
incidences, no overall time trend could be observed (p=0.63). 
Genotypic profiles
The most frequently occurring NRTI mutations were the TAM mutations (table 2). 
The prevalence of these TAMs was higher in North America (7.2%) and Europe
(5.8%) than in the other continents (≤2.4%). The most prevalent TAMs  found in North
America and Europe were the M41L (4.3% and 2.3%, respectively) and the T215 
revertants (3.3% and 3.2%, respectively). In Africa, some small differences were 
seen. Here, the M184V was observed more often (in 1.5% of the patients), whereas 
the TAMs were not found as frequently (2.8%) compared to the other continents. 
In Asia, except for A62V, low frequencies were found for all the three classes of 
antiretroviral drugs. For NNRTIs and PIs, the most prevalent drug resistant mutations 
across all continents were the K103N (ranging between 0-3.8%) and L90M (0.3%-
3.6%) respectively.
The genotypic profiles of the different subtypes are shown in table 3. 
Frequently found mutations are the A62V in subtype A, and M41L and T215 revertants 
in subtype B. In subtype C, only mutations with a low frequency were found. These 
subtype mutation profiles were to a large extent in agreement with the differences 
that were seen among continents. And although the M46I/L mutation occasionally 
occurs naturally in untreated individuals with subtypes A, B, and C [58], this mutation 
was only found in 0.0%, 0.7%, and 0.5% in our study, respectively. 
DISCUSSION
The WATCH study is the first large worldwide study on the epidemiology of 
transmission of drug resistant HIV-1. Using data from 6256 antiretroviral naïve 
patients from all continents (excluding Australia), we found a worldwide prevalence of 
10.1%. Resistance was most frequently found for NRTIs. Importantly, simultaneous 
resistance to two or more different classes of antiretroviral drugs was limited with a 
prevalence of approximately 2%. Notably, only little dissimilarity in the type of drug
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Table 3. Mutation profiles of different subtypes.
A
n=301
%
B
n=3236
%
C
n=658
%
NRTI
     M41L 0.0 2.6 0.6
      A62V 16.3 0.2 0.3
     K65R 0.0 0.0 0.0
     D67N 0.0 1.1 0.3
     K70RE 0.0 0.6 0.0
     M184V 0.3 1.0 0.3
     L210W 0.0 0.8 0.5
     T215FY 0.0 0.9 0.3
     T215revertants 0.0 3.2 0.2
     K219EQ 0.0 0.9 0.0
     TAMsa 0.0 4.4 0.8
     => 2 TAMsa 0.0 1.8 0.3
     TAM +M184V 0.3 6.4 1.1
NNRTI
      K103N 1.0 1.5 0.9
      V108I 0.0 0.5 0.3
      V181C 1.3 0.5 0.3
PI
      L33F 1.0 0.2 0.0
      M46I/L 0.0 0.7 0.5
      V82AFSTL 0.0 0.8 0.0
      L90M 0.0 1.0 0.2
a M41L + D67N + K70R + L210W + 215A/C/D/E/F/N/S/V/
Y+ K219E + K219Q; NRTI, nucleoside reverse transcriptase 
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; 
PI, protease inhibitor; and TAM, thymidine analogue mutation. 
resistance was found between continents.
There are several limitations in this study. The first limitation is heterogeneity. 
Heterogeneity applies to differences in the strategy used to sample patients and 
in research methodology. We reduced the heterogeneity by re-analysing the HIV-1 
sequences and the subsequent application of a single algorithm to score resistance. 
 The second limitation is publication bias. This bias occurs when studies 
that report a higher prevalence of resistance are more likely to be published. In 
recent years, a large number of studies have been published on transmission of 
drug resistant HIV [5, 10-11]. As a consequence, it may be difficult to publish new 
resistance results, especially when no resistance is found. The latter will result in 
an overestimation. Additionally, in African countries without access to antiretroviral 
drugs, resistance studies will not be performed. The relatively low prevalence 
estimate (6.8%) we found in Africa is therefore probably an overestimation. 
The final limitation relates to the quality of the data. For instance, convenience 
sampling (i.e. a relative over-representation of patients suspected to carry a drug 
resistant virus) may have an impact on our prevalence estimates. Although we 
cannot rule out that convenience sampling occurred, the vast majority of included 
studies used well-defined sampling strategies to identify relevant patients.
The studies that were collected in WATCH used population sequence 
71
analysis. This method fails to detect minor populations of drug-resistant quasi-
species that are present in <20% of the virus population infecting a patient [59-
60]. These minority variants have been detected in almost 14% of antiretroviral 
naïve HIV-infected individuals [61]. The presence of minorities, particularly involving 
NNRTI resistance, is associated with an increased risk of virological failure to first-
line therapy [61]. Due to these minority viral variants, population-sequence analysis 
will underestimate the prevalence of drug resistant HIV-1.
The prevalence numbers we found for Europe are consistent with the 
independent European SPREAD study, where a resistance prevalence of 9% was 
reported [62]. In Asia a higher prevalence was observed and can be ascribed to a 
monophyletic cluster among intravenous drug users in Kazakhstan which included 
the NRTI-resistance related amino acid substitution A62V [63]. 
Prevalence of transmitted resistance varied geographically. A trend was 
seen of higher resistance prevalences in the Northern hemisphere compared to 
the Southern hemisphere. This trend could result from the relatively early start of 
prescribing antiretroviral drugs in North America and Europe, leading to a longer 
exposure time for viruses that circulate in North America and Europe. In addition, 
before 1996 antiretroviral drugs were prescribed as part of suboptimal therapy 
leading to an increased propensity of emergence of drug resistance.
WATCH found a limited differential distribution of resistance for particular 
classes of antiretrovirals between the continents. This is interesting as drugs were 
introduced at different moments in time.  
The mutations profiles that were seen for the continents were in large 
agreement with the mutations profiles seen among subtypes. The profile of Asia 
was closely related with the profile of subtype A, and the profiles of North America 
and Europe were very similar to the profile of subtype B. This is not surprising since 
subtype B is the dominant subtype in Europe and North America, whereas in the 
other continents subtype A and C are more prevalent. 
The most commonly observed mutations were associated with resistance to 
the thymidine analogues, especially the T215 variants and M41L. These mutations 
might reflect the extensive use of the NRTI zidovudine mono-therapy in the past. 
T215 variants arise in the absence of antiretroviral drugs due to reversion [5]. At 
codon 215, the resistance-associated substitutions T215F and T215Y require two 
nucleotide mutations for reversion to wild type. But in isolates obtained from patients 
who had not received antiretroviral treatment for their HIV-1 infection, revertant 
codons are frequently found that are intermediates between wild type and T215F/Y 
[5, 65-66]. Interestingly, viruses with a reversion at codon 215 have a decreased 
genetic barrier for the selection of the resistance-associated amino acid substitution 
T215Y [67]. This may indicate an increased risk for developing resistance when a 
subsequent treatment is given with zidovudine or stavudine [66].
The high frequency of the M41L mutation may be partly explained by the 
remarkable persistence of the M41L mutation in plasma over time, shown in several 
studies [68-71], indicating that reversion of some mutational patterns only occurs 
to a limited extent. In addition, a recent study proposed compensatory fixation as 
a possible explanation for the in vivo persistence of some mutational patterns [72]. 
The study reported the prolonged persistence (up to 4 years) of viruses with multiple 
protease mutations after treatment with protease inhibitors was stopped (treatment 
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with RT inhibitors was continued). It was found that these viruses have partially 
compensated for the initial loss in replication capacity. Reversion of a single mutations 
therefore causes a further reduction in replication capacity and, as a consequence, 
the route to wild-type is blocked [67].
In this paper, we gave an overview of the epidemiology of resistance to 
antiretroviral drug in drug-naïve patients worldwide. The resistance profiles of the 
three antiretroviral drug classes seem to be different among continents. Although 
the prevalence of resistance to antiretroviral drugs decreases, resistance can 
become a larger problem in third world continents, where antiretroviral drug therapy 
is becoming more widespread. Continuous global surveillance is needed to monitor 
the circulating HIV-strains and ensure that the development of treatment is adjusted 
to the drug resistance evolution.
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ABSTRACT
Background: One out of ten newly diagnosed patients in Europe was infected with 
a virus carrying a drug resistant mutation. We analysed the patterns over time for 
transmitted drug resistance mutations (TDRM) using data from the European Spread 
program.
Methods: Clinical, epidemiological and virological data from 4317 patients newly 
diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients 
were enrolled using a pre-defined sampling strategy.
Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-
9.8).  Interestingly, significant changes over time in TDRM caused by the different 
drug classes were found. Whereas nucleoside resistance mutations remained 
constant at 5%, a significant decline in protease inhibitors resistance mutations was 
observed, from 3.9% in 2002 to 1.6% in 2007 (p=0.001). In contrast, resistance 
to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 
2002 to 4.1% in 2007 (p=0.004) with 58% of viral strains carrying a K103N mutation. 
Phylogenetic analysis showed that these temporal changes could not be explained 
by large clusters of TDRM.
Conclusions: During the last decade transmitted resistance to NNRTI has doubled 
to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical 
impact of NNRTI mutations warrants continued monitoring.
79
INTRODUCTION
The use of combination antiretroviral therapy has strongly reduced morbidity and 
mortality among patients infected with HIV [1]. This use of antiretroviral medication 
has, however, also led to transmission of drug resistant HIV-1. Approximately 10-
15% of antiretroviral naïve patients in Europe [2-5] and North America [6-7] were 
infected with a virus carrying at least one transmitted drug resistance associated 
mutation (TDRM). These individuals are at a higher risk for developing virological 
failure to first-line antiretroviral therapy [8]. 
The objective of this study is to determine the trends in transmitted drug 
resistance in newly diagnosed HIV-1 infected patients over time in Europe. For this 
purpose, we analyzed the data collected by the pan-European SPREAD programme. 
This programme combines the efforts of virologists, clinicians and public health 
institutes to study the epidemiology of transmission of drug resistant HIV [2, 9]. 
SPREAD has used since 2002 the same sampling strategies for inclusion of patients 
newly diagnosed with HIV-1.
METHODS
Study population
The SPREAD Program includes patients with newly diagnosed HIV-1 infection 
from September 2002 through December 2007 in 26 European countries (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Germany, Finland, 
Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden) and 
Israel. Although Israel is not officially part of Europe, the WHO includes Israel in the 
WHO European region definition [10]. Patients were included using a pre-defined 
sampling strategy based on the geographical and risk group distribution of patients 
newly diagnosed with HIV in the participating countries. For more details on the 
sampling strategy, inclusion- and exclusion criteria, and ethical clearance see the 
previous publications from the SPREAD Programme [2, 9]. Epidemiological, clinical, 
and behavioral data were collected using a standardized questionnaire within six 
months of diagnosis. A thorough data verification process preceded the analysis of 
the data [2, 9].
 A blood sample was taken for genotypic resistance testing within six months 
after diagnosis. Population-based nucleotide sequencing of parts of the reverse 
transcriptase (RT) and protease (PR) genes of the virus was performed at local 
laboratories by means of commercially available kits or in-house methods [2, 9]. 
All countries took part in a blinded quality control program to verify the quality of 
the genotypic data generated. TDRM was defined according to the mutation list 
published for surveillance of  transmitted drug resistance as recommended by the 
World Health Organization [11].
Seroconversion was documented in a proportion of the newly diagnosed 
patients. For some of these patients (n=882) seroconversion could be established 
because a last negative test was available within 3 years before diagnosis. In these 
patients, the date of infection was estimated as the midpoint between the date of 
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the last negative and first positive test. In addition, for 506 patients primary HIV-1 
infection was documented based on laboratory data. In these 506 patients, the date 
of the first positive (and subsequently confirmed) HIV test was used as the estimated 
date of infection. Patients were defined as recently infected when the duration of 
infection was <1 year. 
For the purpose of analysis, Western Europe was defined to include those 
countries with a long history of good access to antiretroviral drugs. These countries 
included: Austria, Belgium, Cyprus, Germany, Denmark, Spain, Finland, Greece, 
Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Sweden, France, the 
United Kingdom, Switzerland, and Iceland. In our study, Israel was also included in 
the Western Europe category. 
The HIV-1 subtypes were determined by use of the Rega HIV-1 subtyping 
tool (version 2.0, available at http://www.bioafrica.net/subtypetool/html/) [12]. 
Phylogenetic analyses
Phylogenetic analyses were performed to investigate clustering of sequences with 
TDRM. As controls we included 1) the genetically most closely related sequences in 
the entire SPREAD dataset (n=46) as identified by neighbour-joining phylogenetic 
trees constructed using Mega5 [13]; 2) the most closely related sequences (according 
to the percent of matching bases) in the Los Alamos Sequence Database (www.hiv.
lanl.gov) as identified using the HIV BLAST tool (n=55; 3) subtype reference from the 
Los Alamos Sequence Database. 
Sequences were aligned using Clustal W (BioEdit version 7.0.5.3) software 
[14] followed by manual editing and removal of TDRM-related codons [11]. Maximum 
likelihood trees were constructed for each relevant subtype using Mega5 and the 
best fitting nucleotide substitution model estimated by ModelTest v0.1.1 [15] under 
the Akaike information criterion. Robustness and statistical support of the internal 
branches of the maximum likelihood tree were evaluated with bootstrap analysis 
(1000 replicates). Potential non-nucleoside reverse transcriptase inhibitors (NNRTI) 
transmission clusters were defined as cluster including only sequences with at least 
one NNRTI TDRM with >70% bootstrap support and a mean genetic distance of 
<0.03 nucleotide substitutions per site [16-18]. 
Statistical analyses
The data were analyzed using the statistical software R (version 2.11.1). Categorical 
data were compared by use of the χ2 test, Fisher exact test, or logistic regression 
techniques. Continuous data were investigated by means of the Mann-Whitney U 
test, linear regression, or Poisson regression. Prevalence values were calculated with 
a 95% Wilson score confidence interval (CI) on the basis of a binomial distribution. 
Trends in the prevalence of TDRM were calculated by logistic regression. Several 
factors were investigated as potential risk factors for TDRM: route of infection, 
recent infection, subtype, sex, age, continent of origin, CDC stage, CD4 cell 
count (square root transformed), log viral load. All statistically significant (P<0.1) 
univariate predictors of TDRM were considered as possible confounding factors in 
the multivariate time trend analysis. 
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RESULTS
Population characteristics
The SPREAD programme enrolled 4,470 newly diagnosed HIV-1 patients from 
September 2002 through December 2007. Included here are 4,317 patients for 
whom genotypic information was available. Data from patients included until 2005 
(n=2687) have been reported previously [2, 19]. The current analysis contains 1630 
additional patients, included between January 2006 and December 2007. 
Table 1 shows the baseline characteristics for all patients. More than 
half (56%) originated from Western Europe, followed by patients originating from 
Eastern Europe and Central Asia (21%) and from Sub-Saharan Africa (11%). The 
most commonly reported transmission risk groups were men who have sex with men 
(MSM) (48%), followed by heterosexuals (35%) and injection drug users (8%). Most 
patients were male (80%). Most patients were diagnosed with HIV in their thirties. 
Nearly one third of patients were defined as recently infected (<1 year). Subtype 
B was the most frequent viral subtype (66%). At time of diagnosis the median log 
plasma HIV-RNA was 4.9 copies/ml (IQR: 4.3-5.3) and the median CD4 cell count 
352 cells/mm3 (IQR: 180-540). 
Prevalence of resistance
The overall prevalence of TDRM in newly diagnosed patients during the period 
2002-2007 was 8.9% (95% CI: 8.1-9.8), of those 69% were infected with viruses 
carrying a single TDRM. Most mutations found were associated with nucleos(t)
ide reverse transcriptase inhibitor (NRTI) resistance at 5.0% (95% CI: 4.4-5.7), 
but NNRTI resistance mutations at 2.9% (95% CI: 2.4-3.4) and protease inhibitor 
(PI) resistance mutations (2.5%; 95% CI: 2.1-3.0) were also observed. Dual- and 
multi-class resistance was seen in 0.8% and 0.4% of the patients, respectively. 
Most NRTI TDRM (184 of 218, 84.4%) were of the thymidine analogue mutations 
(TAMs) class that are associated with resistance to zidovudine and stavudine. The 
highest prevalence was found for the revertant mutations at position 215 (S/D/C/
E/I/V at 2.7%), followed by M41L (1.7%), and L210W (0.6%). For NNRTI and PI, 
the most prevalent drug resistant mutations were K103N (1.7%), and L90M (0.6%), 
respectively. 
Factors associated with TDRM
We analyzed which factors were associated with drug resistance for both the total 
TDRM group (table S1) as well as for the subgroups by drug class (table S2). In 
a univariate analysis, several factors were significantly associated with an overall 
increase in TDRM. These factors included a Western European origin (P=0.008), 
CD4 cell count (square root transformed) (P=0.01), MSM (P<0.0001), subtype B 
(P<0.0001) and recent infection (P=0.001). The NRTI and NNRTI drug classes 
showed the same significant predictors for resistance, although the square root CD4 
cell count was not being associated with resistance for the NRTI drug class. For the 
protease inhibitors class, the factors associated with TDRM were log HIV-RNA load, 
age per 10 years, square root CD4 cell count, and recent infection. 
Table 1 shows that most characteristics were similar for patients infected 
with an NRTI-TDRM, an NNRTI-TDRM, or a PI-TDRM virus. For example, similar
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proportions originating from Western Europe were seen in patients infected with 
a virus with NRTI-TDRM (62%), NNRTI-TDRM (68%), or PI-TDRM (62%). The 
proportion of males ranged between 82 and 87%, and the proportion of MSM 
between 53 and 63% in the three resistance groups. The duration of infection was 
similar in all three groups. The proportion of patients recently infected was 34% in 
the NRTI, 39% in the NNRTI and 38% in the PI TDRM groups.
TDRM trends over time
Logistic regression showed that the overall prevalence of TDRM (8.8% in 2002 
and 9.8% in 2007) was stable over time (odds ratio [OR], 1.03 [95% CI, 0.97-1.10]; 
p=0.37) (figure 1A). Interestingly, we did observe significant changes in resistance 
to particular classes of antiretroviral drugs. For the NNRTI TDRM, the prevalence 
was 2.0% in 2002 and increased to 4.1% in 2007. Logistic regression showed that 
this increase was significant (OR, 1.18 [95% CI, 1.06-1.32]; p=0.004). In contrast, 
for PI TDRM, the highest prevalence was found in 2002 at 3.9% and it decreased 
significantly over time to 1.6% in 2007 (OR, 0.81 [95% CI, 0.72-0.92]; p=0.001). The 
prevalence of NRTI TDRM was stable, at 5.0% in 2002 and 5.2% in 2007 (OR, 1.03 
[95% CI, 0.95-1.13]; p=0.44). Factors associated with TDRM (P<0.1) were included 
Figure 1. Smoothed line of prevalence 
of transmitted drug resistant mutations 
(TDRM) in patients diagnosed from 
2002 to 2007 at time of sequence sam-
pling. 
(A) Prevalence of TDRM associated 
with any of the drug classes (any class), 
nucleoside reverse transcriptase in-
hibitor (NRTI), non-nucleoside reverse 
transcriptase inhibitor (NNRTI), and 
protease inhibitor (PI). (B) Prevalence 
of mutations associated with nucleo-
side reverse transcriptase inhibitors 
(NRTI), thymidine analogue mutations 
(TAM) and revertants, and the M184V 
mutation. The p-values of the time 
trends are shown. 
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in the multivariate time trend analyses. Adjusting for these factors did not affect the 
time trend estimates and significance.
We investigated several hypotheses that could explain the increase in 
transmission of NNRTI TDRM. The first possible explanation could be that a few 
patients infected with a strain that contains transmitted NNRTI resistance transmitted 
their virus to substantial numbers of other individuals. However, this explanation is 
not plausible as phylogenetic analyses showed only a limited number of clusters 
containing the K103N amino acid substitution and these clusters were comprised of 
only a small number of patients (figure 2). Second, an increase in transmitted NNRTI 
resistance could be explained by migration from Africa, as nevirapine is frequently 
used for prevention of mother-to-child-transmission in Africa. From Table 1 it can be 
concluded that this is unlikely given that only eight (9%) patients with a single NNRTI 
mutation were coming from Sub-Saharan Africa.
We further investigated the time trends for specific TDRM within the NRTI 
drug class. TAMs were selected in many treated patients before the HAART era by 
single and dual therapy including zidovudine or stavudine. The M184V mutation can 
be selected by the drugs emtricitabine, lamivudine, and abacavir. Any of these drugs 
have been part of the recommended NRTI backbones in treatment that were in use 
during the time that we collected our data [20-23]. We detected the M184V mutation 
in 16 patients (0.4%). Figure 1B shows that both the prevalence of the TAMs and 
corresponding revertants and the M184V mutations were stable over time (OR, 1.07 
[95% CI, 0.98-1.18]; p=0.13 and 0.79 [95% CI, 0.56-1.10]; p=0.16, respectively). 
DISCUSSION
We studied the prevalence of transmission of drug resistance among patients newly 
diagnosed with HIV-1 in Europe. The overall prevalence of TDRM remained stable 
over time in Europe at a level that is just below 10%. But, the underlying prevalence 
of TDRM associated with particular antiretroviral drug classes showed important 
changes over time. We found a significant increase in the prevalence of transmitted 
NNRTI resistance, doubling from 2.1% in 2002 to 4.1% in 2007. In contrast, 
transmitted PI resistance decreased significantly from 3.9% to 1.6%. Transmitted 
NRTI resistance mutations remained stable over time (5.7%) and generally involved 
TAM mutations.
Several studies reported on the changes of TDRM over time in single 
countries in Europe [24-28]. Recent data from Italy are in agreement with our results. 
The Italian study reported a similar significant decrease in resistance to PIs and 
NRTIs and an increase in resistance to NNRTIs in the same time frame [26]. Also, a 
study in seroconverters in Germany found stable overall resistance and an increase 
over time for NNRTI resistance (although not significant) between 1996 and 2007. 
However, transmitted NRTI resistance was decreasing and PI resistance was stable 
over time [27]. In Sweden, a low overall prevalence of resistance was found (5.8%) 
and no clear trend over time [28].  In addition, a study from Belgium found no changes 
over time, which can partly be explained by the smaller sample size in this study and
thus the reduced power to detect statistically significant changes [25]. 
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 In the previous study published by the SPREAD programme, transmitted 
NNRTI resistance showed a statistically significant parabolic time trend over the time 
period of 2002 to 2005 with a peak at the end of 2004 (p=0.02)[2]. The change from 
a parabolic to a linear increase over time that was found in this study, which includes 
the years 2006 and 2007, could be explained by the longer time period covered and 
the increase in power to calculate time trends. Furthermore, the data from 2006 
and 2007 showed that the initial increase in NNRTI resistance that was seen in the 
previous study persisted in these later years.
We investigated several factors that could explain the increase of transmitted 
NNRTI resistance in Europe. Migration from Africa could have explained the increase 
as a single-dose of the NNRTI nevirapine has been used extensively for prevention 
of mother-to-child-transmission, which resulted in increased levels of NNRTI 
resistance [29-30]. However, this is highly unlikely because only 8 (9%) patients with 
a single NNRTI mutation came from Sub-Saharan Africa in our dataset. Second, it 
is important to note that virological studies showed that the K103N, a major NNRTI 
mutation, can persist in the absence of treatment [31]. However, our phylogenetic 
analyses indicated that an increase in transmitted NNRTI resistance did not occur 
within phylogenetic clusters thus suggesting that TDR with K103N originated from 
different sources.
Changes in prescribing practices most likely explain the increased rates of 
transmitted NNRTI resistance mutations. NNRTIs have become more popular in 
first-line treatment as they have good clinical efficacy [32-33] and are convenient to 
use (low pill burden) which improves adherence [34]. Unfortunately, NNRTIs have 
a low genetic barrier to drug resistance. A single amino acid change is sufficient for 
high level drug resistance to the most commonly used NNRTIs in first-line treatment 
[35]. We believe that with the use of NNRTIs in first line regimens (in combination 
with emtricitabine/lamivudine plus either tenofovir or abacavir) resistant viruses can 
become selected in failing patients. Early after failure these viruses carry a single 
NNRTI mutation often combined with the M184V/I [36]. M184V has a strong effect 
on replication capacity and if transmitted, reverts back to wild-type rapidly (68% after 
6 months of HIV infection [37]). In contrast, the K103N has a limited effect on viral 
replication capacity and persist for long periods after transmission [31] and strains 
with this mutation are therefore also transmitted to others (onward transmission) [30, 
38]. 
The decreasing transmission of PI resistant mutations can also be explained 
by changes in prescribing practices over time. First, PIs have become less popular 
as randomized clinical trials showed that NNRTIs results in a better virological 
outcome [32-33]. In addition, over time PIs have increasingly been given with low 
dose ritonavir (or boosted PIs), which have a high genetic barrier for drug resistance. 
Therefore the chance of selecting resistant viruses upon treatment failure is very 
low, likely resulting in a decreased rate of PI versus NNRTI- TDR [39-42].
The persistent high levels of TAMs and revertants over the years are not 
in line with prescribing practices. TAMs were originally selected by the thymidine 
analogues stavudine and zidovudine, which have been used extensively in the past 
but have over time become uncommon in first-line treatment. The persistently high 
levels of TAMs and revertants can be explained by initial selection in the early 1990s, 
and subsequently the original selected mutations may have persisted. In addition, 
revertants or intermediates have evolved in the absence of drug pressure and 
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persisted since then. This is confirmed by several studies showing that TAMs and 
revertants tend to persist in the absence of antiretroviral drugs [31, 37]. Given that 
we find transmitted TAMs also in patients with recent infection despite the limited use 
of zidovudine during the study period indicates that these viruses are descendants of 
resistant viruses generated ten to fifteen years ago that still are circulated and being 
transmitted. 
A limitation of our study is that we used population sequencing to identify 
drug resistance associated mutations. Although population sequencing is standard 
practice across Europe, this technique fails to identify drug-resistant minority variants 
that are present in <20% of the virus population infecting a patient [43-44]. These 
minority variants have been detected in almost 20% of antiretroviral naïve HIV-
infected individuals [45]. The presence of minorities, particularly involving NNRTI 
resistance, is associated with an increased risk of virological failure to first-line 
therapy [45]. The increasing levels of transmitted NNRTI resistance are therefore 
worrying, as we most probably underestimate the real prevalence in this study.
Representativeness of the data could also be a limitation in our study. We 
assessed the representativeness by comparing the distribution of the transmission 
groups in all countries included in SPREAD with the HIV surveillance data from the 
European Centre for Disease prevention and Control (ECDC) (data not shown). The 
proportional distribution of the different transmission groups was very comparable. 
However, compared to the data from ECDC, MSM were somewhat over-represented 
in some of the countries participating in SPREAD. This may suggest that the 
estimated prevalence in our study might be slightly overestimated.
A strength of our study is the data collection that is performed within the 
SPREAD programme. The SPREAD programme is a large and sufficiently powered 
pan- European study that has been running since almost ten years. During this time 
the programme included patients newly diagnosed with HIV using a predefined 
strategy that is based on the transmission routes and geographical distribution of 
HIV in the participating countries.
The SPREAD programme studies the prevalence of TDRM in newly 
diagnosed patients, of which most patients are chronically infected. Several studies 
showed that resistance levels in recently infected patients are higher compared to 
those in chronically infected patients [27, 46]. The reason for choosing to investigate 
newly diagnosed patients is that these patients reflect the patients coming under 
medical attention. Furthermore, to limit the analyses only to recently infected patients 
might give a biased result, as MSM (which have higher prevalence of TDRM) are 
being tested more frequently and are therefore more often recently infected at HIV-
diagnosis compared to other risk-groups.
The results from this study have several implications for clinical practice 
and public health. The single TAMs and revertants found do generally not cause 
resistance to nucleos(t)ides currently popular in first-line regimens (emtricitabine, 
tenofovir, lamuvidine, abacavir). Therefore, the high prevalence of resistance to 
single TAMs that was found in Europe probably will not have a great impact on the 
efficacy of first-line therapy. The low prevalence of PI mutations and their negligible 
effect on the efficacy of boosted PIs also implies that they will not have a major public 
health implication. Conversely, the increasing prevalence of transmitted NNRTI 
resistance is likely to negatively influence the therapy response to NNRTI-containing 
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regimens. Since it is it unknown whether the increasing NNRTI resistance levels will 
increase even more or will level-off, surveillance of TDRM will remain important.
In conclusion, during the last decade, rates of transmitted resistance to 
certain drug classes have changed considerably. PI resistance declined between 
2002 and 2007. In contrast, a significant increase in transmitted NNRTI resistance 
was observed. This finding underscores the importance of baseline drug-resistance 
testing prior to the beginning of treatment, given the medical evidence that transmitted 
NNRTI reduces the efficacy of current first line NNRTI-based regimens [8].  
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SUPPORTING INFORMATION
Table S1. Predictors of TDRM: univariable and multivariable models. 
Univariable Multivariable
Variable OR (95% CI) P OR (95% CI) P
Continent of Origin
Western Europe 1.35 (1.08-1.67) 0.008 1.12 (0.87-1.44) 0.38
other
Baseline values
HIV-RNA load, log 1.02 (0.90-1.16) 0.77
Age, per 10 years 1.07 (0.77-1.48) 0.68
CD4, square root 1.02 (1.00-1.03) 0.01 1.01 (0.99-1.02) 0.45
Risk group
MSM* 1.80 (1.44-2.27) <0.0001 1.41 (1.07-1.87) 0.02
other 
CDC stage
C 0.82 (0.58-1.15) 0.25
A and B
Subtype
B 2.06 (1.59-2.68) <0.0001 1.49 (1.08-2.06) 0.02
non-B
Duration of infection
<1 year 1.43 (1.15-1.78) 0.001 1.13 (0.88-1.46) 0.34
other
TDRM, transmitted drug resistance mutations; MSM, men who have sex with men. P<0.1 was 
chosen as the cut-off for selecting the predictors into the multivariable analyses; * gender was 
not included in the model due to multicolinearity with MSM. 
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ABSTRACT
Background: In Europe 10% of newly diagnosed patients in Europe become 
yearly infected with drug resistant HIV-1. Little is known about the risk factors for 
transmission of drug resistant HIV. We analysed data from the SPREAD programme, 
to gain insight in the prevalence and associated time trends of transmitted drug 
resistance mutations (TDRM) in different transmission groups.
Methods: The SPREAD programme recruited newly diagnosed HIV-1 patients 
from September 2002 through December 2007. Sampling was representative for 
transmission group and geographical distribution in the participating countries. 
Trends over time were calculated by logistic regression.
Results: From the 4317 patients included, the majority was men-having-sex-with-
men -MSM (2084, 48%), followed by heterosexual patients (1501, 35%) and injection 
drug users (355, 8%). MSM were more often originating from Western Europe, infected 
with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of 
TDRM was highest in MSM (prevalence of 11.1%), followed heterosexuals (6.6%) 
and injection drug users (5.1%, p<0.001). TDRM was predominantly ascribed to 
nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in 
MSM, 3.3% in heterosexuals and 2.0% in injecting drug users (p=0.001). The overall 
prevalence of TDRM was stable for both the MSM (p=0.19) and the heterosexual 
group (p=0.09). Interestingly, a significant increase in resistance to non- nucleoside 
reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease 
inhibitors was observed in MSM (p=0.008 and p=0.006, respectively), but not in the 
heterosexual patients (p=0.68 and p=0.14, respectively).
Conclusion: MSM showed to have significantly higher TDRM prevalence compared 
to heterosexual patients and injection drug users. We observed a sharp increase of 
transmitted NNRTI resistance in MSM requiring further action given that NNRTIs are 
frequently used in first line regimens.
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INTRODUCTION
Antiretroviral therapy has strongly reduced morbidity and mortality in HIV infected 
individuals [1]. This use of antiretroviral medication, however, also led to transmission 
of drug resistant HIV-1. Transmission of drug resistance has important clinical 
ramifications as it is associated with an increased probability for virological failure 
[2]. Importantly, the problem is large, with prevalence ranging between 10 and 15% 
of antiretroviral naïve patients infected with a virus carrying at least one transmitted 
drug resistance associated mutation (TDRM) mutation in Europe [3-6] and North 
America [6-8]. 
The prevalence of TDRM is expected to be different among different routes 
of transmission in Europe. Men having sex with men (MSM) are mostly originating 
from resource-rich countries where antiretroviral drugs have been available for many 
years. Until the early 1990s, patients infected with HIV received mono- or dual-therapy 
with nucleoside reverse transcriptase inhibitors (NRTI). This mono- and dual-therapy 
led to a rapid development of resistance mutations [9-10]. In contrast, heterosexually 
infected patients in Europe are mostly immigrants from Sub-Saharan Africa or 
individuals from Eastern Europe areas where large scale use of antiretrovirals has 
only recently been initiated. These differences in drug use between the transmission 
groups are reflected in several studies showing a higher likelihood in MSM patients 
to be infected with a resistant virus compared to other patients [3, 11]. 
However, access to antiretrovirals has rapidly been scaled-up during the past 
decade, leading to prevalence of TDRM already as high as 11.6% in some areas in 
sub-Saharan Africa [12]. The TDRM epidemic in Africa is often associated with non-
nucleoside reverse transcriptase inhibitors (NNRTIs), which is consistent with the 
use of single-dose nevirapine in Africa to prevent mother-to-child transmission [13]. 
However, in many areas the size of the problem of TDRM remains limited with a 
prevalence of <5% [14]. 
Besides a difference in the overall prevalence of TDRM between HIV 
transmission groups, variation in particular antiretroviral drug use may therefore also 
result in differences in the prevalence of TDRM to specific HIV drug classes. However, 
these differences are difficult to estimate, since the prevalence of resistance to a 
particular drug class often does not exceed 5% [3-5, 11], leaving a small number of 
patients with resistant virus in each transmission group. As a result most studies are 
underpowered to detect statistical significant differences in case there are relevant 
differences in the prevalences of resistance to specific drug classes between MSM, 
heterosexuals and injection drug users. 
Due to differences in the use of these drug classes over time, TDRM to 
specific drug classes may have evolved differently over time. Yet, there are no studies 
performed which analyse these time trends in the different transmission groups 
European-wide. Therefore, the aim of our study was to examine the prevalence of 
TDRM for the individual drug classes between various HIV transmission groups in 
Europe and to study temporal trends of TDRM in these subgroups. 
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METHODS
Study population
Our analyses included data from the SPREAD Programme. The SPREAD programme 
recruited individuals newly diagnosed with HIV-1 from September 2002 through 
December 2007 in 26 European countries. Patients were included using either a i) 
pre-defined sampling strategy based on the geographical and risk group distribution 
of patients newly HIV diagnosed or ii) a random sample if there was access to >80% 
of all patients newly diagnosed within a particular country. These approaches for 
including patients allowed representative sampling of newly diagnosed patients 
in the participating countries. For more details on the sampling strategy, see the 
previous reports of the SPREAD Programme [3, 15]. Epidemiological, clinical, 
and behavioural data were collected using a standardized questionnaire within six 
months of diagnosis. 
A blood sample was taken for genotypic resistance testing within six months 
after diagnosis. Population-based nucleotide sequencing of the reverse transcriptase 
(RT) and protease (PR) genes of the virus was performed at local laboratories by 
means of commercially available kits or in-house methods. TDRM was defined 
according to the mutation list published for surveillance of TDRM as recommended 
by the World Health Organization [16]. 
Seroconversion was documented in a proportion of the newly diagnosed 
patients. For some of these patients (n=882) a short term infection could be established 
because a last negative test was available within 3 years before diagnosis. In these 
patients, the date of infection was estimated as the midpoint between the date of 
the last negative and first positive test. In addition, for 506 patients primary HIV-1 
infection was documented based on laboratory data. In these 506 patients, the date 
of the first positive (and subsequently confirmed) HIV test was used as the estimated 
date of infection. Patients were defined as recently infected when the duration of 
infection was <1 year. 
Statistical analyses
The HIV-1 subtypes were determined by use of the Rega HIV-1 subtyping tool 
(version 2.0, available at http://www.bioafrica.net/subtypetool/html/) [17]. The data 
were analyzed using the statistical software R (version 2.11.1). Prevalence values 
were calculated with a 95% Wilson score confidence interval (CI) on the basis of 
a binomial distribution. Categorical data were compared using the chi-square 
test, Fisher’s exact test, or logistic regression techniques. Continuous data were 
investigated by means of a Mann-Whitney U-test or the Kruskal Wallis test. 
Trends in the prevalence of TDRM were calculated by logistic regression. 
All statistically significant (P<0.1) univariate predictors of TDRM were considered as 
possible confounding factors in the multivariate time trend analysis. 
RESULTS
Population characteristics
A total of 4317 newly diagnosed HIV-1 patients were included in the SPREAD
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programme from September 2002 through December 2007. From these 4317 
patients, the majority (2084, 48.3%) was infected through MSM, followed by 
heterosexuals (1501, 34.8%) and injection drug users (355, 8.2%). The baseline 
characteristics of these three transmission groups are summarized in table 1. 
MSMs were more often recently infected (<1 year) (43.0%) than injection drug users 
(23.4%) and heterosexuals (13.5%) (p<0.001). As a result of the higher proportion of 
recent infections in MSMs, these patients had a higher median CD4 cell count (435, 
interquartile range (IQR) 259-585 cells/mm3) than the corresponding CD4 values 
found in heterosexually infected patients (median 280, IQR 110-458 cells/mm3) and 
in injecting drug users (median 392, IQR 197-521 cells/mm3) (p<0.0001). Similarly, 
CDC stage C (advanced stage of the HIV disease) was observed in only 8.0% in MSM 
compared to 16.7% in heterosexually infected patients and 10.4% in injection drug 
users (p<0.0001). Furthermore, the proportion of patients originating from Western 
Europe was highest in MSM (69.9%), followed by injection drug users (50.4%) and 
heterosexual patients (39.2%) (p<0.0001). Large differences were seen in subtype 
distribution (p<0.0001). The most reported HIV subtype in viral isolates from MSM 
was B (90.4%) whereas in injection drug users and heterosexual patients subtype 
B was only seen in 61.4% and 33.5% of the patients, respectively. In injection drug 
users, the most commonly found non-B subtype was subtype A, which was observed 
in 22.2%. In heterosexual infected patients both subtype A (18.3%) and subtype C 
(17.3%) were the most frequently observed non-B subtype.
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Genotypic resistance analysis
The prevalence of overall TDRM in MSM was 11.1% (95% CI: 9.9-12.6%). This was 
significantly higher (p <0.001) than in heterosexual patients (6.6%; 95% CI: 5.4-
8.0%) and injection drug users (5.1%; 95% CI: 3.2-7.9%) (figure 1). Similarly, for 
resistance in the NRTI drug class, the prevalence was at least twice as high in MSM 
(6.6%; 95% CI: 5.6-7.8%) compared to heterosexuals patients (3.3%; 95% CI: 2.5-
4.4%; p<0.001) or injection drug users (2.0%; 95% CI: 1.0-4.0%; p=0.001). Most of 
this NRTI resistance was associated with thymidine analogue resistance mutations 
in MSM (87.7%), in heterosexuals (70.0%) and in injection drug users (100%). 
For the NNRTI drug class, the prevalence in MSM (3.8%; 95% CI: 3.1-4.7%) 
was significantly higher compared to heterosexual patients (1.9%; 95% CI: 1.3-2.7%; 
Figure 1. Prevalence of transmitted drug 
resistance mutations (TDRM) to the specific 
drug classes in the three main transmission 
groups. 
Prevalences are shown of resistance to at 
least one of the drug classes (Any), nucleo-
side reverse transcriptase inhibitor (NRTI), 
non-nucleoside reverse transcriptase inhibi-
tor (NNRTI) and protease inhibitor (PI) in men 
who have sex with men (MSM), heterosexual 
patients, and injection drug users (IDU).
              Prevalence of TDRM 
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p<0.001) but not to injection drug users (2.8%; 95% CI: 2.3-1.3%; p=0.44). Notably, 
the prevalence of NNRTI TDRM in injection drug users was higher than the TDRM 
prevalence for NRTI in this transmission group. In other risk groups TDRM to NRTI 
was higher. The most prevalent NNRTI drug resistant mutation was K103N (>57% in 
all three transmission groups). 
In the protease inhibitor (PI) drug class, no statistically significant differences 
were seen. This could be due to the low prevalence of transmitted PI resistance 
found in all risk groups; MSM 2.7%, HSX 2.5%; IDU 1.4%). The most prevalent drug 
resistant mutation was the L90M (>24% in all three transmission groups). 
A large proportion (61%) of the heterosexual patients did not originate from 
Western Europe or North America. We subdivided the heterosexual patients into 
patients originating in Western Europe or North America and patients originating 
outside this region. Of patients originating outside Western Europe or North America, 
51.8% were from Sub-Saharan Africa. The prevalence of resistance in heterosexual 
patients originating from Western Europe or North America was 7.8% for overall, 
4.1% for NRTI, 2.0% for NNRTI and 2.5% for PI resistance. These prevalences did 
not differ significantly from the prevalence of resistance in heterosexual patients 
originating from non-Western countries (5.8% for overall; p=0.14, 2.9% for NRTI; 
p=0.24, 1.8% for NNRTI; p=0.70, and 2.4% for PI; p=0.87). Also, when excluding 
the patients originating from outside Western Europe or North America from the 
analyses, the prevalence of TDRM remained significantly different between MSM 
and heterosexual patients for overall TDRM (p=0.02), NRTI (p=0.02) and NNRTI 
(p=0.04). In patients originating from Western Europe or North America, we 
performed an analysis where we only included patients recently infected (within 1 
year). In these patients we found an overall TDRM prevalence of 13.1% in MSM and 
6.8% in heterosexual patients.
Notably, transmitted drug resistance to protease inhibitors was largely 
ascribed to M46I/L. This mutation was found in 8 of the 22 patients infected with a 
PI-resistant virus and originated from outside Western Europe and North America. 
In patients originating from Western Europe and North America, this mutation was 
found in 6 out of 15 patients infected with a PI-resistant virus. These mutations were 
not associated with a specific subtype. The mutations showed a similar prevalence in 
patients originating from Western Europe and North America and patients originating 
from outside this region (1.0 and 0.9%, respectively; p=0.86).
Time trends
Trends over time were only examined in MSM and heterosexuals, as the number of 
injection drug users was too low for this analysis. The prevalence of overall TDRM 
slightly increased - but not statistically significant- over time in the MSM group, with 
10.1% in 2003 and 12.5% in 2007 (odds ratio [OR], 1.06 [95% CI, 0.97-1.15]; p=0.19) 
(figure 2A). Conversely, the prevalence declined slightly among the heterosexually 
infected individuals with a prevalence of 4.4% in 2003 and 2.3% in 2007 (OR, 0.89 
[95% CI, 0.78-1.02]; p=0.09) (figure 2B). The NRTI prevalence followed the same 
time trend as the overall TDRM prevalence, with an OR of 1.07 (95% CI: 0.96-1.19; 
p=0.22) in MSM and 0.84 (95% CI: 0.69-1.01; p=0.07) in the heterosexual group. 
In prevalence of resistance to other drug classes, different trends were 
observed. Importantly, the NNRTI resistance prevalence increased three fold from 
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Figure 2. Smoothed line of 
prevalence of TDRM in pa-
tients diagnosed from 2002 
through 2008 at time of se-
quence sampling.
Prevalence of transmitted 
drug resistance is shown for 
any of the drug classes (any 
class), nucleoside reverse-
transcriptase inhibitor (NRTI), 
nonnucleoside reverse-tran-
scriptase inhibitor (NNRTI) and 
protease inhibitor (PI) in (A) 
Men having sex with men, and 
in (B) heterosexual patients. 
The p-values of the time trends 
are shown on the right side of 
the graph.  
1.7% in 2003 to 5.0% in 2007 in MSM patients (OR, 1.21 [95% CI, 1.05-1.39]
p=0.008). For PI resistance, the prevalence was significantly decreasing over time 
from 4.6% in 2003 to 2.0% in 2007 (OR, 0.79 [95% CI, 0.66-0.93]; p=0.006). This 
increase of NNRTI resistance and the decrease of PI resistance was not observed 
in the heterosexual patients (p=0.68 and p=0.14, respectively). Adjusting for factors 
significantly associated with TDRM in the univariate analyses did not change any of 
the time trend effects that were found. 
When splitting up heterosexuals into individuals infected in Western Europe 
or North America and people not infected in this region, no significant time trends 
were found for any of the drug classes in the heterosexuals infected in Western 
Europe or North America. In the heterosexuals infected in regions outside Western 
Europe and North America, the overall TDRM decreased significantly (p=0.03) from 
8.1% in 2003 to 3.1% in 2007. This can be explained by the significant (p=0.02) 
decrease in the NRTI resistance from 4.4% in 2003 to 1.3% in 2007 (data not shown).
 
A   Prevalence of TDRM over time
  P-value
Any: 0.19
NRTI: 0.22
NNRTI: 0.008
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DISCUSSION
In this study we examined the prevalence and time trends of TDRM in the three 
most relevant HIV-transmission groups, MSM, heterosexual patients, and injection 
drug users. We found significant differences in prevalence of resistance between 
these three transmission groups. MSM showed to have significantly higher TDRM 
prevalence of 11.1% compared to 6.6% in heterosexual patients and 5.1% in 
injection drug users. We were also able to compare the prevalence of resistance to 
the specific drug classes between transmission groups. The largest difference was 
found in NRTI resistance, where the prevalence was significantly higher in MSM 
(6.6%), compared to heterosexual patients (3.3%) and injection drug users (2.0%). 
But also for the NNRTI drug class, the resistance prevalence were higher in MSM 
(3.8%) compared to heterosexual patients (2.8%). The prevalence of TDRM to PIs 
was low in all risk groups (≤2.7%).
Similar observations in overall TDRM were found in the United Kingdom 
in 2004 to 2006 where MSM showed a significantly higher prevalence of 10.3% 
compared to other transmission groups (3.5%) [11]. In Germany, the prevalence of 
resistance in MSM was 10.4% compared to the other transmission groups of 7.6% 
between 2001 and 2005 [18]. The SPREAD programme also includes data from 
Germany, so this agreement is not surprising. Our results are in contrast with a time 
trend study performed in Canada, where a significant decrease in overall TDRM 
was observed in both MSM (from 12.1% 1997-2000 to 0.0% in 2001-2003) and the 
injection drug user patients (from 17.0% in 1997-2000 to 7.1% in 2001-2003). The 
change from 8.3% to 12.5% in the same time ranges in heterosexual patients was 
not significant (p=0.72) [19]. The differences with the results from our study might be 
due to the sampling in earlier years (1997-2003), the smaller sample size (180) and 
the sampling of recent infected patients in the Canadian study.
The prevalence of TDRM in heterosexuals originating from Western Europe 
and North America was still lower than the TDRM prevalence in MSM originating 
from the same region. Therefore, the difference in TDRM prevalence between 
heterosexuals and MSM could not be fully explained by heterosexual migrants 
originating from countries outside Western Europe or North America. One possible 
explanation for the low TDRM prevalence in heterosexual patients originating from 
Western Europe and North America is that heterosexuals in western countries 
are frequently infected by individuals originating from outside this region. This is 
supported by a model of Xiridou et al. [20] which showed that a 53% of new HIV 
infections in the Netherlands was acquired by an African migrant of which most 
(32%) via sexual contact in the Netherlands . The model was based on data from 
the Netherlands where migrants reported sexual mixing with Dutch partners and with 
both Dutch and non-Dutch partners in only 15 and 5%, respectively [21].
Another explanation of the lower TDRM prevalence found in heterosexual 
patients could be that heterosexual patients are more often chronically infected. In 
chronically infected patients, virus variants with resistance mutations may revert to 
wild-type viruses which often have a better replicative capacity. In that case, the 
resistant virus variants can no longer be detected by population sequencing used 
in our study, because this method fails to detect minor populations [22-23]. In our 
study, however, we did not found higher TDRM prevalence in heterosexual patients 
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originating from Western Europe or North America who where recently infected 
(6.8%) compared to all patients originating from Western Europe or North America 
(7.8%). An another explanation for the higher TDRM prevalence in MSM might be 
that resistance viruses may have spread by onward transmission in HIV clusters of 
MSM forming a sub-epidemic in these patients [24-26]. Also, MSM may show higher 
risk behaviour as compared to heterosexual patients by having more often sexual 
contacts while being on treatment. If they fail treatment and harbour TDRM, they 
could transmit this resistant virus to other individuals. 
In MSM patients, we observed an increase of NNRTI TDRM and decrease in 
PI TDRM. This could be explained by the change in therapy use in the Western world. 
NNRTI are described as first line therapy in many patients and have a low genetic 
barrier as development of resistance can occur after only a single mutation [27]. The 
use of PI has decreased over time and boosted PI have been recommended in the 
more recent guidelines minimizes the development of resistant mutations [28-31]. 
TDRM in injection drug users was found to be very low in our dataset. An 
explanation for this low resistance prevalence is the high proportion of injection drug 
users that are originating from East and Central Europe. In many countries from this 
region, the proportion of HIV-1 patients who receive therapy has been relatively low 
[32-34]. Additionally, even in countries where the access to antiretrovirals for the 
general population is good, injection drug users have lower rates of access [35-37]. 
We observed a similar PI TDRM prevalence between heterosexual patients 
infected in Europe and North America, heterosexual patients infected outside this 
region and MSM. This is an interesting finding as PI drugs have often only been used 
in second-line regimens in regions outside Europe and North America. We found 
that the PI resistance is often explained by the presence of the M46I/L mutation in 
patients both infected in Europe and North America and in patients infected outside 
this region. This mutation was found in a similar proportion of patients originating 
from Western Europe and North America and patients originating from outside 
this region. Therefore, this mutation might be present due to natural occurring 
polymorphisms. This was already reported in Bennett et al. [16] where the M46I/L 
mutation explains approximately half of the total polymorphisms reported in the PI 
gene in all subtypes [16]. This mutation could therefore lead to an overestimation of 
the PI TDRM prevalence [38]. 
In this study, time trends for TDRM prevalence were analyzed for MSM and 
heterosexuals using data from countries from different regions in Europe. Regions 
in Europe can be dissimilar in HIV and TDRM epidemics. For example, Eastern-, 
Central-, and Western Europe are very different in distribution of transmission groups 
[39], in (prior) access to antiretrovirals [33] and in the size of the HIV epidemic [39]. 
Therefore, the difference in resistance prevalences between the transmission groups 
might also be caused by the patients’ region of origin. However, region of origin did 
not change the time trends, which suggest that the time trend found in MSM and in 
heterosexuals are not caused by a difference over time in the originating region of 
patients in Europe.
Alongside the region, other variables also differed between the transmission 
groups. An example is CD4 count, which was highest in MSM (435 cells/mm3) and 
very low in heterosexual patients (280 cells/mm3). This indicates that heterosexual 
patients are often diagnosed at a late stage of their disease. This data suggest 
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focusing HIV testing more to these patients to detect an HIV infection at an earlier 
stage. 
A limitation of our study can lay in the categorizing of transmission group 
which was done with self-reporting information. This information might be misreported 
due to the urge to give socially desirable answers. Discrimination and homophobia 
can lead to fear of disclosure of being MSM [40-41].
A strength of our study is the data collection that is performed within the 
SPREAD programme. The SPREAD programme is a large and sufficiently powered 
pan- European study that has been running since almost ten years. During this time 
the programme included patients newly diagnosed with HIV using a predefined 
strategy that is based on the transmission routes and geographical distribution of 
HIV in the participating countries.
In conclusion, TDRM prevalence in MSM is high compared to heterosexuals. 
Especially a concern is the NNRTI resistance prevalence which increased three 
times from 1.7% to 5.0% within the study period of five years. This increasing NNRTI 
resistance is likely to negatively influence the therapy response of first-line therapy, 
as most include NNRTI drugs. Therefore, special attention is needed to the further 
development of the prevalence of NNRTI TDRM in MSM patients.
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ABSTRACT
Background: International travel plays a role in the spread of HIV-1 across Europe. 
It is, however, not known whether international travel is more important for spread 
of the epidemic as compared to endogenous infections within single countries. In 
this study, phylogenetic associations among HIV of newly diagnosed patients were 
determined across Europe.
Methods: Data came from the SPREAD programme which collects samples of 
newly diagnosed patients that are representative for national HIV epidemics. 4260 
pol sequences from 25 European countries and Israel collected in 2002-2007 were 
included. 
Results: We identified 457 clusters including 1330 persons (31.2% of all patients). 
The cluster size ranged between 2 and 28. A number of 987 patients (74.2%) were 
part of a cluster that consisted only of patients originating from the same country. 
In addition, 135 patients (10.2%) were in a cluster including only individuals from 
neighbouring countries. Finally, 208 patients (15.6%) clustered with individuals from 
countries without a common border. Clustering with patients from the same country 
was less prevalent in patients being infected with B subtype (P-value <0.0001), in 
men who have sex with men (P-value <0.0001), and in recently infected patients 
(P-value =0.045).
Conclusions: Our findings indicate that the transmission of HIV-1 in Europe is 
predominantly occurring within individual countries.
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INTRODUCTION
Travel and migration have contributed to the worldwide spread of HIV-1. For 
instance, HIV was introduced in the America’s through travel and migration from 
Africa and Haiti in the 1960s [1]. Travel has also played a role in the early spread 
of HIV in East Africa. A phylogenetic study that included geographic information 
found that the HIV epidemic spread more rapidly in areas in East Africa with a good 
infrastructure that facilitates travelling [2]. Moreover, we recently showed that within 
Europe, Mediterranean countries are a source of HIV-1 subtype B infections for 
other European countries [3]. 
Although travel and migration played a key role in the early spread of HIV, 
it is not known to what extent travel currently explains transmission of HIV. On the 
one hand, the importance of travel may have strongly declined over the years. Travel 
from sub-Saharan Africa may have decreased due to stricter European immigration 
laws. But also among native Europeans travel may have become less important for 
the spread of HIV. In Europe, the HIV prevalence is generally low, and stable at 0.2% 
over the last decade [4] and is concentrated mainly in specific risk groups (men who 
have sex with men (MSM) and injection drug users) [5]. Because the HIV epidemic 
is well spread in all European countries, many transmissions could take place within 
a country. On the other hand, the role of travel in transmission of HIV-1 may also 
have increased further in recent years. International travelling has become easier in 
Europe in the last decade because of low cost airlines and the absence of border 
control between most countries. 
In this study we used data from the pan-European SPREAD project. SPREAD 
includes individuals newly diagnosed with a HIV-1 infection that are representative 
for the risk group and geographical distribution of the HIV epidemic in participating 
countries [6-7]. By performing phylogenetic analyses on this data we estimated the 
proportion of individuals newly diagnosed with HIV that was infected within their own 
country.
METHODS
Study population
Data came from the SPREAD programme which included newly diagnosed HIV-1 
infected patients of 18 years and older who had never been exposed to antiretroviral 
drugs from 2002-2007. The sampling strategies were defined in close collaboration 
with the national public health institutes in the participating countries that had access 
to the latest information on national HIV epidemics. To obtain representative samples 
from every country, the investigators selected individuals randomly or according to 
the national distribution of transmission risk groups and the geographical distribution 
of patients with new diagnoses of HIV-1 infection. Epidemiological, clinical, and 
behavioural data were collected using a standardized questionnaire within six 
months of diagnosis. More details on the sampling strategy are provided in previous 
publications from the SPREAD Programme [8-9].
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Table 1. Characteristics of patients.
Characteristics Categories Total patients
Patients 4260
Continent of Origin, no. (%) Western Europe 2361 (55.4)
Eastern Europe & Central Asia 915 (21.5)
Sub-Saharan Africa 467 (11.0)
Other 517 (12.1)
Baseline values HIV-RNA load, mean (IQR), log 
copies/ml
4.8 (4.3-5.3)
CD4 cell count, median (IQR), 
cells/mm3
354 (181-540)
Age, mean years (IQR) 36.3 (29-42)
Gender, no. (%) male 3361 (78.9)
Risk group, no. (%) MSM 2061 (48.4)
Heterosexual contact 1477 (34.7)
Injection drug use 347 (8.1)
Other 39 (0.9)
unknown 336 (7.9)
CDC stage, no. (%) A and B 3537 (83.0)
C 516 (12.1)
Subtype, no. (%) B 2820 (66.2)
A 477 (11.2)
C 291 (6.8)
02_AG 197 (4.6)
G 137 (3.2)
F 92 (2.2)
others 167 (3.9)
unassigned 79 (1.9)
non-B 1361 (31.9)
Duration of infection, no. 
(%)
<1 year 1228 (28.8) 
1-2 years 141 (3.3)
Unknown duration 2891 (67.9)
TDRM, no. (%) present 380 (8.9)
Data are no. (%) of patients, unless otherwise indicated; CDC, Centers for Disease Control 
and Prevention; IQR, interquartile ranges; MSM, men who have sex with men; TDRM, 
transmitted drug resistant mutations.
Phylogenetics
HIV-1 subtypes were determined by the Rega subtyping tool (version 2.0) [10]. Isolates 
suggestive of intersubtype recombination in protease and reverse transcriptase 
fragments were analyzed by SimPlot 3.5.1 software [11]. All sequences were aligned 
to consensus sequences from the Los Alamos Sequence Database using Clustal W 
as implemented in the BioEdit software [12]. Sequences were then trimmed to equal 
length and the gaps were removed. In order to remove the influence of convergent 
evolution at antiretroviral drug resistance mutations on the phylogenetic analysis, 
we excluded all sites associated with major resistance according to the International 
AIDS Society-USA [13]. In protease these positions are 30, 32, 33, 46, 47, 48, 50, 
54, 58, 74, 76, 82, 84, 88, and 90. In reverse transcriptase the following positions 
were excluded: 41, 62, 65, 67, 69, 70, 74, 75, 77, 100, 101, 103, 106, 108, 115, 116, 
151, 181, 184, 188, 190, 210, 215, 219 and 225. This resulted in 920 nucleotides that 
were used for phylogenetic analysis. 
Phylogenetic analyses are computationally intensive. We therefore created 
two different datasets in order to analyse subtype B sequences (which is the most 
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common subtype in Europe [6, 9]) separately from non-B subtype sequences. 
Subtype C was chosen as out-group for analysis of sequences of subtype B. 
Similarly, subtype B was taken as an out-group for the analysis of non-B subtypes. 
Phylogenetic trees were constructed using the MEGA5 integrated analysis software 
[14] by maximum likelihood methods under the general time-reversible model. 
Bootstrapping was performed on the maximum likelihood trees (1000 replicates) to 
assess the reliability of the obtained topologies. To identify transmission clusters, the 
novel methodology for large-scale phylogeny partition was used [15]. This method 
identifies transmission chains by conjugating the evaluation of node reliability, tree 
topology and patristic distance analysis and was validated in a large Italian cohort 
[15]. 
Clustering was based on high bootstrap values (>98%) and intra-cluster 
average branch lengths less than 0.03 nucleotide substitutions per site [16]. There is, 
however, no consensus on the cut-off for bootstrap values and for genetic distances 
that should be used for defining a cluster. Choosing different cut-off values could, in 
theory, have a profound impact on clustering. We therefore performed a sensitivity 
analysis in which clusters were defined using a less strict bootstrap value of 90%. In 
addition, we also did a sensitivity analysis using stricter cut-off values for the genetic 
distances of 0.02 and 0.01.
To study the demographics of the transmission clusters, we divided the 
clusters into clusters containing patients from the same country of residence, clusters 
with patients from countries of residence with a common border, and clusters with 
patients from different countries of residence which do not share a common border. 
RESULTS
Characteristics
A total of 4,260 patients newly diagnosed with HIV-1 were included. The 
characteristics of these patients are summarized in table 1. The most commonly 
reported transmission risk groups were MSM (48%), followed by heterosexuals 
(35%) and injection drug users (8%). Most patients were male (80%). The most 
frequently found subtypes were B (66%), A (11%) and C (7%). Other subtypes or 
circulating recombinant forms were CRF02_AG (5%), G (3%), F (2%), and other 
(4%). 1.9% of the sequences could not be classified. Nearly one third (29%) of 
patients were defined as recently infected (<1 year). The median CD4 cell count 354 
cells/mm3 (IQR: 181-540), which indicates that approximately half of the included 
patients were diagnosed at a stage of their infection where they were eligible to 
receive antiretroviral treatment. 
The number of patients per country of residence was for Austria 138, for 
Belgium 340, for Bulgaria 2, for Croatia 83, for Cyprus 55, for Czech Republic 325, 
for Denmark 295, for Finland 95, for Germany 685, for Greece 230, for Ireland 93, 
for Israel 120, for Italia 197, for Latvia 72, for Lithuania 11, for Luxembourg 52, for 
the Netherlands 97, for Norway 118, for Poland 193, for Portugal 238, for Romania 
67, for Serbia 16, for Slovakia 26,  for Slovenia 84, for Spain 352, and for Sweden 
333. More than half of all patients (55%) originated from Western Europe, followed 
by patients originating from Eastern Europe and Central Asia (22%) and from Sub-
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Saharan Africa (11%). A total of 3322 (77%) patients, patients were originating from 
a country in Europe. A number of 3035 (70%) patients were living in their country of 
origin. 
We found numerous differences between patients infected with a subtype 
B virus and patients infected with a non-B subtype virus. Not surprisingly, patients 
infected with a subtype B virus were less often originating from Sub-Saharan countries 
(0.7%) as compared to 31.7% in non-B subtype strains (P-value <0.0001). From this 
it follows that individuals harbouring a subtype B strain were more often originating 
from European countries (89.8%) compared to 50.9% of individuals infected with a 
non-B strains (P-value <0.0001). Furthermore, patients with subtype B strains were 
more often MSM (71.9%) and recently infected (34.9%), than patients infected with 
a non-B subtype virus (13.6% and 15.9%,  respectively) (both P-values <0.0001).
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Phylogenetic analyses
We identified 457 clusters including 1330 persons (31.2% of all patients). The 
distribution of the cluster size is shown in figure 1. The cluster size ranged between 
2 and 28. Most clusters included two individuals (310 of 457 clusters, 67.8%), 112 
clusters contained 3-5 persons (24.5%) and 35 clusters contained >5 persons (7.7%).
Patients that were part of a phylogenetic cluster had different characteristics 
as compared to patients that were not in a cluster. First, patients included in any 
cluster were more frequently infected through MSM (63.2% in a cluster vs. 41.3% of 
individuals that did not cluster, P-value <0.0001). Patients that were part of a cluster 
were more frequently infected with subtype B (82.5%; P-value <0.0001), recently 
infected (39.5%; P-value <0.0001) and harbouring a transmitted drug resistance 
mutation (10.4%, P-value =0.03) as compared to non-clustering patients (58.8%, 
23.9%, and 8.3%, respectively).
Of the clustering patients infected with a subtype B virus, 1013 (92.1%) 
patients were originating from a European country (table 2). In patients infected 
with a non-B subtype that were clustering, a smaller percentage of 63.5% 
originated from Europe (P-value <0.0001). Nonetheless, we found high proportions 
of patients originating from Europe in clustering patients infected with subtype 
F (25 out of 26, 96.2%), subtype A (44 out of 61, 72.1%) and subtype G (12 
out of 19, 63.2%). Most of these patients infected with subtype F were living in 
Romania (n=10) and Italy (n=10) and were heterosexually infected (n=17). 
Figure 1. Distribution of cluster 
size. 
Frequency of clusters as defined in 
the text, of size of 2 or higher, identi-
fied by subtype.
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Table 2. Proportion of patients originating from Europe per subtype group.
category Originating from Europe,
 n (%)
Total 1159 (87.1)
Subtype B 1013 (92.1)
Non-B subtype 146 (63.5)
Table 3. Characteristics of clusters and patients.
Characteristics category all clusters clusters with 
one country of 
residence, n (%)
Clusters with 
neighbouring 
countries, n (%)
Characteristics of clusters
Total 457 380 (83.2) 31 (6.8)
Subtype Subtype B 357 291 (81.5) 26 (7.3)
Non-B subtype 100 89 (89.0) 5 (5.0)
Characteristics of patients in clusters
Total 1330 987 (74.2) 135 (10.2)
Subtype Subtype B 1100 787 (71.5) 119 (10.8)
Non-B subtype 230 200 (87.0) 16 (7.0)
Risk group MSM 839 578 (68.9) 103 (12.3)
Heterosexual 278 240 (86.3) 13 (4.7)
IDU 85 72 (84.7) 10 (11.8)
other 128 97 (75.8) 9 (7.0)
seroconverters yes 523 372 (71.1) 61 (11.7)
no 807 615 (76.2) 74 (9.2)
TDRM yes 134 100 (74.6) 21 (15.7)
no 1196 887 (74.2) 114 (9.5)
MSM, men who have sex with men; IDU, injection drug users; TDRM, transmitted drug resistant 
mutations.
Most of these patients infected with subtype A strains were living in Greece (n=12), 
Latvia (n=8), Cyprus (n=6) and Austria (n=6). In these patients, transmission through 
MSM was the most common route of transmission in patients from Greece (11 out of 
12) and from Cyprus (3 out of 6), whereas in the other countries subtype A viruses 
were mostly transmitted among heterosexual patients. The 12 patients that were 
part of a cluster and were infected with subtype G were living in many different 
countries and were mainly heterosexual patients (n=10). 
Most patients (a number of 987, 74.2%) were part of a cluster that consisted 
only of patients originating from the same country of residence. The largest clusters 
were found in Poland (n=15), Germany (n= 12 and 11), and the Czech Republic 
(n=10). Among the remaining international clusters containing 343 patients, 135 
(10.2%) of patients were in a cluster including only individuals from neighbouring 
countries (the largest had 10 individuals from Denmark and Germany). Finally, 208 
patients (15.6%) clustered with individuals from countries without a common border 
(including the largest cluster of 28 patients). The cluster size of 28 contained patients 
mostly living in the Czech Republic (n=25) with two patients living in Slovakia and 
one patient living in Italy. Of these 28 patients, 24 patients reported to be MSM. In 
the 46 international clusters without a common border, most involved patients living 
in Spain (n=18) or Germany (n=15).
Table 3 shows the characteristics of the clusters and the patients involved. 
The proportion of patients in national clusters was different compared to international 
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clusters for several characteristics. First, clustering with patients from the same 
residence country was less prevalent in patients infected with a B subtype (71.5% of 
all clusters) vs. non-B subtypes (87.0% of all clusters; P-value <0.0001. Also, MSM 
(68.9%) and recently infected patients (71.1%) showed less clustering with patients 
from the same residence country compared to heterosexual (86.3%) or injection drug 
user (84.7%) (P-value <0.0001) and patients with a chronic or unknown duration of 
infection (76.2%; P-value =0.045). The presence or absence of transmitted drug 
resistance mutations did not influence the proportions of patients clustering in 
national clusters (74.6 and 74.2%, respectively). 
We performed sensitivity analyses using different cut-off values for bootstrap 
values and for genetic distance (table 4). When we changed the bootstrap value 
from 98% to 90%, the number of clusters found increased from 457 to 529, including 
1643 persons (38.6% of all patients). The smaller bootstrap value did not change 
the percentage of clusters containing individuals with the same country of residence 
(from 83.2 to 82.0%; p=0.67). The number of clusters which included persons from 
neighbouring countries was also highly comparable (7.9 and 6.8%). When we 
changed the genetic distance of 0.03 to a more stringent value of 0.01, the number 
of clusters found decreased to 327, including 811 persons (19.0% of all patients). 
Here, more clusters contained individuals with the same country of residence (90.8%; 
p=0.002) and a 3.7% of clusters were found with neighbouring-country-patients. 
Table 4. Sensitivity analyses on proportion of clusters containing individuals with the same country of 
residence.
Bootstrap value Cluster type Genetic distance
0.01 0.02 0.03
90 Within one country 90.6 84.1 82.0
Neighbouring country 4.5 7.7 7.9
Without common border 4.9 8.3 10.0
98 Within one country 90.8 84.2 83.2
Neighbouring country 3.7 6.9 6.8
Without common border 5.5 9.0 10.1
DISCUSSION
In this representative sample, we found phylogenetic associations between viruses 
in one third of newly diagnosed individuals. In these clusters, the vast majority of 
sequences were sampled from persons living in the same country. This suggests 
that a large part of the spread of HIV-1 in Europe can be explained by transmission 
of infections taking place between patients within the same country. 
A strength of our study is the data collection that is performed within the 
SPREAD programme. The SPREAD programme is a large and sufficiently powered 
pan- European study that has been running since 2002. During this time the 
programme included patients newly diagnosed with HIV using a predefined strategy. 
This strategy allowed us to include patients that are representative for the national 
HIV epidemic in participating countries.
The results of this study are in agreement with phylogenetic studies 
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performed in single European countries [17-18]. First, a phylogenetic transmission 
study performed in Belgium found that local onward transmission of subtype B virus 
contributes to an important extent to the epidemic as virtually all patients part of a 
transmission cluster were of Caucasian origin [17]. Second, a study from Switzerland 
found that clustering was segregated between different regions in the country, as 
transmission events occurred preferentially within the same Swiss region [18]. 
 Our study found that patients infected with a non-B subtype virus were 
less often found in phylogenetic clusters (17.5%) as compared to patients infected 
with a subtype B virus (39.2%). This finding reflects differences between patients 
infected with HIV of non-B subtypes and patients infected with a B subtype. First, 
a much higher proportion of migrants originating from Sub-Saharan countries are 
infected with a non-B subtype. A Dutch modeling study showed that the migrant 
groups did not have a large influence on the Dutch HIV epidemic, due to the small 
number of migrants, their relatively moderate sexual risk behaviour and low mixing 
with the Dutch heterosexuals [20]. This is in concordance with phylogenetic studies 
in Switzerland which showed that non-B subtypes are a combined result of both 
migration and domestic transmission [21] whereas the subtype B epidemic is mainly 
driven by domestic transmission [18]. Second, patients infected with a non-B subtype 
are less frequently recently infected (<1 yr) as compared to patients infected with a 
subtype B virus. Thus, because non-B subtype patients are often chronically infected 
at time of diagnosis and have originated from many different countries, the chance of 
phylogenetic clustering in these patients is smaller.
Along these lines, we found that patients involved in non-B clusters had a 
higher proportion of patients originating from European countries than non-clustering 
non-B subtype infected patients. Proportions of patients originating from European 
countries were especially high for clustering patients infected with subtype F, A, and 
G.
The patients infected with subtype F virus that were phylogenetically related 
in our study were mainly living in Romania, Italy, and Austria. The spread of subtype 
F in Europe is explained by nosocomial infections in Romania. In this country, around 
10,000 abandoned children have been infected with HIV-1 subtype F due to use of 
infected hospital equipment or microtransfussions of whole blood around 1990 [22]. 
Subtype F virus has also been described in Italy, where almost all patients infected 
with subtype F were originating from Italy [23].
Most clustering patients originating from European countries and infected 
with subtype A strains were living in Greece, Latvia, Cyprus, and Austria. Subtype 
A has been described previously in Greece, where most subtype A sequences fell 
into a single monophyletic cluster, suggesting ongoing transmissions within Greece 
[24]. In Austria, subtype A infected patients were already reported in 2001, with all 
patients being immigrants or partners of immigrants [25]. These introductions of 
subtype A through immigrants could be the start of the circulation of subtype A within 
Austria. However, no study has yet been published showing the transmission of 
subtype A within the Austrian country. Furthermore, in Latvia, an HIV-1 subtype A 
outbreak among injecting drug users was reported which showed shared ancestry 
with outbreaks among injection drug users in the Ukraine and southern Russia [26]. 
Transmission of subtype G could, contrary to subtypes F and A, not be 
ascribed to a few specific countries in Europe. Subtype G clustering patients were 
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found in many European countries including Portugal and Spain. The presence of 
subtype G has been described before in these countries (Spain [27] and Portugal 
[28]). The introduction of subtype G in these countries is probably caused by 
immigrants coming from West Africa for which the Canary Islands (and therefore also 
Spain and Portugal) form one of the main gates of entrance of African immigrants 
into Europe [27].
More studies have been performed showing circulation of particular non-B 
subtypes within single European countries using phylogenetic analyses [29-
31]. Other studies have suggested transmission of non-B subtypes in Europe by 
observing infections with non-B subtype infections in native or European-originating 
people [32-34].
In all HIV risk groups, clustering was found mainly between patients with 
the same country of residence. However, differences were seen between the risk 
groups. MSM did less often cluster with patients coming from the same country than 
heterosexuals and injection drug users. This is also reflected in the lower percentage 
of seroconverters clustering within a country compared to the non-seroconverters, 
which could be ascribed to the fact that MSM are more often recently infected [35]. 
The less frequently clustering MSM suggests that MSM more often get infected 
during travels to other European countries whereas heterosexuals and injection drug 
users get infected near home. This is supported by studies reporting an association 
of transmission of HIV-1 in injection users with extensive local epidemics [36-37]. 
Sensitivity analyses showed that our findings were not distorted by the 
arbitrary cut-off values that were used for the bootstrap values and for the genetic 
distance. Using a more stringent genetic distance increased the percentage of 
patients clustering with patients living in the same country. Therefore, the percentage 
of patients clustering with patients living in the same country is at least 83.2% or 
higher, because the initial genetic distance used in the main analyses was taken 
very wide. Larger bootstrap values did not change the results in our study. Therefore, 
these results are generally robust and not influenced by the level of bootstrap values 
used in the cluster definition. 
We did not have access to dense samples in which sequences from virtually 
all newly diagnosed HIV-infected individuals in a particular country are included. We 
may therefore have underestimated the size of the clusters or missed individuals for 
whom we currently did not identify a phylogenetically related sequence. Nonetheless, 
we still found that one out of three individuals was part of a cluster. In addition, 
dense sampling is expected not to have changed the results to a great extent as the 
included individuals were representative for the national HIV epidemics.
Our findings indicate that the transmission of HIV-1 in Europe is for a large 
part occurring between patients coming from the same country. This could have 
implications for HIV-1 transmission prevention programmes. Because infections 
attributed to travelling between countries is not frequently observed it is important to 
have good surveillance of the national HIV-1 epidemics.
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ABSTRACT
Background: Several decision support systems have been developed to interpret 
HIV-1 drug resistance genotyping results. This study compares the ability of the most 
commonly used systems (ANRS, Rega, and Stanford’s HIVdb) to predict virological 
outcome at 12, 24, and 48 weeks. 
Methods: Included were 3763 treatment-change episodes (TCEs) for which a HIV-1 
genotype was available at the time of changing treatment with at least one follow-
up viral load measurement. Genotypic susceptibility scores for the active regimens 
were calculated using scores defined by each interpretation system. Using logistic 
regression, we determined the association between the genotypic susceptibility 
score and proportion of TCEs having an undetectable viral load (<50 copies/ml) at 
12 (8-16) weeks (2152 TCEs), 24 (16-32) weeks (2570 TCEs), and 48 (44-52) weeks 
(1083 TCEs). The Area under the ROC curve was calculated using a 10-fold cross-
validation to compare the different interpretation systems regarding the sensitivity 
and specificity for predicting undetectable viral load.
Results: The mean genotypic susceptibility score of the systems was slightly 
smaller for HIVdb, with 1.92±1.17, compared to Rega and ANRS, with 2.22±1.09 and 
2.23±1.05, respectively. However, similar odds ratios were found for the association 
between each-unit increase in genotypic susceptibility score and undetectable viral 
load at week 12; 1.6 [95% confidence interval 1.5-1.7] for HIVdb, 1.7 [1.5-1.8] for 
ANRS, and 1.7 [1.9-1.6] for Rega. Odds ratio’s increased over time, but remained 
comparable (odds ratio’s ranging between 1.9-2.1 at 24 weeks and 1.9-2.2 at 48 
weeks). The Area under the curve of the ROC did not differ between the systems at 
all time points; p=0.60 at week 12, p=0.71 at week 24, and p=0.97 at week 48.
Conclusions: Three commonly used HIV drug resistance interpretation systems 
ANRS, Rega and HIVdb predict virological response at 12, 24, and 48 weeks, after 
change of treatment to the same extent. 
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INTRODUCTION
The effectiveness of antiretroviral therapy has been limited by the development of 
HIV-1 drug resistance. Resistance occurs frequently in patients and may decrease 
both the magnitude and the duration of the response to treatment [1]. 
Several prospective studies have shown that the use of genotypic resistance 
analysis to guide the new treatment choice for patients failing their current HAART 
improves virologic outcome [2,3,4,5]. The complex mutational patterns are however 
difficult to interpret, due to the many different drug resistance mutations [6] and the 
varying levels of decreased susceptibility of these mutations to different drugs.  This 
led to the development of several interpretation systems [7], which provide rules to 
help physicians interpret HIV-1 drug resistance genotyping results.
ANRS, Stanford HIVdb, and Rega are the three most commonly used and 
publicly available drug resistance interpretation systems, which are all regularly 
updated. The systems are rule based algorithms, providing scores for specific 
(combinations of) mutations. The scores are then translated into different levels of 
susceptibility. The rules for these scores are based on literature and expert’s opinion. 
The Rega system was the first to be validated in drug experienced patients [8,9], 
followed by ANRS [5,9] and Stanford [9]. 
A good way to compare systems is by using virological response data in 
correlation with the prediction of interpretation systems. However, some systems 
may be better for short-term virological outcomes, and others may be better for 
longer-term outcomes. The results of a comparison between systems may therefore 
depend on the virological outcome time point that is used. In this study, a large 
data set of HIV-1 patient’s sequences was collected together with virological data 
to compare the three most commonly used interpretation systems in genotypic 
susceptibility score and in the prediction of virological response. We used 3 different 
virological outcome time points to analyze the effect of therapy duration on the 
prediction of systems. 
 
METHODS
Study population
Data was made available through the EU-sponsored ViroLab and EuResist projects 
[10,11,12]. The ViroLab project comprises data from Belgium (Katholieke Universiteit 
Leuven), Italy (University of Brescia and Catholic University of the Sacred Heart of 
Roma), Spain (IrsiCaixa Badalona), and the Netherlands (Erasmus Medical Centre 
Rotterdam). The EuResist project consists of data from Italy (ARCA database; http://
www.hivarca.net/), Germany (AREVIR database); Sweden (Karolinska Infectious 
Diseases and Clinical Virology Department), and Luxembourg (Retrovirology 
Laboratory, CRP-Santé). The time-periods of available therapies in the ViroLab 
and EuResist database ranged between 1996 and 2008. These databases were 
used to extract treatment change episodes (TCEs). TCEs were defined, in patients 
aged ≥18, as follows (figure 1): (1) a baseline genotype (reverse transcriptase and 
protease region) and viral load (detectable being >50 copies/ml) obtained within 90 
days before and 8 days after treatment change; (2) at least one follow-up viral load
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measurement at 12 (range: 8-16), 24 (16-32), or 48 (44-52) weeks; (3) no changes 
in therapy between the time of the baseline viral load and the follow-up viral load 
measurement. In case more genotypic tests or viral load measurements were 
performed within an analyzed treatment period, the value closest to the start of 
therapy or the follow-up measurement time was used.
Interpretation systems and genotypic susceptibility scores (GSSs)
The genotypic results were interpreted using three commonly used rule-base 
interpretation systems: Agence Nationale de recherches sur le SIDA (ANRS) version 
17; Stanford HIVdb, version 5.1.2; and Rega Institute version 8.0.1. The ANRS and 
Rega both report 3 levels of resistance: susceptible, intermediate, and resistant. 
For ANRS, we translated the definitions ‘susceptible’, ‘intermediate’, and ‘resistant’ 
into susceptibility scores of 1, 0.5, and 0, respectively. For the Rega scores, we 
used the weighted score suggested by Rega, which uses the following changes: 
non-nucleoside reverse transcriptase inhibitors (NNRTI) were scored 0.25 (with the 
exception of etravirine with a score of 0.5) for intermediate resistance, and ritonavir-
boosted protease inhibitors (PI) were scored 0.75 and 1.5 for intermediate resistance 
and susceptible, respectively. The Stanford algorithm uses 5 levels of resistance. 
We assigned the following scores to these 5 levels of Stanford: 0, 0.25, 0.50, 0.75, 
and 1 for respectively the high-level resistance, intermediate resistance, low-level 
resistance, potential low-level resistance, and susceptible. In a separate analysis 
we used the unweighted scores for Rega. We assigned the scores 0, 0.5, and 1 to 
the ‘resistant’, ‘intermediate’, and ‘susceptible’ groups for all drugs, respectively. The 
three systems did not include a score for ritonavir. We therefore excluded eleven 
TCEs that used ritonavir as only protease inhibitor, as we could not calculate a GSS 
of their treatment regimens. 
The arithmetic sum of the individual score for the specific drugs provided 
the total GSS of that treatment. For brevity, we classified the total GSS score in the 
following categories: 0 to <1, 1 to <2, 2 to <3, 3 to <4, and ≥4. The 0 to <1 group 
contains viral sequences almost entirely resistant to the drugs in their regimen, and 
the ≥4 group contains viral sequences susceptible to more than 3 drugs given in their 
regimen. 
To calculate the prevalence of drug resistance we used the mutation list 
published by the International AIDS Society USA (IAS-USA) [13]. 
Statistical analysis
Kaplan-Meier curves were estimated to determine the association between GSSs 
and the proportion of TCEs having an undetectable viral load (<50 copies/ml). The 
Figure 1. Schematic definition of a 
treatment change episode. 
The treatment change episode 
requirements are as follows: (1) a 
baseline genotypic drug-resistance 
and viral load test (GT + VL) between 
90 days before and 8 days after change 
of therapy (2) at least one follow-up 
viral load measurement at 12 (8-16), 
24 (16-32), or 48 (44-52) weeks. 
follow-up   change of treatment 
week   -13                                  0        1                              12                         24                                                                    48
GT + VL
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association between GSS scores and undetectable viral load was analyzed with a 
logistic regression. In the multivariate analyses we adjusted for real time to viral load 
measurement (i.e. number of days between the TCEs and the follow-up viral load 
measurement) and log viral load at start of therapy. Furthermore, we used logistic 
regression, to calculate odds ratios for each GSS group compared to the GSS group 
of 0 to <1. The receiver operating characteristic (ROC) curves were calculated 
to analyze the trade-off between the proportion of true-positive (correct virologic 
response prediction) and false-positive (incorrect virologic response prediction) 
results across the range of possible prediction cut-offs. The AUC (Area Under the 
Curve) is a value between 0 and 1 that corresponds to the probability that a randomly 
selected virologic success receives a higher score than a randomly selected virologic 
failure. We used the AUCs to calculate how well the systems separate the GSS 
groups into those with and without undetectable viral load (<50 copies/ml). Robust 
extra-sample error estimation was obtained by 10-fold cross-validation [14]. We 
compared the multiple independent runs of the 10-fold cross validation results with 
a Kruskal-Wallis test.  Analyses were performed with the SPSS software package 
(version 15.0 for Windows, SPSS).
RESULTS
Baseline characteristics of the study population
The baseline characteristics are shown in table 1. We included 3131 patients in our 
study, of which most were male (73%), most were infected with subtype B viruses 
(81.9%), and the median age was 39 years (range 18-78). Of the 3131 patients, 476 
(12.7%) had more than one TCE, which leads to a total of 3,763 TCEs included in 
the study. Of these TCEs, 2,152 had a viral load measurement at week 12, 2,570 at 
week 24, and 1,083 at week 48. TCEs were retrospectively included between 1996 
and 2008. Most TCEs (2085, 55.4%) were included between 2001 and 2004, and 
fewer TCEs were included between 2005 and 2008 (1029, 27.3%) and between 
1996 and 2000 (649, 17.2%). The median HIV RNA level of the TCEs was 4.43 log10 
copies/ml [interquartile range (IQR), 3.65-5.08], and the median CD4+ cell count 
was 233 cells/mL (IQR, 120-371 cells/mL). The most commonly given treatments 
were lamivudine (59%), tenofovir (37%), and lopinavir (35%). A combination 
of lamivudine, zidovudine, and lopinavir/r was the most frequently given therapy 
combination, with a percentage of 8%, followed by 6% for the therapy combination 
lamivudine, tenofovir, and lopinavir/r. 
Prevalence of mutations at baseline
The percentage of sequences having a drug resistance mutation is shown in figure 
2. Nucleoside reverse transcriptase inhibitor (NRTI) resistance associated mutations 
were most frequently found with a prevalence of 62% [13]. The most prevalent 
NRTI resistance mutations were M41L (27.0%), D67N (23.2%), M184V (35.6%), 
and T215FY (32.9%). Mutations associated with resistance to NNRTI and PI, were 
detected less frequently, in 34% and 32% of the cases, respectively. K103N (18.6%), 
V181C (10.2%), and G190A (8.0%) were the most prevalent NNRTI mutations. 
The PI mutations with highest prevalences were M46IL (13.2%), V82A (9.6%), and 
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Table 1. Baseline patient characteristics. 
Characteristics Categories
Number of patients 3131
Male, number (%) 272 (72.6)
Age, median (IQR*) 39 (18-78)
HIV-1 subtype, number (%) Subtype B 2563 (81.9)
Subtype A 158 (5.0)
Subtype G 118 (3.8)
Subtype C 90 (2.9)
Subtype F 62 (1.9)
CRF 02_AG 28 (0.9)
CRF 12_BF 24 (0.8)
other 76 (2.4)
unclassified 12 (0.4)
Number of treatment-change episodes 3763
Baseline CD4 count (cells/mm3), median (IQR) 233 (120-371)
Baseline viral load (log10)(copies/ml), median (IQR) 4.43 (3.65-5.08)
Number (%)
Treatment-change episodes 1 treatment-change episode 1555 (41.3)
>1 treatment-change episodes 476 (12.6)
>2 treatment-change episodes 108 (2.9)
Year of treatment 1996-2000 649 (17.2)
2001-2004 2085 (55.4)
2005-2008 1029 (27.3)
NRTI Drug treatment lamivudine 2224 (59)
tenofovir 1400 (37)
zidovudine 1082 (29)
didanosine 1007 (27)
stavudine 932 (25)
abacavir 590 (16)
didanosine 653 (18)
emtricitabine 246 (7)
NNRTI Drug treatment                        efavirenz 660 (18)
nevirapine 447 (12)
etravirine 1 (0)
delavirdine                                1 (0)
PI Drug treatment                                                        lopinavir 1309 (35)
nelfinavir 332 (9)
atazanavir 274 (7)
indinavir 263 (7)
saquinavir 221 (6)
amprenavir 202 (5)
tipranavir 70 (2)
darunavir 28 (1)
Other drug treatment enfuvirtide                                  135 (4)
therapy combinations lamivudine + lopinavir + zidovudine  315 (8)
lamivudine + lopinavir + tenofovir 244 (6)
lamivudine + zidovudine + abacavir 133 (4)
lamivudine + tenofovir + efavirenz 133 (4)
lamivudine + zidovudine + efavirenz 114 (3)
tenofovir + lopinavir + didanosine 102 (3)
* IQR is interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; PI, protease inhibitor.
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L90M (16.9%). The comparisons of the mutation patterns showed no substantial 
differences between TCEs with a follow-up viral load at 12, 24, and 48 weeks. 
Genotypic Susceptibility Score distribution
The genotypic susceptibility scores for a TCE was calculated as the total score 
of genotypic susceptibility scores for all drugs in one regimen as explained in the 
‘method’ section. Figure 3 displays the proportions of cases in each susceptibility 
category, according to ANRS, HIVdb, and Rega. All systems show that at least three 
active drugs were started in a large proportion of TCEs. The mean GSS of the three 
systems were slightly smaller for HIVdb, with 1.92 ± 1.17, compared to Rega and 
ANRS, with 2.22 ± 1.09 and 2.23 ± 1.05, respectively. The unweighted Rega scores 
did not differ much from the other scores with a mean of 2.15 ± 1.09.
The GSS of TCEs with longer follow-up were slightly higher compared to 
TCEs with a short follow-up time (data not shown), with baseline GSS means ranging 
between 1.93 and 2.23 at 12 weeks, 1.98 and 2.29 at 24 weeks, and 1.98 and 2.32 
for TCEs with viral load measurement available at 48 weeks. 
Prediction of virologic outcomes
The virologic responses of all TCEs are described in table 2. The percentage of an 
undetectable viral load (<50 copies/ml) was higher in week 24 compared to week 12. 
Figure 2. Drug resistance preva-
lences.
Percentage of sequences having re-
sistance mutations to nucleoside re-
verse transcriptase inhibitor (NRTI) 
(black), non-nucleoside reverse 
transcriptase inhibitor (NNRTI) (dark 
gray), protease inhibitor (PI) (light 
gray), and Multi drug resistance 
(MDR) (white).
    
 
Figure 3. Total Genotypic Sus-
ceptibility Scores for ANRS, 
HIVdb, and Rega.
Total Genotypic Susceptibil-
ity Scores were calculated us-
ing the arithmetic sum of the 
individual scores given by the 
systems for each specific drug 
given in a regimen. We classi-
fied the GSS score for ANRS, 
HIVdb, and Rega in the follow-
ing categories: 0 to <1, 1 to <2, 
2 to <3, 3 to <4, and ≥4. GSS 
scores were calculated for 
3759 TCEs. 
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Table 2. The viral load response and GSS groups at different time points.
ANRS HIVdb Rega
week 12 24 48 12 24 48 12 24 48
GSS 0-<1 7.3 8.3 8.1 12.4 14.8 18.0 10.0 9.3 12.0
GSS 1-<2 23.7 30.0 33.5 28.6 39.4 41.6 19.7 26.4 27.4
GSS 2-<3 36.7 47.6 51.7 44.7 55.9 61.7 39.2 50.2 54.9
GSS 3-<4 46.2 64.4 66.7 47.1 66.4 68.1 46.0 65.0 67.2
GSS ≥4 47.2 69.0 74.6 45.0 68.0 72.0 47.3 65.1 72.1
The percentages of treatment-change episodes with an undetectable viral load (<50 copies/ml) are shown 
for each GSS group at week 12, week 24, and week 48 for ANRS, HIVdb and Rega.
Week 48 did not show a large increase in percentage compared to week 24. TCEs 
with higher Genotypic Susceptibility Score had a higher change of reaching an 
undetectable level of viral load. At 48 weeks, in more than 70% of the TCEs with a 
Genotypic Susceptibility Score of ≥4, the viral load became undetectable.
Adjusted odds ratios for reaching a viral load below 50 copies/mL for each unit 
increase in GSS are reported in figure 4. These predictions of the virological response 
were similar to the odds ratios without adjusting for log viral load at start of therapy 
and real time to viral load measurement (data not shown). At all time points, the 
interpretation systems were significantly predictive of the virological response. Odds 
ratios for each unit increase of the GSSs ranged from 1.77 (95% Confidence Intervals 
(CI): 1.62-1.94), 1.87 (95%CI: 1.69-2.06), and 1.88 (95%CI: 1.70-2.08) at 12 weeks 
to around 1.99 (95% CI: 1.84-2.16), 2.20 (95%CI: 2.01-2.41), and 2.16 (95%CI: 1.97-
2.37) at 24 weeks for HIVdb, Rega, and ANRS, respectively. Furthermore, the odds 
ratios for the unweighted Rega scores were similar, ranging between 1.86 (95% CI: 
1.69-2.05) at week 12 and 2.16 (95% CI: 1.98-2.36) at week 24. The ROC curves 
in figure 5 depict different cut-off points, for the three interpretation systems. In the 
table below the graph, the sensitivity, 1-specificity, and specificity are given for these 
cut-off points. The sensitivity and specificity of the ROC curves for the systems are 
all similar. The calculated AUCs were around 0.63 at week 12 and 0.68 at week 24
and 48 (table 3). These AUCs did not significantly differ among the systems (with 
p-values ranging between 0.60-0.97) at all time points. The AUCs of the unweighted
Figure 4. Association between Genotypic Susceptibility Score and undetectable viral load.
The adjusted odds ratios (ORs) with 95% confidence intervals for RNA levels <50 copies/ml at (A) 
12 weeks, (B) 24 weeks, and (C) 48 weeks per unit increase of GSS according to ANRS, HIVdb, and 
Rega. These odds ratios were adjusted for log viral load at start of therapy and real time to viral load 
measurement, and similar to the unadjusted odds ratios.
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GSS
score
sensitivity 1-specificity specificity
ANRS HIVdb Rega ANRS HIVdb Rega ANRS HIVdb Rega
A 0.5 0.98 0.95 0.97 0.88 0.78 0.86 0.12 0.22 0.14
B 1.5 0.87 0.78 0.89 0.66 0.53 0.66 0.34 0.47 0.34
C 2.5 0.64 0.52 0.64 0.43 0.35 0.43 0.57 0.65 0.57
D 3.5 0.08 0.07 0.09 0.06 0.05 0.06 0.94 0.95 0.94
Table 3. Multiple cross-validation for calculating AUC for the different interpretation systems. 
week system AUC* sd Kruskal-Wallis test
Chi-square p-value
Week 12 ANRS 0.629 0.05
HIVdb 0.634 0.05 0.280 0.597
Rega 0.620 0.05
Week 24 ANRS 0.677 0.04
HIVdb 0.689 0.03 0.143 0.705
Rega 0.689 0.03
Week 48 ANRS 0.671 0.06
HIVdb 0.680 0.06 0.001 0.970
Rega 0.679 0.06
All weeks ANRS 0.671 0.03
HIVdb 0.680 0.03 0.322 0.570
Rega 0.680 0.02
* AUCs (area under the receiver operating characteristic curve) were obtained from 
10-fold cross-validated predictions. AUCs of 0.5 indicate that the interpretation 
system is not an explanatory factor for the percentage undetectable viral load. 
Figure 5. ROC curves for the logistic 
models for ANRS, HIVdb, and Rega 
at 12 weeks. 
The sensitivity, 1-specificity, and 
specificity are given in the table for 
the cut-off points 0.5 (A), 1.5 (B), 2.5 
(C), and 3.5 (D) for ANRS, HIVdb, and 
Rega. 
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Figure 6. Association of undetectable viral load and Genotypic Susceptibility Score over time.
Kaplan Meier curves showing the association between time to undetectable viral load and the proportion 
of TCEs having an undetectable viral load for the 5 Genotypic Susceptibility Score groups for (A) ANRS 
(B) HIVdb and (C) Rega. Due to lost to follow-up at later viral load measurement time points, we limited 
the follow-up time to 30 weeks.
Rega did not differ from the normal ANRS, HIVdb, and Rega scores, with means of 
0.63 at week 12 and 0.68 at week 24 and 48. (data not shown) 
In figure 6, Kaplan-Meier curves are given, showing clear associations 
between the GSS groups and the proportion of TCEs having an undetectable viral 
load. The GSS group of 4 or higher show the highest proportion of TCEs having 
an undetectable viral load. The odds ratios of each GSS group are given in table 
4 for all time point measurements. In the comparison between the different GSS 
groups and the GSS group of 0 to <1, increasing odds ratios were found for an 
increasing GSS. Odds ratios were higher at week 24 compared to week 12 for all 
GSS groups and in all three interpretation systems, whereas the results at week 
48 did not differ much from those at week 24. Due to the low numbers of included 
TCEs in GSS group ≥4 and at week 48, large confidence intervals were seen in 
these groups. At week 24, the odds ratios increased from 4.70 (95% CI: 2.57-8.60) 
to 26.42 (95% CI: 13.49-51.77) for ANRS, from 3.62 (95% CI: 2.56-5.13) to 13.49 
(95% CI: 8.25-22.06) for HIVdb, and from 3.46 (95% CI: 2.03-5.91) to 19.34 (10.70-
34.94) for Rega. 
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Table 4. Logistic regression for calculating association between undetectable viral load and the GSS 
groups.
system GSS group OR (95% CI)
week 12 week 24 week 48
ANRS 0-<1 ref. ref. ref.
1-<2 3.86 (2.07-7.20) 4.70 (2.57-8.60) 5.70 (2.17-14.95)
2-<3 7.20 (3.94-13,18) 9.89 (5.48-17.83) 11.94 (4.62-30.83)
3-<4 13.54 (7.50-24.44) 21.24 (11.87-37.99) 23.11 (9.09-58.72)
≥4 15.01 (7.65-29.45) 26.42 (13.49-51.77) 34.29 (11.56-101.70)
HIVdb 0-<1 ref. ref. ref.
1-<2 2.55 (1.73-3.75) 3.62 (2.56-5.13) 3.19 (1.91-5.33)
2-<3 5.39 (3.69-7,89) 7.14 (5.06-10.08) 7.21 (4.33-12.00)
3-<4 8.05 (5.59-11.59) 12.51 (8.9-17.51) 10.06 (6.14-16.46)
≥4 7.48 (4.51-12.39) 13.49 (8.25-22.06) 12.28 (5.72-26.35)
Rega 0-<1 ref. ref. ref.
1-<2 2.03 (1.20-3.45) 3.46 (2.03-5.91) 2.75 (1.27-5.99)
2-<3 5.55 (3.41-9.02) 9.72 (5.83-16.22) 8.83 (4.21-18.52)
3-<4 8.97 (5.61-14.38) 19.15 (11.60-31.61) 15.26 (7.42-31.37)
≥4 9.73 (5.53-17.11) 19.34 (10.70-34.94) 19.40 (7.93-47.48)
 Logistic regression analysis evaluating the association between undetectable viral load and the GSS 
groups (with GSS group 0 - <1 as reference) at different time points for the three interpretation systems. 
The number of treatment-change episodes for the GSS group 0-<1, 1-<2, 2-<3, 3-<4, and ≥4 are: 178, 
389, 485, 959, and 142 at 12 weeks; 157, 433, 638, 1206, and 142 at 24 weeks; 62, 182, 242, 540, and 
59 at 48 weeks. These numbers were similar for the three systems. 
DISCUSSION
In this study, data from treated HIV-1 patients were modeled to predict virological 
outcome comparing genotypic drug resistance with the most commonly used 
interpretation systems. We used logistic regression and AUC calculations and 
showed in 3,763 treatment change episodes that ANRS, HIVdb, and Rega, do not 
differ in predicting virological outcomes. 
Comparisons of interpretation systems have been previously reported 
[9,10,15,16,17]. In this work, due to the large study population, we were able to 
compare genotypic susceptibility scores between patients using many different drug 
therapy combinations and control for important possible confounders. The results of 
our study were in agreement with previous findings [10,16]. In addition to previous 
work, our study has extensively looked at the differences between the prediction 
ability of the systems at different time points. We both included short term responses 
(week 12) and longer term responses (week 24 and 48).  
An explanation for the findings in this study is that the systems all make use 
of the same literature available on correlations between genotypic and phenotypic 
analyses as well as correlations with treatment history and clinical response. 
Several studies showed small changes in genotypic susceptibility scores 
between different systems. For example Ravela et al. [18], that compared 4 different 
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interpretation systems (including ANRS, HIVdb, and Rega), reported a 4.4% 
complete discordance, with at least 1 system assigning susceptible and another 
system assigning resistant; 29.2% displayed partially discordance; and 66.4% were 
complete concordant. However, in this study we found that these differences do not 
have a large influence on the virological outcome of treatment. 
A possible limitation of studies comparing different interpretation systems 
lies in the translation of the indications from the interpretation systems into numeric 
values, which are taken arbitrarily. However, we have used the same principles 
used by authors of HIV drug-resistance algorithms for calculating the genotypic 
susceptibility score. Therefore we were able to compare the three systems in the way 
they are used in practice. We also used the Rega scores without the suggestions 
about weighting of scores for boosted PI drugs and NNRTI. Using these unadjusted 
scores did not change in GSS distributions and virological outcome to a great extent. 
Some novel drugs (etravirine, darunavir, tipranavir) were not frequently used 
in our study population. Similarly, drugs belonging to the newly approved classes, 
such as raltegravir and maraviroc, were not included. Therefore, the predictive value 
we found is not a validation for all individual rules in the system and we did not 
attempt to validate individual rules. Continuous validations in large dataset with 
recent drug data will therefore remain needed. 
No restriction on therapies was performed; therefore suboptimal regimens 
(fewer than three full-dose drugs) were included. However, the group of patients 
receiving suboptimal regimens was small and the same for all three interpretation 
systems. Furthermore, it was previously demonstrated that removal of suboptimal 
treatment reduces the accuracy of the models [19].
Much discussion has been going on about which follow-up period is most 
suitable to validate a system. Short term responses might be more directly attributable 
to the antiviral drug activity whereas longer term outcomes might be more clinically 
relevant but more easily confounded by other issues such as loss in adherence, drug 
discontinuations and switches [20]. In our study less than 1/3 of all cases were left 
at the 48 week time point measurement. This loss to follow up creates selection bias 
in this group. Therefore, this 48-week-group may not be representative of the whole 
study population. The patients, who remain on therapy until the 48th week after start 
of therapy, will do better on therapy and will have better virological responses than 
patients who switch to another therapy at earlier stages. In accordance, we found 
stronger associations between interpretation systems and virological outcomes at 
later time points compared to earlier time points in the logistic regression analyses. 
However, in the logistic regression that compared the different GSS groups to the 
GSS group of 0 to <1, the odds ratios were similar between week 24 and week 
48. Therefore, week 24 may be a well suitable time point to measure long term 
responses. However, confidence intervals in week 48 were large, because of low 
numbers of included TCEs, therefore creating a bias at this time-point.
In conclusion, we found that the three most commonly used interpretation 
systems do not differ in their ability to predict virological response. Also, when looking 
into different time points, the prediction abilities between the systems were similar. 
Since the overall performance is comparable, these systems might evolve towards 
a more consistent scoring in the future. New breakthroughs might be needed for 
further improvement in genotypic resistance test interpretation. 
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TO THE EDITORS:
Transmitted drug resistance (TDR) can limit treatment options in patients newly 
infected with human immunodeficiency virus (HIV) [1]. The increasing global access 
to antiretroviral drugs and a prevalence of TDR of around 10% in many countries 
[2-4] are indications that TDR is an important problem. For this reason the WHO has 
developed a consensus list of mutations for the global surveillance of TDR as well as 
detailed guidelines for TDR surveillance and prevention [5-6]. The WHO lists have 
been updated regularly and used extensively [1, 7-13]. The most recent WHO list, 
which was published by Bennett et al., is based on mutations that are included in 
three or more of five expert lists of drug resistance mutations. Furthermore, mutations 
had to be non-polymorphic defined (with a few exceptions) as being present at a 
frequency <0.5% in all major subtypes in a dataset of more than 6000 antiretroviral 
therapy-naive individuals. Thus, Bennett et al. have provided the best available 
estimates of polymorphisms levels in treatment-naïve patients. Nonetheless, 
application of the WHO list may result in overestimation of TDR because the sum 
of polymorphisms across all surveillance drug-resistance mutation positions may be 
as high as 4.8% (for CRF01_AE), which is a substantial proportion of TDR reported 
from many developed and developing countries [2-4, 7-14].  
The purpose of this study was to examine how polymorphisms in the WHO 
consensus list affect the accuracy for surveillance of TDR. Furthermore, the WHO 
has recommended a threshold survey that classifies TDR prevalence in resource-
poor settings into three categories to avoid large-scale expensive genotypic 
resistance testing. We have evaluated the effect of polymorphisms at amino acid 
sites associated with drug resistance on this WHO classification
We define polymorphisms as naturally occurring amino acid substitutions 
seen in low proportions in the absence of selective drug pressure at the drug-
resistance-related positions included in the WHO consensus list [5]. Bennett et 
al. calculated the levels of these polymorphisms by excluding sequences with two 
or more drug-related-mutations for the reason that these sequences would likely 
have resulted from previous treatment. We calculated the overall polymorphism 
prevalence as the sum of the prevalence of individual polymorphisms for the three 
drug classes: nucleoside reverse transcriptase inhibitors; non-nucleoside reverse 
transcriptase inhibitors; and protease inhibitors. This calculation was justified 
because no sequence had more than one resistance mutation. We choose to 
investigate the two most common subtypes B (polymorphism prevalence: 4.0%) and 
C (2.1%), as well as subtypes G and CRF01_AE which had the lowest and highest 
prevalence of polymorphisms (1.4% and 4.8% respectively). Positive predictive 
values were calculated, which indicated the proportion of patients with surveillance 
drug-resistance mutations that represented real TDR (hereafter called true TDR), 
rather than the presence of polymorphisms, among all patients with observed TDR 
mutations. 
 For the classification of TDR prevalence, the WHO threshold surveys 
recommend to perform resistance testing on a minimum of 34 samples and assess 
if between 1 - 5 samples have resistance mutations [15]. If the number is outside 
this range further sampling is not required and the prevalence of TDR is classified as 
being <5% or >15%, otherwise additional samples are tested. Sampling is continued 
until 47 samples have been tested or until the number of samples with resistance 
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mutations is outside a pre-defined range. Therefore, we set up a simulation where 
34 patients where checked for having TDR. If at the 34th patient, no decision could 
be made according to the WHO threshold, then up to 13 more patients were included 
in the simulation. The TDR prevalences were categorized into three strata, <5%, 
5-15%, and >15%, according to WHO recommendations. Using 1000 different Monte 
Carlo simulation, we classified resistance based on randomly generated uniformly 
distributed numbers which created specific resistance levels we were interested in. 
Different scenarios were set up to investigate the impact of polymorphisms on the 
WHO classification of TDR prevalence.
Table 1. Proportion of correct WHO TDR prevalence categorizations simulated (n=1000) for different 
prevalences of true TDR and polymorphisms for subtypes B, C, G and CRF01_AE.
Subtype True 
prevalence of 
TDR (%)
Prevalence of 
polymorphisms1
(%)
Distribution of TDR categorizations (%)
TDR category
<5%
TDR category 
5-15%
TDR category
>15%
Any 4 0 48 52 0
Any 10 0 7 85 8
B 0 4.0 51 49 0
C 0 2.1 77 23 0
G 0 1.4 87 13 0
CRF 01_AE 0 4.8 40 60 0
B 4 4 15 85 4
C 4 2.1 26 73 1
G 4 1.4 33 67 0
CRF 01_AE 4 4.8 10 86 4
B 10 4.0 1 68 31
C 10 2.1 3 80 17
G 10 1.4 4 82 13
CRF 01_AE 10 4.8 1 64 35
Proportion of correctly categorized simulated TDR prevalences is highlighted in light gray. 1 For subtypes 
B, C, G and CRF01_AE the prevalence of polymorphisms were obtained from Bennett et al. [5]; TDR, 
transmitted drug resistance.
 We calculated positive predictive values for subtype B, C, G and CRF01_AE 
for observed TDR levels of 5%, 10%, and 15%. At an observed TDR level of 5%, 
positive predictive levels were low especially in CRF01_AE (4%) and subtype B 
(20%), which have high reported levels of polymorphism, and somewhat higher in 
subtype C (48%) and G (72%). At a higher observed TDR prevalence of 10%, the 
proportion of correctly identified cases of TDR increased and ranged from 52% in 
CFR01_AE to 86% in subtype G. At an observed TDR level of 15% the positive 
predictive value ranged from 68% in CRF01_AE to 91% in subtype G. 
Table 1 shows the effect of different levels of polymorphisms and true 
prevalence of TDR on the accuracy of the WHO approach for TDR sampling and 
categorization, calculated in the different simulation-scenarios. In the first two 
scenarios we simulated the WHO approach in populations with no polymorphism 
(0%) and a true prevalence of TDR of 4% and 10%, respectively. We found that the 
WHO categorization strategy was correct in less than 50% of the simulations when 
the true prevalence of TDR was low (4%), but successful in 85% of the simulations 
when the true TDR prevalence was higher (10%). We next simulated more realistic 
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scenarios with the specific polymorphism levels for the different subtypes estimated 
by Bennett et al. and a true TDR prevalence of 0%, 4% and 10%. As shown in table 
1, the high level of polymorphisms in CRF01_AE had a dramatic impact on the 
classification of the prevalence of TDR. If we set the true TDR prevalence at 0% in 
our simulations, we found that there was a 60% probability that TDR was classified 
as 5-15%. Furthermore, incorrect categorization was even more common when the 
true TDR prevalence was just below the 5% cut-off, i.e. 4%. In these scenarios the 
TDR prevalence was typically incorrectly classified into the 5-15% category. Thus, 
the WHO TDR categorization would be expected to be incorrect 85% of the time for 
subtype B and 86% of the time for CRF01_AE when the true prevalence of TDR 
is 4%. As further discussed below these results are based on the assumption that 
Bennett et al. have correctly estimated the prevalence of polymorphisms in treatment 
naïve patients. 
In this paper the effect of naturally occurring sequence polymorphisms on 
TDR was evaluated using different ranges of polymorphism levels and TDR. With 
these approaches we showed that polymorphisms can have a large impact on the 
estimated prevalence of TDR. 
There is an inverse relationship between the likelihood of correctly 
estimating the prevalence of TDR and the presence of polymorphisms: the higher 
the prevalence of polymorphisms, the lower the likelihood of correctly estimating 
the prevalence of TDR. Therefore, the presence of polymorphisms affects the 
accuracy of the classification method recommended by the WHO and may lead to an 
incorrect categorization of TDR prevalence. This is especially relevant in resource-
poor settings, where WHO recommends that TDR prevalences greater than 5% 
should trigger several actions, such as performing extra research and more frequent 
surveillance studies [15].
It is important to stress that our findings are based on the assumption that 
the prevalence of polymorphisms have been correctly estimated by Bennett et al. 
[5]. In fact, they give two possible explanations for the non-zero background level 
of mutations at drug resistance positions. First, the mutations may be caused by 
true polymorphisms. This can be caused by nucleotide misincorporations by the 
error-prone reverse transcriptase enzyme during replication of the HIV-1 genome 
in combination with cytotoxic T lymphocyte immune selection pressure; an example 
is the M46I mutation [16]. Secondly, the dataset may have contained patients with 
unreported prior treatment or TDR. We feel that it would be very valuable to dissect 
the relative contribution of these two possibilities. Thus, we advocate for studies 
on sufficiently large numbers of samples for which unreported prior treatment or 
TDR can be ruled out with 100% certainty, i.e. ideally samples collected before 
antiretroviral therapy had been introduced. However, the collection of such a dataset 
is difficult to achieve. 
Because the level of polymorphisms levels might be biased by patients 
with unreported prior treatment and TDR, the impact of these polymorphisms on 
the estimated prevalence of TDR might be smaller than indicated in our paper. 
However, even if a perfect estimate of polymorphism levels could be generated, it is 
very likely that some low-level of polymorphisms will always be present. Therefore, 
we feel that it always will be necessary to adjust TDR estimates for the level of 
polymorphisms, especially when the true prevalences of TDR are expected to be 
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low. In this context, it should be pointed out that the prevalence of TDR may also 
be under-estimated because routine assays for genotypic resistance testing (i.e. 
population Sanger sequencing) cannot detect minority resistance mutations [17]. 
These minority mutations can influence the response to therapy [18]. 
In conclusion, polymorphisms are likely to have a large impact on the 
estimates of TDR prevalence and the level of polymorphisms need to be more 
accurately estimated and adjusted for in TDR surveillance and prevention. 
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ABSTRACT
Background: About 10% of all patients newly diagnosed with HIV-1 are infected 
with a virus carrying a drug resistance mutation. HIV-1 genotyping before start of 
treatment is therefore recommended in most guidelines. In recent years, however, 
baseline genotyping mostly identifies mutations conferring resistance to antiretroviral 
drugs that are not used anymore. The aim of this study is therefore to determine 
cost-effectiveness of baseline-genotyping in the Netherlands.
Methods: We designed a probabilistic state-transition model to project clinical 
and cost outcomes in a hypothetical cohort of antiretroviral-naïve patients with 
a HIV-infection in the Netherlands. The overall prevalence of transmitted drug 
resistance mutation (TDRM) was taken to be 8.7% from the 2010 Dutch prevalence 
data. This most frequently involved TDRM for nucleoside reverse transcriptase 
inhibitors (5.7%), followed by protease inhibitors (2.1%) and non-nucleoside reverse 
transcriptase inhibitors (1.9%). Rates of efficacy of treatment, virological failure, 
opportunistic infections, mortality and health-related utilities were derived from 
published randomized clinical trials, observational cohort studies, and data from a 
Dutch HIV care centre.
Results: The magnitude of the cost-effectiveness ratio decreased when the reduction 
in failure rate of first line regimens increased (€1.2 million, €220,000, and €94,000 
per QALY gained for absolute failure rate differences of 1, 5, and 10%, respectively). 
A 10% absolute failure rate difference would be achieved, for example, when TDRM 
is found in 20% of HIV patients. Subsequently, of these TDRM, half would cause 
resistance to the prescribed first-line regimen and therefore experience virological 
failure, while genotypic testing would prevent all these failures. The cost-effectiveness 
did not decrease to reasonable values unless the absolute reduction rate difference 
in patients with baseline genotypic testing exceeded 20% (€30,000). Nonetheless, 
genotypic testing showed to be more cost-effective in patients with a CD4 count 
below 200 cells/mm3 compared to patients with a CD4 count of >200 cells/mm3, with 
cost-effectiveness ratios of €65,000 and €330,000 per QALY gained, respectively, 
at an absolute reduction in failure rate of 5%. Additionally, reducing the costs of 
genotypic testing by half (by limiting sequence testing to reverse transcriptase only) 
lowered the cost-effectiveness ratio by 50%.  
Conclusion: In 2012, routine use of baseline genotypic testing in all newly HIV-1 
infected patients is no longer cost-effective. The use of routine baseline genotypic 
testing should therefore be reconsidered for use in sub-groups.
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INTRODUCTION
The use of combination antiretroviral therapy has strongly reduced morbidity and 
mortality among patients infected with HIV [1]. Unfortunately, transmission of drug 
resistant mutations, currently at a rate of 10-15% [2-7], can hamper the success of 
antiretrovirals. This has recently been shown in a pan-European study, which showed 
that transmission of drug resistance is associated with an increased probability for 
virological failure [8]. Detection of drug resistance associated mutations through 
genotypic testing can help to construct a first line antiretroviral regimen that is 
virologically fully effective against the drug resistant virus [9]. Therefore, current 
treatment guidelines recommend use of resistance testing in naïve patients [10-11]. 
Furthermore, the economic impact of baseline genotypic testing has been addressed 
by several studies in the past [12-14], showing that baseline genotypic testing was 
cost effective. 
To a great extent, the cost-effectiveness of baseline genotypic testing 
depends on, among other things, the prevalence and nature of transmitted drug 
resistance mutations (TDRM) in the population. We showed in a recent European 
TDRM surveillance study that most TDRM do not cause resistance to nucleos(t)
ides (tenofovir, emtricitabine, and lamivudine) currently popular in first-line regimens 
[15]. As a consequence, the three published cost-effectiveness studies (performed 
in 1998-2001 [12-14], when these data and drugs were not available) do not reflect 
the current situation in Europe. Mortality rates and opportunistic infections in HIV 
patients have also decreased substantially over time, irrespective of the CD4 cell 
count as a reflection of improved clinical care [16-17]. Therefore, data on clinical 
parameters and resistance prevalences used in previously published studies on 
cost-effectiveness of baseline genotypic testing are no longer valid. 
In light of the issues mentioned above we decided to evaluate the cost-
effectiveness of routine baseline genotypic using data from the Netherlands. 
METHODS
Model structure
Population
The analyses were performed using a probabilistic state-transition model to project 
clinical and cost outcomes in HIV-infected individuals. The target population consisted 
of HIV-infected patients with characteristics similar to HIV-infected individuals 
that started HAART in the Netherlands in 2010 (table 1) [18]. The prevalence of 
TDRM among newly diagnosed patients in the Netherlands was 8.7%. This most 
frequently involved TDRM for nucleoside reverse transcriptase inhibitors (NRTIs) 
(5.7%), followed by protease inhibitors (PIs) (2.1%) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (1.9%). We predicted resistance to particular drugs 
using the Stanford HIV database system (version 6.2.0). It was found that 4% of all 
patients were infected with a virus with intermediate or high-level resistance [19]. 
High-level resistance was mostly found in the NNRTI drug class (1.7%), followed by 
PI (0.5%) and NRTI (0.4%), while intermediate resistance was more often observed 
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to the NRTI drug class (1.7%), followed by PI (1.4%) and NNRTI (0.2%). Resistance 
to NRTIs usually involved the thymidine analogues zidovudine and stavudine (97% 
of all isolates with NRTI resistance) that were popular in past treatment. Resistance 
to tenofovir, emtricitabine, and lamivudine was less common (34%, 6%, and 6% of 
isolates with NRTI resistance). Almost all patients carrying NNRTI resistance showed 
high-level resistance to nevirapine (97%), while this was lower for efavirenz (62%). 
Resistance to PIs involved nelfinavir in all patients, which is no longer recommended 
[11, 20]. Resistance to the currently popular boosted PIs atazanavir (19%) and 
darunavir (5%) was much lower. For more details on the target population see the 
report of the Dutch HIV monitoring foundation [18].
  
Treatment
In our cost-effectiveness analyses, we compared a scenario where baseline 
genotyping was not available and a scenario where baseline genotyping was 
available at start of first-line therapy. In the approach where baseline genotyping was 
not available patients received treatment according to current treatment guidelines 
[11, 20]. This means that a random proportion of 80% of patients received first-line 
treatment with tenofovir, emtricitabine and efavirenz. To account for heterogeneity 
in the standard of care for first-line treatment, 10, 5, and 5% received nevirapine, 
boosted darunavir or boosted atazanavir, respectively, instead of efavirenz. In the 
approach where baseline genotyping was available, patients infected with a wild-type 
virus also received treatment according to treatment guidelines as outlined before. In 
patients that were infected with a drug resistant virus, treatment was modified so that 
a fully active regimen was prescribed. 
Virological failure
The proportion of patients experiencing virological failure for different susceptibility 
levels in Europe is reported by Wittkop et al. [21]. In summary, a patient without 
TDRM that received a NNRTI-containing regimen had a probability of virological 
failure of 2.8%. Similarly, patients receiving a PI-containing regimen had probability 
of virological failure of 2.7%. They found that patients with TDRM that received a 
fully active NNRTI-containing regimen had probability of virological failure of 4.3%, 
while for PI-containing regimens the same probability was seen as was observed in 
patients without TDRM. The probability of virological failure was 10.6% and 10.9% 
in patients infected with a virus resistant to the received NNRTI- and PI-containing 
regimen, respectively [21]. 
However, the virological failure rates found in Wittkop et al. seem quite low 
compared to the virological failure rates ranging between 0 to 14% [22] in randomized 
clinical trials and 4.6 [23], 7 [24], and 8% [25] in recent cohort studies. We therefore 
increased the virological failure rate to 50% and 100% in all patients infected with a 
virus being intermediate- or fully resistant to the prescribed regimen to examine its 
effect on cost-effectiveness. 
Impact on CD4-count
In patients experiencing virological failure, drug plasma levels were measured in 
20% of the patients and CD4 cell counts and HIV RNA levels were measured three 
additional times compared to standard HIV care. Furthermore, in patients with 
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Table 1. Model parameters.
Variable Baseline value Source [Ref]
Cohort characteristics
    Age, mean years 40.9 [19]
CD4 cell count, median cells/mm3  (IQR) 300 (180-360) [19]
Prevalence of transmitted drug resistance [19]
       - Overall 8.7%
       - NRTI 5.7%
       - PI 2.1%
       - NNRTI 1.9%
Virological failure at 12 months in NNRTI-
containing regimens
10% [21]
          - no transmitted drug resistance 2.8%
          - TDRM and full-active cART 4.3%
          - TDRM and resistance to cART 10.6%
Virological failure at 12 months in PI-containing 
regimens
[21]
          - no transmitted drug resistance 2.7%
          - TDRM and full-active cART 2.7%
          - TDRM and resistance to cART 10.9%
Monthly increase in CD4 cell count in patients 
receiving effective HAART, cells/mm3  
          - first half year 23 [27, 43]
          - second half year 10 [27, 43]
Monthly decrease in CD4 cell count in patients 
experiencing virological failure
         - NNRTI regimen 3.7 [26]
         - PI regimen 1.7 [26]
Costs, €
         - therapy (per month) 638-2,230 [32]
         - genotypic testing (per test) 340
         - CD4 cell count (per test) 98
         - HIV RNA level (per test) 67
         - plasma level (per test) 80
         - opportunistic infections (per infection) 1,624-34,697
Health-related quality-of-life score according to 
CD4 cell count, cells/mm3
[34]
         - 0 to 50 0.79
         - 51 to 100 0.81
         - 101 to 200 0.87
         - >201 0.94
     opportunistic infections 0.56 – 0.65
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase 
inhibitors; PI, protease inhibitor; TDRM, transmitted drug resistance mutations; cART, combination 
antiretroviral therapy.
virological failure, we assumed that CD4 cell counts began to decrease, following 
a 1-month lag time after HAART failure [26]. These patients were switched to 
another regimen 6 months after start of therapy. If treatment was successful, the 
CD4 cell count increased [27-28] and treatment was continued. The slope for the 
increase or decrease of CD4 cell count was fixed for 6 months. Every month, the 
distribution of patients was calculated for the following 6 CD4 groups: 0 to 50, 51 
to 100, 101 to 200, 201 to 350, 350 to 500, and >500 cells/mm3. The CD4 count 
was used to predict rates of opportunistic infections and HIV-related death [17, 
29-30]. We assumed decreased rates of opportunistic infections and HIV-related 
death for patients successfully on treatment, independent of CD4 cell count [29-
30]. Patients could enter and exit temporary health states corresponding to acute 
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episodes of cytomegalovirus (CMV) retinitis; Mycobacterium avium complex (MAC) 
infection; cerebral toxoplamosis (TOXO) Pneumocystis jirovecii pneumonia (PCP); 
esophageal candidiasis (EC); pulmonary or extrapulmonary tuberculosis (TB); 
Kaposi’s sarcoma; and non-Hodgkin’s lymphoma. The model was programmed in 
Matlab 7.7.0.
Costs
Calculations were performed according to Dutch cost calculation guideline in health-
care [31], and medication costs were based on Dutch whole-sale prices [32]. Costs 
of opportunistic infections were obtained from the Erasmus medical centre, which 
is a large Dutch HIV care centre. With the large dataset of HIV patients from this 
hospital we were able to calculate costs based on micro-costing assessment. 
Resource utilization included physician visits, emergency visits, and the number of 
hospital days. Use of medical imaging services, medications, laboratory test, and 
blood transfusions were based on expert opinion. The prices of plasma levels, CD4 
cell count levels, and HIV RNA levels were based on hospital integral cost prices 
(Erasmus Medical Centre, Rotterdam). We used the figure of €340 for genotypic 
resistance testing. All costs prices were inflated to 2010 using Dutch consumer price 
index figures [33] (Table 1). All costs are presented in 2010 Euros.
Quality-Adjusted Life-Years (QALYs)
We expressed clinical benefits in quality-adjusted life-years (QALYs) gained, to 
reflect the potential gains in both longevity and quality of life associated with the use 
of baseline resistance testing. Data on health-related quality of life were obtained 
from AIDS Clinical Trials Group protocols 019, 108, 157, and 204 as published in 
Freedberg et al. [34]. These utilities correspond closely to utilities obtained in more 
recent studies [35] where utilities were not available per CD4 cell count group and 
per opportunistic infection. In a 12-month follow-up, this can lead to a value between 
0 and a maximum of 1 QALY, where a QALY of 1 is a year lived in perfect health. 
Given that the analysis was restricted to a 1-year period, discounting was not used.
Scenario analyses
In the baseline scenario, overall prevalence of TDRM was 8.7%. This corresponded 
with relatively high susceptibility scores in the Dutch antiretroviral naïve population. 
In table 2, the proportion of patients in the different susceptibility groups are shown. 
The numbers were multiplied with failure rates for each susceptibility group reported 
in Wittkop et al.[21]. This resulted in a small difference in failure rate (0.18%) 
between the group with and without baseline genotypic testing. Wittkop et al. [21] 
reported low failure rates. We therefore performed worst-case scenario analyses, 
where virological failure was experienced in 50% and 100% of all patients infected 
with a virus being intermediate- or fully resistant to the prescribed regimen. 
Also, to estimate the effect of higher TDRM levels on the cost-effectiveness 
of baseline genotypic testing, we increased failure rates to an absolute difference 
of 1, 5, 10, and 20%. A 10% absolute failure rate difference would be achieved, 
for example, when TDRM is found in 20% of HIV patients. Subsequently, of these 
TDRM half would cause resistance to the prescribed first-line regimen and therefore 
experience virological failure, while genotypic testing would prevent all these 
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failures. This was considered as the most pessimistic scenario possible. An absolute 
difference in failure rate of 20% is an extreme value, which could only be seen if 
TDRM causing resistance to first-line therapy increase strongly.
Finally, we investigated the effect of changing the baseline failure rate 
(failure rate in patients where genotypic testing was performed) from 3 to 10% for 
various levels of absolute reduction in failure rate between patients with and without 
genotypic testing. This analysis was first performed in the baseline scenario. In the 
second scenario targeted testing was carried out for patients with CD4 counts that 
were either below or above 200 cells/mm3 (a CD4 <200 cells/mm3 is associated with 
an increased risk for opportunistic infections and mortality). We also examined the 
effect of physicians prescribing PI-containing regimens (which are more expensive 
than NNRTI-containing regimens) when genotypic testing results are not available 
to avoid virological failure due to NNRTI (minority) mutations. In this scenario, we 
assumed that all patients that did not have a baseline genotypic test result were 
receiving a PI-containing regimen. Finally, prevalence of PI mutations was low. 
We therefore investigated the effect of baseline genotypic testing in the reverse 
transcriptase gene only. 
  
Sensitivity analyses
With the use of sensitivity analyses, we examined the impact of varying key model 
parameters. We studied sensitivity in the scenario of 1 and 10% absolute failure 
rate difference. Antiretroviral treatment and NNRTI drug costs were increased and 
decreased with 50%, as NNRTIs are likely to become generically available in the 
near future and thus less expensive. To assess the impact of a lower or higher 
probability of acquiring an opportunistic infection and related treatment costs, we 
varied the probability and costs by 50%. The costs of genotypic testing and the 
QALYs were increased and decreased with 10%. The impact of these changes on 
the cost-effectiveness was presented in a tornado diagram. 
The results of the cost-effectiveness analysis are summarized using the cost-
effectiveness ratio, in which each strategy with testing is compared incrementally 
with a strategy that does not employ resistance testing. 
RESULTS
Main results
We performed different analyses in which we used various levels of virological failure 
that could be observed in the presence and absence of baseline genotyping. We 
first did an analysis in which we calculated expected rate of virological failure based 
on a previous paper by Wittkop et al. [21]. Only a small proportion of patients in the 
group where genotypic testing was not performed were infected with a virus that 
was intermediate- or fully resistant to the drugs that were prescribed (table 2). As a 
consequence, the expected absolute difference in virological failure rate between the 
group of patients with or without genotypic testing was only 0.18% using failure rates 
reported by Wittkop et al. [21] (table 3). This small difference in proportion of patients 
failing treatment led to a very small difference in CD4 counts and subsequently 
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Table 2. Proportion of patients in different susceptibility groups. 
without baseline genotypic testing with baseline genotypic testing
NNRTI regimen PI regimen NNRTI regimen PI regimen
No TDRM 82.17 9.13 82.17 9.13
TDRM and fully-active cART 5.23 0.63 7.83 0.87
TDRM and intermediate 
resistance to cART 1.53 0.22
TDRM and resistance to cART 1.07 0.02
NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; TDRM, transmitted drug 
resistance mutation; cART, combination antiretroviral therapy.
Table 3. Effectiveness, cost and cost effectiveness.
Scenarios Reduction 
in failure 
rate, %
QALYs Total costs, € Costs per 
QALY 
gained, €
Baseline 
genotype 
test
No baseline 
genotype 
test
Baseline 
genotype 
test
No baseline 
genotype 
test
Absolute failure 
rate difference
      1% 1 0.920 0.920 11,280 10,933 1.2 million
      5% 5 0.920 0.919 11,217 10,970 220,000
     10% 10 0.920 0.918 11,217 11,017 94,000
     20% 20 0.920 0.915 11,217 11,109 30,000
Wittkop scenario 0.18 0.920 0.921 11,217 10,926 6.6 million
worst-case 
scenario 1 1.30 0.920 0.920 11,217 10,936 935,000
worst-case 
scenario 2 2.72 0.920 0.920 11,217 10,949 430,000
QALY, quality adjusted life year; Worst-case scenario 1: the virological failure rate in untested patients 
with intermediate- or fully resistance to the prescribed drugs was assumed to be 50%. This led to a failure 
rate difference between the tested and untested patients of 1.30%; Worst-case scenario 2: the virological 
failure rate in untested patients with intermediate- or fully resistance to the prescribed drugs was assumed 
to be 100%. This led to a failure rate difference between the tested and untested patients of 2.72%. 
opportunistic infections and mortality between patients where a baseline genotype 
was available or not. This also explains that the QALY estimations in both groups 
were approximately equal (0.92). On the other hand, baseline genotypic testing 
increased health-care costs with 347 euro per person, leading to an incremental 
cost per QALY of €6.6 million for the baseline genotypic testing strategy.
 We also determined cost-effectiveness using higher absolute differences in 
virological failures between patients with and without baseline genotyping. In the 
worst-case scenario where 50% of all patients experienced virological failure when 
showing intermediate- or fully resistance to the prescribed drugs, the reduction in 
failure rate increased slightly to 1.30%. This failure rate reduction resulted again 
in a substantial cost-effectiveness ratio of €935,000 per QALY gained. When we 
assumed that all patients showing intermediate- or full resistance to the prescribed 
drugs were experiencing virological failure, the absolute reduction in failure rate 
increased to 2.72% and testing cost changed to €430,000 per QALY gained. 
The magnitude of this cost-effectiveness ratio decreased in the other 
scenarios that were analyzed. For example, if a subset of patients showed an 
absolute reduction in failure rate of 10% in patients with- compared to patients 
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without baseline genotypic testing, cost-effectiveness decreased to €94,000 per 
QALY gained. The cost-effectiveness did not decrease to reasonable values unless 
the reduction rate difference exceeded 20%.
Changing baseline failure did not have any effect on the results, as shown 
in table 4. Furthermore, this table shows the effect of targeted genotypic testing 
in patients who were diagnosed with a CD4 <200 cells/mm3. When performing 
genotypic testing in patients with a CD4 cell count below 200 cells/mm3 we observed 
reasonable cost-effective ratios of €65,000 and €24,000 per QALY gained at an 
absolute reduction in failure rate of 5% and 10%, respectively. For patients with 
CD4 counts above 200 cells/mm3, baseline genotypic testing appeared to be less 
cost-effective (€150,000 per QALY gained at an absolute reduction in failure rate 
of 10%). Prescribing PI-containing regimens to patients without baseline genotypic 
testing lowered the cost-effectiveness ratio minimally (from €220,000 to €210,000 
per QALY gained at an absolute reduction in failure rate of 5%). Finally, performing 
genotypic testing in only reverse transcriptase lowered the cost-effectiveness ratio 
with approximately 50%, resulting in a cost-effectiveness ratio of €33,000 per 
QALY gained at an absolute reduction in failure rate of 10%. The increase in failure 
rate is small in this scenario as only 13% and 2% of patients infected with a virus 
intermediate- and fully resistant to the prescribed drugs, respectively, is harbouring 
PI resistance. 
Sensitivity analyses
The results of the sensitivity analyses in the scenario where the absolute failure 
rate difference was 1% are presented in figure 1A. This tornado diagram ranks 
the parameters based on the magnitude of their impact on the cost-effectiveness 
per QALY. The diagram clearly shows that QALY scores and genotypic test costs 
have the highest impact on the model outcome. However, even then, the lowest 
cost-effectiveness ratio fell far from the cost-effective cut-off, revealing that the 
Table 4. Sensitivity analyses: impact of baseline failure rate and absolute difference in failure rate between 
patients with and without genotypic testing on cost-effectiveness. 
Failure rate 
baseline
Absolute reduction in failure rate
1% 3% 5% 10%
Baseline scenario 3% 1.2 million 390,000 220,000 94,000
10% 1.2 million 390,000 220,000 94,000
Targeted testing
<200 CD4 cells/mm3 3% 385,000 120,000 65,000 24,000
10% 390,000 120,000 65,000 24,000
>200 CD4 cells/mm3 3% 1.8 million 580,000 330,000 150,000
10% 1.8 million 580,000 330,000 150,000
Change to PI 
regimen
3% 1.2 million 375,000 210,000 88,000
10% 1.2 million 370,000 210,000 87,000
Genotypic 
testing in reverse 
transcriptase only
3% 575,000 175,000 95,000 33,000
10% 580,000 175,000 95,000 33,000
PI, protease inhibitor.
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Figure 1. Tornado diagram of the sensitivity analyses.
This diagram summarizes the results of the sensitivity analyses on the incremental cost-effectiveness 
of baseline genotypic testing in a) scenario with an absolute failure rate of 1%, and b) scenario with 
an absolute failure rate of 10%; parameter values of 50% and 150% or 90% and 110% of the baseline 
scenario value were evaluated and these values are shown on both sides of the bars; QALY, quality 
adjusted life year; NNRTI, non-nucleoside reverse transcriptase inhibitors.
parameters did not have a very large impact on the results. Opportunistic infection
rate and treatment costs had a moderate effect on cost-effectiveness. For the 
remaining parameters, the model proved to be robust to changes. In the scenario 
with an absolute failure rate difference of 10%, the tornado diagram showed a very 
similar structure (figure 1B). However, due to lower cost-effectiveness ratio in this 
scenario, a larger decrease in costs of genotypic testing than shown here could 
make baseline genotypic testing cost-effective. 
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DISCUSSION
Our results show that baseline genotypic testing is not cost-effective. The magnitude 
of this cost-effectiveness ratio decreased with increasing reduction in failure rate 
(€1.2 million, €220,000, and €94,000 per QALY gained for absolute failure rate 
differences of 1, 5, and 10%, respectively). When we applied the expected rates of 
virological failure as reported by Wittkop et al. [21] we found a cost-effectiveness 
of more than 6 million euro’s per QALY gained. Increasing the virological failure to 
50 and 100% in patients infected with a virus intermediate- of fully resistant to the 
prescribed drugs, gave lower cost-effectiveness ratios of €935,000 and €430,000 
per QALY gained, respectively. In the Netherlands, no fixed threshold for cost-
effectiveness is used. However, there is a reasonable consensus about the cost-
effective threshold lying between 20.000 to 80.000 Euros per QALY depending on 
the disease [36]. Therefore, even in the most extreme scenario, baseline genotypic 
testing would not be considered cost-effective. However, in patients with low CD4 
cell counts, the cost-effectiveness ratio decreased to €65,000 per QALY gained 
at an absolute reduction in failure rate of 5%. Furthermore, if resistance testing is 
performed in the reverse transcriptase gene only, the cost-effectiveness ratio was 
reduced by approximately 50%.
Our results are very different from the cost-effectiveness studies on baseline 
genotypic testing that have been performed in the past when different drugs were used 
in first line therapy [12-14]. Corzillius et al. [14] reported in 2004 a cost-effectiveness 
ratio of €22,510 per life-year gained in Germany. Sax et al. [13] showed in 2005 that 
the cost-effectiveness ratio remained less than $50,000 per QALY gained, unless 
the prevalence of resistance was ≤1%. Weinstein et al. [12] reported in 2001 a cost-
effectiveness of $22,300 per QALY gained with a TDRM prevalence of 20%, and 
$69,000 per QALY gained with 4% prevalence. 
This large discrepancy between our study and the reports in literature can 
predominantly be explained by the difference in calculating the failure rate. Previous 
studies based virological failure rates on studies among treatment experience 
patients that failed treatment [37-38]. To calculate failure rates Weinstein et al. [12] 
used the VIRADAPT trial and the Havana trial, and Corzillius [14] the VIRADAPT 
trial. The VIRADAPT trial showed a relative risk of 0.79, that is, the probability of 
primary treatment failure was reduced by 21% [37]. The Havana trial showed a fairly 
similar value of 0.81% [38]. Sax et al. [13] used several clinic trials where in some of 
the trials genotypic testing was performed and in others not. All these trials estimated 
the effect of genotypic testing on virological failure in treatment-experienced patients 
and not in treatment-naïve patients. 
In our study, we used a different approach. We assumed that patients could 
only fail due to TDRM, when these TDRM were causing intermediate- or full resistance 
to the prescribed drugs. For the failure rate in these patients we used failure rates 
reported by Wittkop et al. [21], which gave us a fairly low proportion of patients 
without TDRM experiencing virological failure (2.91%). Many studies have examined 
the efficacy of current treatments, showing virological failure rates varying between 0 
to 14% [22] in clinical trials and 4.6 [23], 7 [24], and 8% [25] in recent cohort studies. 
This can be explained by the fact that Wittkop et al. [21] estimated failure rates in 
patients after being six months on therapy. Also, the virological failure rates found 
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in Wittkop et al. [21] may be dependent upon underlying mutation profiles, which 
might be different in our study population. We therefore performed a worst-case 
scenario analysis, increasing the virological failure by assuming that 50 and 100% 
of all patients infected with a virus intermediately- or fully resistant to the prescribed 
drugs experienced virological failure. This increase lowered the cost-effectiveness 
ratio by approximately 7 and 15 times, respectively. However the cost-effectiveness 
ratio was still far from being cost-effective. Increasing the baseline virological failure 
from 3 to 10% did not have any effect on the cost-effectiveness analyses.
The difference between the results in this study and baseline genotypic 
testing studies previously published could not only be described to difference in 
failure rate calculations. Even when looking at cost-effectiveness ratios at the same 
reduction in failure rate as was used in the Weinstein et al. study [12], we found 
higher cost-effectiveness ratios. Weinstein et al. reported cost-effectiveness ratios 
of $69,000, $22,300, and $16,100 per QALY gained at a reduction in failure rate of 
1, 5, and 10%, respectively. We however, found at the same reduction of failure rate 
levels, respectively, higher ratios of €1.2 million, €220,000, and €94,000 per QALY 
gained.
 The difference between cost-effectiveness ratios at similar failure rate levels 
between our study and Weinstein et al. [12] can be explained by several other 
parameters in our model, for which we used differing estimates. First, other values 
were taken for CD4 decrease in failing patients. All three previously published studies 
took estimates from a study reporting a CD4 decrease of 76.5 cells/mm3 at HIV-1 
RNA concentrations of >30,000 per year [39]. This study started when antiretroviral 
therapy was not yet available and consequently 63% of participants received mono-
therapy. In the subgroups that did or did not receive antiretroviral therapy during 
follow-up, no difference was seen in rate of developing AIDS. Today, the efficacy 
of antiretroviral therapy has increased greatly [22] and even in patients failing on 
treatment, a smaller decrease in CD4 is reported [26] than in Mellors et al. [39]. For 
the definition of the increase in CD4 count in patients successful on treatment, the 
previous studies used data from clinical trials [40-42] that showed lower efficacies 
compared to those reported in clinical trials of current regimens [27, 43]. Additionally, 
rate of opportunistic infections has decreased largely over time. Opportunistic rates 
from the recent EuroSIDA study [29] are small as compared to opportunistic rates 
observed in the Multicenter AIDS Cohort Study [44] as used by Weinstein et al. 
[12]. The mortality rates also came from the Multicenter AIDS Cohort Study [44], 
but not specifically mentioned. However, use of antiretroviral treatment has reduced 
mortality independent of CD4 count [30]. Sax et al. [13] also adjusted for the benefits 
of antiretroviral treatment as they decreased the opportunistic infection rate and 
death to 54% in treated patients as was shown in Mellors et al. [39].
A large difference was seen in the cost-effectiveness of baseline genotypic 
testing between patients with a CD4 cell count above or below 200 cells/mm3. In 
patients with low CD4 cell counts, the cost-effectiveness ratio decreased to €65,000 
per QALY gained at an absolute reduction in failure rate of 5%. This can be explained 
by the association of low CD4 cell counts and an increased risk for opportunistic 
infections and mortality [17, 29-30].
A limitation of this study is the short-term follow-up. The viruses in failing 
patients may develop extra resistance; therefore extra costs may be needed for 
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second-line and salvage antiretroviral regimens. Also, the decrease in treatment 
options will lower the potential years of life lost due to premature death [45]. 
However, the development of extra mutations would not be a major problem as this 
is only limited to the first half year in our study. Furthermore, we should be careful in 
extrapolating results from this study to other European countries due to differences 
in costs. However, our expectation would be that cost-effectiveness studies in other 
European countries would point in the same direction.
The costs of opportunistic infections were calculated with patient data. When 
patient data did not follow guidelines, we checked expert opinion to validate this. 
We noticed that hospital-days are the major contribution to costs of opportunistic 
infections. Co-morbidity complicates the calculation of hospital days contributed by 
one opportunistic infection. However, this would not have a major impact on our 
cost-effectiveness calculations as costs of opportunistic infections was a parameter 
with only a small impact on the model outcome as shown in the sensitivity analyses.
Our data suggest that especially in patients with high CD4 cell count, baseline 
genotypic testing is not cost-effective. However, if baseline genotypic testing were 
no longer standard practice, this could have major implications. First, the data of 
genotypic testing assays can be used for surveillance purposes. When baseline 
genotypic testing is not standard practice, we might have a great loss of insight 
into the epidemiology of TDRM. Also, the cost-effectiveness study was performed 
on a population level, whereas on an individual basis some patients may benefit 
significantly from baseline genotypic testing. Furthermore, when physicians would 
not have access to genotypic information of a patients’ virus, they might change their 
prescribing behaviour. Because NNRTI mutations often cause full resistance to NNRTI 
drugs, physicians might more often choose to prescribe PI drugs in order to avoid 
virological failure. PIs are more expensive than NNRTIs and costs may therefore go 
up once baseline-genotyping is no longer performed. We adjusted for this effect in 
our analyses, thereby showing that the change to PIs only causes a small decrease 
in the cost-effectiveness ratio. The cost-effectiveness could, however, decrease 
more in the near future as NNRTIs are likely to become generically available. Since 
the costs of these generic NNRTIs are not yet known, we were not able to take this 
into account in our analyses. 
Besides targeting baseline genotypic testing, we could limit population-
based nucleotide sequencing to only the reverse transcriptase gene of the virus. 
Because TDRM levels to PIs are low in our dataset, and other published surveillance 
studies [2], sequencing the protease gene of the virus seems unnecessary. Without 
sequencing the protease gene, the population sequencing test cost would be 
substantially reduced to half of the current sequencing cost. We showed in this study 
that this also lowers the cost-effectiveness by approximately 50%. Also, performing 
NNRTI minority assays might be a good alternative. Population sequencing fails 
to identify drug-resistant minority variants that are present in <20% of the virus 
population infecting a patient [46-47]. These minority variants have been detected 
in almost 14% of antiretroviral naïve HIV-infected individuals [48]. The presence of 
minorities, particularly involving NNRTI resistance, is associated with an increased 
risk of virological failure to first-line therapy [48]. If minority assays would be 
implemented as standard practice, costs may lower considerably. With low costs and 
the provision of valuable information on minority NNRTI mutations, this test could 
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improve health care in HIV patients. 
In conclusion, with different calculations of failure rate reduction and 
improvement of health-care in HIV-patients cost-effectiveness ratios changed from 
being cost-effective in previous studies to being far from cost-effective in our study. 
The use of routine baseline genotypic testing should therefore be reconsidered. 
Possibilities for reducing costs could be to limit baseline genotypic testing to a 
targeted population, to perform resistance testing only for the reverse transcriptase 
gene, or performing NNRTI minority assays only.
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1 Introduction
The use of combination antiretroviral therapy has strongly reduced morbidity and 
mortality among patients infected with HIV [1]. However, the success of antiretroviral 
drugs has been limited by the emergence of drug-resistant variants which occur 
frequently in patients with virological failure and may decrease both the magnitude 
and the duration of the response to treatment [2]. Transmission of resistant viruses 
between individuals has been observed in approximately 10-15% of antiretroviral 
naïve patients in Europe [3-6] and North America [7-8]. These individuals are at 
higher risk for developing virological failure to combination antiretroviral therapy [9]. 
 This PhD thesis deals with transmitted drug resistance mutations (TDRM) and 
has been divided in three different parts. The first part focuses on the epidemiology 
of transmission of drug resistance and includes studies on the prevalence and 
time trends of transmitted drug resistance in, respectively, the world, Europe and 
among individual transmission groups in Europe. The second part examines the 
interpretation of acquired- and transmitted- drug resistance mutations. In the last 
part of the thesis, a study is presented on cost-effectiveness of baseline genotypic 
testing in the Netherlands. 
2 Overall trends in transmitted drug resistance
2.1 Overall trends in resource-rich settings
High prevalence of TAM
As shown in chapter 2, 3, and 4, high TDRM prevalence to nucleos(t)ide reverse 
transcriptase inhibitors (NRTIs) was found in North America (8.2% -WATCH study 
in chapter 3 and 7.4% -systematic review in chapter 2) and Europe (>5.0%). Also, 
in chapter 3 and 4, we reported that most NRTI TDRM in Europe (62% in chapter 
3, 84.4% in chapter 4) and in North America (79%) were of the thymidine analogue 
mutations (TAMs) class that are associated with resistance to zidovudine and 
stavudine. The highest prevalence on these continents was found for the revertant 
mutations at position 215 (>45% of NRTI TDRM). 
This high prevalence of NRTI TDRM and especially TAMs can be explained 
by the prolonged use of these drugs in non-suppressive regimens.  The NRTI drugs 
zidovudine and stavudine have been used extensively in the past as mono- and dual 
therapy in Western countries. The use of the mono- and dual therapy of these drugs 
has led to the selection of TAMs in many patients [10-11]. The toxicity associated 
with these drugs and the availability of novel, equally active but less toxic drugs 
such as tenofovir, lamivudine and emtricitabine, has led to a strong decrease in their 
use and they have become uncommon in first-line treatment over time. Although 
the prevalence of NRTI mutations has declined over time due to treatment change, 
the NRTI-associated TDRM still remain the most frequent. This is due to the long 
persistence of TAMs in the absence of antiretroviral drugs [12-13]. In the treated 
failing patients, multiple compensatory mutations may appear after the initial selection 
of resistance mutations that lower the replicative capacity. After transmission to a 
new host, evolution may be expected to occur in a stepwise manner. However, if 
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all possible nucleotide changes would initially decrease the replicative capacity, 
reversion to wild-type will be blocked [12]. 
If we carry on along this line of thought, the risk of resistance lowered after 
HAART was introduced and zidovudine and stavudine are no longer used as mono- 
and dual therapy. As a consequence, patients starting new on therapy developed 
TAMs at a much lower frequency. In the patients treated earlier, a part of the viruses 
containing TAMs did not yet develop compensatory mutations. When this virus was 
transmitted it could therefore revert to wild-type in the newly infected individual. Other 
patients were infected with a virus harbouring TAMs together with compensatory 
mutations. When such viruses were transmitted, the TAMs persisted over time and 
could be transmitted further. These viruses with compensatory mutations have 
therefore formed a sub-epidemic spread through North America and Europe. Also 
in Latin America, this sub-epidemic was observed (although with lower prevalences) 
due to the universal access to antiretroviral drugs since 1990 in several countries. In 
Africa, a similar sub-epidemic was described in Uganda [14] which had an early start 
in the roll-out of antiretroviral treatment [15]. Possible mutations causing fixation 
have been mentioned before (V60I, K104R and S162A) [16]. The compensative role 
of these mutations, however, has not yet been confirmed.
As the T215revertant mutation is the most prevalent TAM mutation, the 
clinical relevance of this high TAM prevalence is limited. T215revertant viruses are 
only one step away from the resistant variants, compared to the two mutational 
steps that are needed from wild-type. These revertants do not, by themselves, cause 
resistance, although an increased risk for developing resistance under treatment 
with zidovudine or stavudine has been observed [17]. Additionally, single TAMs 
do not cause resistance to nucleos(t)ides currently popular in first-line regimens 
(emtricitabine, tenofovir, lamuvidine, and abacavir) [18-20]. As a result, the high 
prevalence of single TAMs that was mainly observed in Europe and North America 
will not have a great impact on the efficacy of modern first-line therapy.   
Increasing transmitted NNRTI resistance
The increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) TDRM 
prevalence coincides with the more frequent use of this drug class in the developed 
world in recent years. NNRTIs have become more popular in first-line treatment as 
they have good clinical efficacy [21-22] and are convenient to use (low pill burden) 
which improves adherence [23]. Unfortunately, NNRTIs have a low genetic barrier 
to drug resistance. A single amino acid change is sufficient for high level drug 
resistance to the most commonly used NNRTIs in first-line treatment [24]. The most 
prevalent NNRTI mutation K103N has a limited effect on viral replication capacity 
and persist for long periods after transmission [12]. Strains with this mutation can 
therefore also be transmitted to others (onward transmission) [25-26]. This increase 
in NNRTI resistance is worrying as it is likely to negatively influence the therapy 
response of first-line therapy, as most include NNRT inhibitors.
Low prevalence of TDRM to PIs
Transmitted drug resistance to protease inhibitors (PI) was uncommon in resource-
rich settings (<3.5%). This is be explained by the high genetic threshold for 
resistance to boosted PIs [27]. Moreover, PIs are not frequently used in first-line 
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therapy compared to NNRTI-containing regimens as these last regimens showed 
better clinical efficacy than PI-containing regimens [21]. 
TDRM in phylogenetic clusters
Although travel and migration played a key role in the early spread of HIV, it is not 
known to what extent travel currently explains transmission of HIV. We therefore 
performed phylogenetic analyses on the data of the SPREAD programme to estimate 
the proportion of individuals newly diagnosed with HIV that was infected within their 
own country (Chapter 6). We found phylogenetic associations between viruses in 
one third of newly diagnosed individuals. Patients that were part of a cluster were 
more frequently harbouring a TDRM (10.4%) as compared to non-clustering patients 
(8.3%, P-value=0.03).
The vast majority of patients were part of a cluster that consisted only of 
patients originating from the same country. This suggests that a large part of the 
spread of HIV-1 in Europe can be explained by transmission of infections taking 
place between patients within the same country. As travel is not of major importance 
in the transmission of HIV, public health should not make a large effort to focus on this 
aspect of HIV transmission. The presence or absence of TDRM did not influence the 
proportions of patients clustering in national clusters (74.6 and 74.2%, respectively). 
2.2 Trends in resource-poor countries
NRTI transmitted resistance
In both chapter 2 and 3, we observed different patterns of TDRM to particular 
antiretroviral drug classes in Africa compared to other parts of the world. Contrary 
to the Americas and Europe, the prevalence of NRTI TDRM was low and increased 
over time. 
The low prevalence of NRTI TDRM in Africa is due to the limited use of 
mono-therapy of NRTIs on this continent. The increase of NRTI TDRM can be 
explained by the antiretrovirals becoming more widely available during recent years 
(e.g. due to the efforts of the Global Fund and PEPFAR -President’s Emergency 
Plan for AIDS Relief). Due to the increased use of HAART (which includes NRTIs as 
the backbone), TDRM have developed, and as a consequence NRTI TDRM in Africa 
has been rising.
In chapter 5, however, we observed a decreasing trend in NRTI resistance 
in heterosexuals infected in regions outside Western Europe and North America. 
The difference between the regions could be due to differences in the collection 
of data. The SPREAD data were collected using representative sampling for the 
transmission route and geographical distribution of HIV in the participating countries. 
In SPREAD only 40% of the heterosexual patients who were infected in regions 
outside Western Europe or North America, originated from Sub-Saharan Africa. Thus 
SPREAD also represents TDRM time trends also from other continents besides 
Africa. In Latin America, for example, we observed a decreasing trend in the TDRM 
prevalence to NRTIs, as reported in chapter 2. Finally, patients migrating to Europe 
are often chronically infected at time of diagnosis. In chronically infected patients, 
virus variants with resistance mutations can be outgrown by or revert to wild-type 
viruses which often have a better replicative capacity. In that case, the resistant virus 
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variants can no longer be detected by population sequencing as used in our study, 
because this method fails to detect minority populations [28-29]. The drug class in 
which reversion to wild-type often occurs is the NRTI drug class. Here, the M184V 
mutation is replaced by wild-type rapidly (86% within 16 months) [12]. The M184V 
causes resistance to abacavir, emtricitabine and lamivudine, and the use of these 
drugs has been increasing over time.  
NNRTI transmitted drug resistance 
In Africa, we also observed an initially high proportion of NNRTI-resistance, which 
decreased over time. This high prevalence reflects the prophylactic use of single 
dose  NNRTI-monotherapy for prevention of mother-to-child-transmission [30-31]. 
Due to the low genetic barrier, resistant viruses were selected [25]. Currently, the 
WHO recommends combinations of antiretroviral drugs (including NRTIs) to prevent 
vertical transmission, instead of using the simplest regimen of single-dose nevirapine 
[32]. Furthermore, access to HAART has been scaled up in developing countries 
[33-34]. As a consequence, the TDRM prevalence to NRTIs has increased and the 
contribution of NNRTI TDRM to total resistance has decreased. 
Overall prevalence of TDRM
In the review, we reported lower prevalences of TDRM for all individual drug classes 
in Africa compared to Europe and North America, resulting in a low overall prevalence 
of TDRM in Africa (6.8%). Similar to Europe, we found limited TDRM to PIs in Africa 
(1.2%). The review however, only included studies published through 2009. A recent 
surveillance study in Africa showed an overall TDRM prevalence of 5.6%, ranging 
from 1.1% in Latin Africa, to 12.3% in Uganda [14]. This higher prevalence found 
in Uganda is probably related to the earlier start of antiretroviral treatment roll-
out in Uganda [15]. So in conclusion, in some areas of Africa with early roll-out of 
antiretrovirals such as Uganda, TDRM can be high. Nevertheless, the overall TDRM 
prevalence in Africa still seems to be low (though increasing) compared to Europe 
and North America. Continuous surveillance is needed to follow the development of 
this trend on the African continent.
2.3 TDRM in different transmission groups
Supported by other studies [3, 5] we can state that in newly diagnosed patients 
from Europe higher TDRM prevalence can be found in men who have sex with men 
(MSM) (11.1%) compared to heterosexual patients (6.6%) (chapter 5). The likely 
reasons for this are again related to the differences in use of antiretroviral drugs 
as described before. Heterosexual patients are often migrants infected in countries 
outside Western Europe or North America. These patients did not have access 
to antiretroviral treatment until recently. Interestingly however, the prevalence of 
resistance in heterosexuals originating from Western Europe and North America 
was still lower than the resistance prevalence we found in MSM patients from 
these areas. One possible explanation is that heterosexuals in Western Europe are 
frequently infected by individuals originating from outside Europe. This is supported 
by a model of Xiridou et al. [35] which showed that a 53% of new HIV infections in 
the Netherlands was acquired by an African migrant of which most (32%) via sexual 
contact in the Netherlands . The model was based on data from the Netherlands 
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where migrants reported sexual mixing with Dutch partners and with both Dutch and 
non-Dutch partners in only 15 and 5%, respectively [36].
Another explanation for the difference in TDRM between MSM and 
heterosexual patients can be due to the fact that heterosexual patients are often 
chronically infected. The resistant variant in heterosexual patients may have reverted 
to wild-type HIV by that time, and thus undetectable with standard population 
sequencing. However, we did not observe higher TDRM prevalence in recently 
infected heterosexual patients originating from Western Europe or North America 
compared to patients originating from outside these regions. A better explanation 
might be that resistance viruses may have spread by onward transmission in HIV 
clusters of MSM, forming a sub-epidemic in these patients.
3. The interpretations of HIV-1 drug resistant mutations
In the second part of the thesis, we discussed the complexity of interpretation of 
resistance for estimating the prevalence of TDRM in surveillance studies. We started 
with comparing different interpretation systems and also investigated the influence of 
low-level polymorphisms in the estimation of TDRM prevalence. 
3.1 Comparison of interpretation systems
Interpretation systems have been developed [37] which provide rules devised by 
experts using information extracted from databases of genotypic and correlated 
phenotypic or treatment response data. A good way to compare the interpretation 
systems is by using virological response data in correlation with the prediction of 
interpretation systems. We performed a comparison between the ANRS, HIVdb, 
and Rega interpretation systems in patients with virological failure (transmitted and 
acquired resistance) using three different virological outcome time points (Chapter 
7). We were able to show that the ANRS, HIVdb, and Rega interpretation systems 
do not differ in predicting virological outcomes at all time points at week 12, week 
24, and week 48. 
3.2 The influence of the presence of low-level polymorphisms
The interpretation of TDRM can be complicated by natural occurring polymorphisms, 
which could result in an overestimation of TDRM prevalence (chapter 8). In this thesis 
we showed that these polymorphisms can have a large impact on the estimated 
prevalence of TDRM (Chapter 8). This is not surprising as the sum of polymorphisms 
across all surveillance drug-resistance mutation positions varied from 1.4% (for 
subtype G) to 4.8% (for CRF01_AE) in Bennett et al. [38]. We found an inverse 
relationship between the likelihood of correctly estimating the prevalence of TDRM 
and the presence of polymorphisms: the higher the prevalence of polymorphisms, 
the lower the likelihood of correctly estimating the prevalence of TDRM. Furthermore, 
a small sample size can decrease the positive predictive value of TDRM even more. 
Therefore, both the presence of polymorphisms and the number of samples analyzed 
affects the accuracy of the classification method recommended by the WHO and may 
lead to an incorrect categorization of TDRM prevalence. This is especially relevant in 
resource-poor settings, where WHO recommends that TDRM prevalences greater 
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than 5% should trigger several actions, such as performing extra research and more 
frequent surveillance studies [39].
4 Cost-effectiveness of baseline genotypic testing
In the last part of this thesis, a cost-effectiveness analysis of baseline genotypic 
testing was performed (chapter 9). Cost-effectiveness of baseline genotypic testing 
depends on the prevalence of TDRM in a population. We showed, in chapter 3, 4, and 
5 that most TDRM do not cause resistance to the nucleos(t)ides currently popular in 
first-line regimens (tenofovir/emtricitabine or abacavir/lamivudine with efavirenz or 
a boosted PI). However, the three previously published cost-effectiveness studies 
could not incorporate this data as they were performed before these drugs were 
available (1998-2001) [40-42]. We were able to show that the magnitude of the cost-
effectiveness ratio of baseline genotypic testing decreased with increasing levels 
of an absolute reduction in failure rate to first line regimens (€1.2 million, €220,000, 
and €94,000 per QALY gained for absolute failure rate differences of 1, 5, and 10%, 
respectively). A 10% absolute failure rate difference would be achieved, for example, 
when TDRM is found in 20% of HIV patients. Subsequently, of these TDRM, half 
would cause resistance to the prescribed first-line regimen and therefore experience 
virological failure, while genotypic testing would prevent all these failures. The cost-
effectiveness did not decrease to reasonable values unless the absolute reduction 
rate difference in patients with- and without baseline genotypic testing exceeded 
20% (€30,000). Nonetheless, genotypic testing showed to be more cost-effective in 
patients with a CD4 count of below 200 cells/mm3 compared to patients with a CD4 
count of >200 cells/mm3, with cost-effectiveness ratios of €65,000 and €330,000 
per QALY gained, respectively, at an absolute reduction in failure rate of 5%. 
Furthermore, if resistance testing is performed in reverse transcriptase gene only, 
the cost-effectiveness ratio was lowered by approximately 50%.
5 Future development of the epidemiology of transmission of drug resistant 
HIV-1
New developments in HIV prevention and treatment might influence the trends 
of TDRM in Europe and other continents. Pre- and post-exposure prophylaxis, 
microbicides, test and treat and the development of new drugs are examples of these 
new developments. We will discuss their effect on TDRM in the following section.
5.1 Pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is used in high-risk HIV-seronegative populations 
to prevent HIV infection. The PrEP strategies evaluated for efficacy all consist of the 
NRTI tenofovir alone or in combination with the NRTI emtricitabine [43]. The use of 
PrEP in MSM led to a reduction in the incidence of HIV of 73% with high and 21% 
with low drug adherence [44]. In the patients using PrEP who became with HIV, no 
resistance was detected to tenofovir or emtricitabine. However, of the 10 subjects 
who were infected at enrollment, 3 had emtricitabine-resistant infections (2 of 2 in 
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PrEP group and 1 of 8 in placebo group) [44]. This indicates that testing at the time 
of initiation of PrEP is very important to limit the development of drug resistance 
mutations. Fortunately, TDRM to tenofovir and emtricitabine is only found in few 
patients as shown in this thesis. Circulating TDRM will therefore only have a limited 
impact on the effectiveness of PrEP. However, since TDRM patterns can change 
over time, it is important to keep monitoring this in order to change PrEP drugs 
accordingly.
5.2 Post-exposure prophylaxis
Post-exposure prophylaxis (PEP) is used to prevent HIV infection after sexual 
or occupational exposure [45]. For PEP, the European guidelines recommend 
regimens including two NRTIs (tenofovir/emtricitabine or zidovudine/lamivudine) and 
a ritonavir-boosted PI (lopinavir/r or saquinavir/r). PEP should be started ideally <4 
hours after the exposure, and no later than 48 hours for a duration of four weeks 
[46]. Again, these drugs would not encounter problems related to TDRM, as the 
prevalence of TDRM to these NRTIs and boosted PIs are not often found in this 
review. The exception is zidovudine, to which the circulating viruses in approximately 
half of the patients infected with a transmitted drug resistance virus, are resistant 
to. Resistance was reported in one patient using PEP who was RNA-positive but 
antibody-negative. This patient initiated PEP 14 hours after exposure and underwent 
baseline laboratory evaluation 3 days later [47]. PEP is not likely to cause a rise 
in TDRM as PEP is prescribed as a combination of antiretrovirals and is not often 
assessed.
5.3 Microbicides
Microbicides are products that can be applied to vaginal or rectal mucosa and thus 
prevent or reduce the transmission of sexually transmitted infections including HIV-
1. So far, no study reported efficacy of microbicides use for a rectal application. To 
date only the CAPRISA study found that use of a vaginal tenofovir gel can reduce 
new infections by approximately 40% [48]. Resistance to tenofovir is rare. TDRM will 
therefore only have limited impact on the effectiveness of microbicides.
5.4 Test and treat
‘Test and treat’ is a prevention strategy in which universal testing for HIV is combined 
with immediate antiretroviral therapy for those individuals being HIV infected [49]. 
The ‘test and treat’ strategy has so far mainly been evaluated in modelling studies 
which predominantly predicted that the strategy can prevent new infections [50]. The 
most recent HPTN 052 study in serodiscordant couples showed a 96% reduction 
in HIV transmissions in patients with CD4 count between 350 and 550 cells/mm3 
which started antiretroviral therapy immediately compared to patients who delayed 
start of therapy to a CD4 cell count of <250 cells/mm3 [51]. The strategy could lead 
to an increase in the number of patients being infected with a resistant virus as more 
patients will receive treatment. If this strategy would be implemented in Europe, 
the prevalence of TDRM could increase as 50% of the patients newly diagnosed in 
Europe have a CD4 cell count below 350 copies/mm3 as indicated by Chapter 4. With 
the ‘test and treat’ strategy, patients would be diagnosed and treated in a much earlier 
stage of their disease than currently is achieved. As more HIV infected patients would 
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go on treatment, more resistance can be acquired, and the probability of transmitting 
a resistant virus would increase. This increase could be relatively small as current 
first-line therapy are more potent, have fewer side effects, and have to be taken less 
frequently to improve adherence and maintain viral suppression at lower levels of 
adherence [52] which decreases the risk of drug resistance [53]. Furthermore, new 
HIV infections can for a large part be explained by the transmission through recently 
infected patients [54-58]. As recent infections are hard to be identified, the ‘test and 
treat’ strategy may be difficult to realize.
5.5 New drugs
Currently, only few HIV drugs are in development.  Since these new drugs, after FDA 
approval will be expensive and often used in highly treated patients only, we do not 
expect a large change in TDRM prevalences as a consequence of this. In the trials 
that have been performed recently, resistance to enfuvirtide, maraviroc, elvitegravir/
cobicistat, and dolutegravir is seen in only few patients [54, 58-60]. Therefore, we 
do no expect an increase of resistance prevalences due to these new antiretrovirals.
6 Implications of TDRM
In this thesis we found that half of patients newly diagnosed in Europe have a CD4 
cell count below 350 copies/mm3. Early treatment is important as it has shown to 
reduce the risk for opportunistic infections and mortality [61-63] and the reduction 
of transmission of HIV [51, 64-68]. We therefore think substantial effort should be 
taken to reduce the proportion of patients being diagnosed with HIV in a late stage 
of their disease.
 In this thesis TDRM prevalence remains below 10% in Europe of which 
most mutations cause resistance to thymidine analogues. These TAMs do not 
cause resistance to the drugs given in current first-line regimens. Additionally, we 
demonstrated that baseline genotypic testing would only become cost-effective if 
it would lead to a 20% of absolute reduction in the probability of failing treatment. 
Therefore, the use of standard baseline genotypic testing becomes disputable. This 
is especially true for patients with a CD4 count of >200 cells/mm3, where failure 
would not directly lead to a prolonged time of having a high risk of opportunistic 
infections and mortality. 
As a first step in reducing the cost of a baseline genotypic test we would 
suggest to implement a targeting strategy by performing baseline genotypic testing 
only in patients with a CD4 cell count <200 cells/mm3. These patients have an 
increased risk of developing opportunistic infections and mortality [61-63] and baseline 
genotypic testing showed to be more cost-effective in these patients compared with 
patients with a CD4 cell count >200 cells/mm3. In these late presenters it is more 
important to prevent ineffective treatment due to TDRM, since virological failure will 
increase the change of developing opportunistic infections as CD4 cell counts will 
decline further [69]. 
Another possibility to reduce costs of baseline genotypic testing would be to 
limit the population-based nucleotide sequencing to only the reverse transcriptase 
gene of the virus. Because we have shown low PI TDRM levels on all continents 
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and no increase over time, the sequencing of the protease gene of the virus seems 
rather unnecessary. We showed that baseline resistance testing only in reverse 
transcriptase would lower the cost-effectiveness by 50%. Therefore, without 
sequencing the protease gene, the population sequencing test cost would become 
half of the current sequencing cost, which could save sufficient money.
A good alternative for population sequencing is to perform NNRTI minority 
assays. Population sequencing fails to identify drug-resistant minority variants that 
are present in <20% of the virus population infecting a patient [28-29]. These minority 
variants have been detected in almost 14% of antiretroviral naïve HIV-infected 
individuals [70]. The presence of minorities, particularly involving NNRTI resistance, 
is associated with an increased risk of virological failure to first-line therapy [70]. If 
minority assays would be implemented as standard practice, the costs may lower 
considerably. With low costs and the provision of valuable information on minority 
NNRTI mutations, this test could improve health care in HIV patients. 
However, when recommending different methods of resistance testing, we 
should take into account the drawback of limiting baseline resistance testing to a 
targeted population or to reverse transcriptase only. Baseline genotypic testing 
provides a large pool of data which can be used for surveillance purposes. If baseline 
genotypic testing is no longer standard practice, we might have a great loss of insight 
into the epidemiology of TDRM. 
7. Overall conclusions
In this thesis TDRM prevalence remains below 10% in Europe of which most 
mutations cause resistance to thymidine analogues. These TAMs do not cause 
resistance to the drugs given in current first-line regimens. Importantly, a rise in 
TDRM to NNRTIs was found in Europe over time. We have also demonstrated 
that baseline genotypic testing would only become cost-effective if it would lead 
to a 20% of absolute reduction in the probability of failing treatment. We therefore 
could consider performing genotypic resistance testing in a targeted population or to 
reverse transcriptase only.
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Summary
In 2009, approximately 33.3 (31.4 -35.3) million individuals were infected with human 
immunodeficiency virus (HIV) worldwide. Although the virus continues to spread, the 
number of new infections has fallen from an estimated 3.2 (3.0 -3.5) million in 1997 
to 2.6 (2.3 – 2.8) million in 2009. One explanation for the decrease in the number 
of new HIV infections is the use of antiretrovirals for which the accessibility has 
increased largely over time. 
The HIV virus is characterized by its high genetic diversity. In the swarm 
of genetic viral variants in a single infected patient, the virus variant showing the 
highest fitness will outgrow other variants and become the dominant viral population. 
In treated patients, this mechanism also can lead to the outgrowth of viral variants 
harbouring drug resistance associated mutations. These resistant viruses can be 
transmitted to other individuals. Patients infected with a drug resistance virus will have 
an increased risk for virological failure when starting therapy. This may decrease both 
the magnitude and the duration of the response to treatment.  Therefore surveillance 
of transmitted drug resistance mutations (TDRM) is necessary. 
In the first part of this thesis, we focus on the epidemiology of TDRM. We 
start with reviewing the literature (chapter 2) on the prevalence of TDRM to determine 
the prevalence and time trends in the different regions across the world. This review 
included 215 studies and a total of 43,170 HIV-infected antiretroviral naïve patients. 
The highest prevalence of TDRM was found in North America (12.9%) and Europe 
(10.9%). Resistance could, for the largest part, be ascribed to TDRM in the nucleos(t)
ide reverse transcriptase inhibitor (NRTI) drug class (in >55% in all continents).
In the WATCH study we collected and analyzed data of available studies on 
TDRM from across the world to examine the mutational patterns between different 
continents (chapter 3). The NRTI drug class showed to have the highest TDRM 
prevalence in all continents. The most frequently occurring NRTI mutations were 
the thymidine analogue mutations (TAMs) that are associated with resistance 
to zidovudine and stavudine. The prevalence of these TAMs was higher in North 
America (7.2%) and Europe (5.8%) than in other continents (≤2.4%).
In chapter 4, 5, and 6 we examined the TDRM prevalence in Europe through 
the SPREAD programme. This programme included patients using a pre-defined 
sampling strategy based on the geographical and risk group distributions of patients 
newly diagnosed with HIV in the participating counties. The SPREAD programme 
started in September 2002 and now includes data until December 2007 enrolling 
4,317 patients from 27 countries. One out of nine patients showed signs of TDRM 
but in most cases it concerned only a single TDRM. Most mutations found were 
associated with NRTI resistance at 5.0% of which 84.4% were TAMs. The prevalence 
of TDRM was stable over time. The underlying prevalence of TDRM associated with 
particular antiretroviral drug classes, however, showed important changes over 
time. We found a significant increase in the prevalence of non-nucleoside reverse 
transcriptase inhibitor (NNRTI) TDRM, doubling from 2.1% in 2002 to 4.1% in 2007.
In contrast, transmitted protease inhibitor (PI) resistance decreased significantly 
from 3.9% to 1.6%. These changes can be explained by the use of different drugs 
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over time. 
Differences in TDRM prevalence were seen between the HIV transmission 
groups. The largest difference was found in NRTI resistance, where the prevalence 
was significantly higher in men who have sex with men (MSM) (6.6%) compared 
to heterosexual patients (3.3%) and injection drug users (2.0%). As heterosexual 
patients are often originating from Africa, the TDRM prevalence for the different drug 
classes in these patients follow that of studies performed in Africa. In MSM we see 
prevalences and time trends that could be explained by the history of drug use of the 
different antiretroviral drug classes in the western countries. 
In chapter 6 we examined the impact of travel on the transmission of HIV. 
Phylogenetic analyses showed that one third of newly diagnosed individuals were 
part of a cluster. These patients were more frequently harbouring a TDRM (10.4%) 
as compared to non-clustering patients (8.3%). The vast majority of patients were 
part of a cluster that consisted only of patients originating from the same country. 
This suggests that a large part of the spread of HIV-1 in Europe can be explained by 
transmission of infections taking place between patients within the same country. As 
travel is not of major importance in the transmission of HIV, public health should not 
make a large effort to focus on this aspect of HIV transmissions.
In part two of this thesis we focus on the interpretation of acquired- and 
transmitted- drug resistance mutations. In chapter 7, we examined the interpretation 
systems that are developed to guide the new treatment choice for patients failing 
their current HAART. We have shown that the three most common interpretation 
systems, ANRS, Stanford HIVdb and Rega did not differ in predicting virological 
outcomes at all time points (12, 24, and 48 weeks). 
The interpretation of TDRM can be complicated by natural occurring 
polymorphisms, which could result in an overestimation of TDRM prevalence 
(chapter 8). We found an inverse relationship between the likelihood of correctly 
estimating the prevalence of TDRM and the presence of polymorphisms: the higher 
the prevalence of polymorphisms, the lower the likelihood of correctly estimating the 
prevalence of TDRM. Furthermore, a small sample size can decrease the positive 
predictive value of TDRM even more. Therefore, both the presence of polymorphisms 
and the number of samples analyzed affects the accuracy of the classification 
method recommended by the WHO and may lead to an incorrect categorization 
of TDRM prevalence. This is especially relevant in resource-poor settings, where 
WHO recommends that TDRM prevalences greater than 5% should trigger several 
actions, such as performing extra research and more frequent surveillance studies. 
These findings suggest excluding some TDRM from the consensus list of mutations 
in order to prevent the overestimation of TDRM prevalence.
Besides overestimating TDRM prevalence, the prevalence of TDRM 
can also be underestimated by the presence of minority variants. These minority 
variants cannot be detected by population sequencing, which was the technique 
used in all the studies in this thesis. These minority mutations are associated with 
virological failure, particular involving NNRTI resistance. This finding supports the 
recommendation of using NNRTI minority assays in routine testing of TDRM. 
The high prevalence of TAMs will only have a small clinical relevance as 
they generally do not cause resistance to nucleos(t)ides currently popular in first-line 
regimens. We have shown in part 3 of this thesis that with current TDRM prevalence 
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in the Netherlands baseline genotypic testing is not cost-effective (chapter 9). The 
magnitude of this cost-effectiveness ratio decreased with increasing the reduction 
in failure rate (€1.2 million, €220,000, and €94,000 per QALY gained for absolute 
failure rate differences of 1, 5, and 10%, respectively). The cost-effectiveness did 
not decrease to reasonable values unless the absolute reduction rate difference in 
patients with- and without baseline genotypic testing exceeded 20% (€30,000 per 
QALY gained). Nonetheless, targeting baseline genotyping only to patients with a 
low CD4 cell count lowered the cost-effectiveness to €65,000 per QALY gained at an 
absolute reduction in failure rate of 5%. This ratio was much higher in patients with 
a CD4 cell count of above 200 cells/mm3 (€330,000 per QALY gained). Therefore, 
a possibility to reduce costs of baseline genotypic testing would be to implement a 
targeting strategy by performing baseline genotypic testing only in patients with a 
CD4 cell count <200 cells/mm3.
Also the prevalence of PI TDRM was low in all continents. Therefore, this will 
not have a great impact on the efficacy of first-line therapy. These findings suggest 
to limit the population-based nucleotide sequencing to only the reverse transcriptase 
gene of the virus. We have shown that the cost-effectiveness ratio decreased by 
50% when baseline genotypic testing was limited to reverse transcriptase only. 
In conclusion, we have shown that TDRM prevalence remain relatively 
low in all continents. Most mutations cause resistance to thymidine analogues. 
These TAMs do not, however, cause resistance to the drugs given in current first-
line regimens. Most importantly, we found a significant doubling in the prevalence 
of transmitted NNRTI resistance in Europe over time. We also demonstrated that 
baseline genotypic testing would only become cost-effective if it would lead to a 20% 
absolute reduction in the probability of failing treatment. We therefore could consider 
performing genotypic resistance testing in a targeted population or only genotyping 
the reverse transcriptase.
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Nederlandse samenvatting
Naar schatting waren er in 2009 33,3 (31,4-35,3) miljoen mensen wereldwijd 
geïnfecteerd met HIV. Hoewel het virus zich blijft verspreiden, is het aantal nieuwe 
infecties gedaald van ongeveer 3,2 (3,0-3,5) miljoen in 1997 naar 2,6 (2,3-2,8) 
miljoen in 2009. Een mogelijke verklaring van deze daling is het toenemend gebruik 
van HIV-remmers.
Het HIV virus heeft een hoge genetische verscheidenheid. Hierdoor is een 
patiënt besmet met een zwerm van genetisch verschillende virus varianten. De 
virussen die zich het beste repliceren zullen de dominante virus populatie worden. 
Een HIV-remmer is een geneesmiddel dat de productie van het virus kan afremmen. 
HIV medicatie wordt altijd in combinatie gebruikt (highly active antriterovral terapy 
of HAART) om resistentie te voorkomen. De bekende HIV-remmers zijn ingedeeld 
bij de nucleoside reverse transcriptaseremmers (NRTIs), de non-nucleoside reverse 
transcriptaseremmers (NNRTIs), en de proteaseremmers (PIs). In patiënten die 
behandeld worden met HIV-remmers kan in bepaalde omstandigheden nog steeds 
resistentie ontstaan. Bijvoorbeeld als patiënten niet altijd even trouw hun HIV-
remmers slikken. In dat geval kan het virus zich repliceren in aanwezigheid van de 
geneesmiddelen en daardoor snel varianten selecteren die resistent zijn tegen de 
cocktail van HIV-remmers die de patiënt gebruikt. Deze resistente virussen kunnen 
worden overgebracht naar andere (dit noemen virologen transmissie van resistentie). 
In patiënten die geïnfecteerd zijn geraakt met een resistent virus is er een verhoogd 
risico dat het virus onvoldoende wordt onderdrukt en virus deeltjes meetbaar blijven 
(dit heet virologisch falen). Daarom is het belangrijk om in kaart te brengen hoe vaak 
transmissie van geneesmiddelen resistentie gerelateerde mutaties optreedt.
In het eerste deel van dit proefschrift ligt de focus op het inzicht verkrijgen 
van de verspreiding van resistente virussen. Hoofdstuk 2 geeft een overzicht van 
de beschikbare literatuur op het gebied van transmissie van resistent HIV in de 
verschillende delen van de wereld. Dit overzicht bevat 215 studies en 43.170 
onbehandelde HIV-geïnfecteerde patiënten. In Noord-Amerika (12.9%) en Europa 
(10.9%) werd de hoogste prevalentie van transmissie van resistente HIV-stammen 
gevonden. Het merendeel van de resistentie kan worden toegeschreven aan 
resistentie tegen NRTIs (in >55% in alle continenten).
Vervolgens hebben we in de WATCH studie beschikbare data verzameld en 
geanalyseerd van studies naar transmissie van resistent HIV vanuit de hele wereld. 
Hierdoor was het mogelijk om de mutatiepatronen tussen verschillende continenten 
te onderzoeken (hoofdstuk 3). Resistentie tegen de NRTI klasse liet de hoogste 
prevalentie zien in alle continenten. De meest voorkomende NRTI mutaties waren 
de thymidine-analoog geassocieerde mutaties (TAMs). Deze TAMs werden dikwijls 
gevonden in Noord-Amerika (7,2%) en Europa (5,8%) en minder frequent in andere 
continenten (≤2,4%). Deze mutaties zijn geassocieerd zijn met resistentie tegen 
zidovudine en stavudine die beide niet meer worden gebruikt in de huidige HIV-
therapie. 
In hoofdstuk 4, 5, en 6 hebben we onderzoek gedaan naar de prevalentie 
van resistentie mutaties in Europa door middel van het SPREAD-project. Dit project 
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includeerde nieuw gediagnosticeerde patiënten die representatief zijn voor de HIV 
epidemie uit de deelnemende landen in Europa. Het SPREAD-project is opgestart 
in september 2002 en includeert op dit moment data tot december 2007, waarbij 
4.317 patiënten uit 27 landen zijn ingeschreven. Eén op de negen patiënten vertoont 
tekenen van een resistent virus. De meeste mutaties waren geassocieerd met NRTI 
resistentie in 5,0%, waarvan 84,4% TAMs waren. De prevalentie van transmissie 
van resistent HIV liet een stabiele trend over de tijd zien. Echter, veranderingen over 
tijd waren wel waargenomen in de onderliggende prevalenties van resistentie tegen 
de individuele klasses van HIV-remmers. De prevalentie van NNRTI resistentie 
verdubbelde van 2,1% in 2002 naar 4,1% in 2007. Echter, de PI resistentie daalde 
van 3,9% naar 1,6%. Een statistische analyse toonde aan dat deze toe- en afname 
niet op toeval berustte. Deze veranderingen kunnen worden verklaard door de 
verandering van het gebruik van HIV-remmers over de tijd. 
Verschillen tussen de prevalentie van transmissie van resistente virussen 
werden ook aangetoond tussen de HIV transmissie groepen. Het grootste verschil 
werd gevonden voor NRTI resistentie, waar de prevalentie hoger was in mannen-
die-seks-hebben-met-mannen (MSM) (6,6%) in vergelijking tot heteroseksuele 
patiënten (3,3%) en injecterende drugs gebruikers (2,0%). Omdat heteroseksuele 
patiënten vaak een Afrikaanse afkomst hebben, volgt de resistentie prevalenties in 
de verschillende HIV-remmers klasses in deze patiënten dat van studies uitgevoerd 
in Afrika. In MSM zien we een prevalentie en trends over de tijd die kunnen worden 
verklaard door de geschiedenis van het medicijn gebruik in de verschillende klasses 
van HIV-remmers in de westerse landen.
In hoofdstuk 6 behandelen we de impact van reizen op de transmissie van 
HIV. Met fylogenetische analyses (het uitwerken van het virus in een stamboom) 
tonen we hier aan dat één derde van de nieuw gediagnosticeerde patiënten deel 
uitmaakten van een cluster (zeer dichte takken op de stamboom). Deze patiënten 
waren vaker geïnfecteerd met een resistent virus dan patiënten die niet clusterden 
(8,3%). Het merendeel van de patiënten maakte deel uit van een cluster die alleen 
bestond uit patiënten uit hetzelfde land afkomstig. Dit suggereert dat een groot deel 
van de verspreiding van HIV in Europa kan worden verklaard door de transmissie 
van infecties die plaats vindt tussen patiënten afkomstig van hetzelfde land. Omdat 
reizen niet van groot belang blijkt te zijn in de transmissie van HIV, is het niet 
nodig om veel aandacht te geven aan dit aspect van de HIV transmissie vanuit de 
volksgezondheid.
In het tweede deel van dit proefschrift bestuderen we de interpretatie 
van mutaties die verworven zijn door therapiefalen of transmissie. In hoofdstuk 7 
vergelijken we de interpretatiesystemen die zijn ontwikkeld om de keuze van nieuwe 
therapie in patiënten die falen op hun huidige HAART te begeleiden. We hebben 
kunnen aantonen dat de drie meest gebruikte interpretatiesystemen – ANRS, 
Stanford HIVdb en Rega – niet verschillen in het voorspellen van de positieve 
resultaten van therapie op alle tijdspunten (week 12, 24 en 48). 
De interpretatie van transmissie van resistent HIV kan gecompliceerd 
worden door natuurlijk voorkomende mutaties, wat kan leiden tot een overschatting 
van de resistentie prevalentie (hoofdstuk 8). We vonden een tegenovergestelde 
relatie tussen de kans op het correct berekenen van de prevalentie van transmissie 
van resistentie en de aanwezigheid van natuurlijk voorkomende mutaties: hoe 
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hoger de prevalentie van de natuurlijk voorkomende mutaties, hoe lager de kans 
op het correct berekenen van de resistentie prevalentie. Bovendien kan een kleine 
steekproefgrootte de positieve voorspellende waarde (het deel van de patiënten met 
een positieve testuitslag dat ook daadwerkelijk met een resistent virus is besmet) zelfs 
meer verlagen. Daarom zal de aanwezigheid van de natuurlijk voorkomende mutaties 
en het aantal patiënten dat geanalyseerd wordt effect hebben op de nauwkeurigheid 
van de classificatiemethode aanbevolen door de wereldgezondheid organisatie 
(WHO- World Health Organisation) wat kan leiden tot een incorrecte categorisatie 
van de prevalentie van transmissie van resistentie. Dit is in het bijzonder relevant 
in ontwikkelingslanden, waar de WHO aanbevelingen doet voor prevalenties hoger 
dan 5% wat dient te leiden tot verschillende acties zoals het uitvoeren van extra 
onderzoek en meer frequent surveillance studies. Deze bevindingen suggereren om 
sommige resistentie mutaties van de consensus mutatielijst te verwijderen, om zo 
een overschatting van de prevalentie van transmissie van resistentie te voorkomen.
Naast een overschatting van de transmissie van resistente virussen, kan de 
prevalentie ook worden onderschat, namelijk door de aanwezigheid van minderheid 
varianten. Deze minderheid varianten kunnen niet worden gedetecteerd met 
populatie resistentiebepaling, een techniek die in alle studies van dit proefschrift is 
gebruikt. Deze minderheid varianten zijn geassocieerd met het falen van therapie, 
in het bijzonder bij de NNRTI resistentie. Dit steunt de aanbeveling voor het gebruik 
van NNRTI minderheid testen als routine test bij resistentiebepalingen.
De hoge prevalentie van TAMs heeft weinig klinische relevantie aangezien 
deze mutaties over het algemeen geen resistentie veroorzaken tegen NRTIs die 
op dit moment populair zijn in eerstelijns combinatietherapieën. In het derde deel 
van dit proefschrift laten we zien dat met de huidige prevalentie van transmissie 
van resistent HIV in Nederland, een resistentietest van het HIV virus bij nieuw 
gediagnosticeerde patiënten niet kosteneffectief is (hoofdstuk 9). De kosteneffectiviteit 
van de resistentietest was berekend als de kosten die nodig zijn als door de test de 
levensverwachting wordt verlengd met één jaar in goede gezondheid. De grootte 
van de kosteneffectiviteitratio nam af wanneer een resistentiebepaling meer falen 
op therapie deed voorkomen (€1,2 miljoen, €220.000, en €94.000 per verkregen 
levensjaar in goede gezondheid wanneer het falingspercentage was afgenomen 
met 1, 5, en 10%, respectievelijk). De kosteneffectiviteit nam niet af naar redelijke 
waardes tenzij het verschil in falingspercentages tussen patiënten met- en zonder 
baseline resistentiebepaling de 20% overschreed (€30.000 per verkregen levensjaar 
in goede gezondheid). Desalniettemin, een baseline resistentietest in patiënten met 
een laag CD4 cel waarde (weinig afweercellen) verlaagde de kosteneffectiviteit 
naar €65.000 per verkregen levensjaar in goede gezondheid bij een daling van het 
falingspercentage van 5%. Deze ratio was veel hoger in patiënten met een hoge 
CD4 cel waarde (€330.000 per verkregen levensjaar in goede gezondheid). Het 
is daarom een goede mogelijkheid om de kosten van baseline resistentietesten te 
verlagen door middel van een gerichte strategie waarbij een baseline resistentietest 
alleen wordt uitgevoerd in patiënten met een lage CD4 cel waarde.
We hebben verder aangetoond dat de prevalentie van de transmissie van PI 
resistentie laag was in alle continenten. Dit zal daarom weinig impact hebben op de 
effectiviteit van eerstelijns combinatietherapieën. Deze bevindingen suggereren het 
beperken van de resistentiebepaling tot alleen het reverse transcriptase gen van het 
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virus. We hebben laten zien dat de kosteneffectiviteitratio af nam met 50% wanneer 
dit geïmplementeerd zou worden.
 Als conclusie kunnen we stellen dat de prevalentie van resistent HIV relatief 
laag blijft in alle continenten. De meeste voorkomende mutaties die we vinden 
zijn de TAMs. Deze TAMs geven geen resistentie tegen de medicijnen die worden 
voorgeschreven in de huidige eerstelijns combinatietherapieën. Uit onze resultaten 
blijkt ook dat de prevalentie van resistentie tegen NNRTI over de tijd verdubbeld is 
in Europa. Ook laten we zien dat baseline genotypering alleen dan kosteneffectief is 
wanneer het zou leiden tot een afname van het falingspercentage van 20%. Daarom 
suggereren we tot slot dat de kosten van resistentiebepalingen zouden kunnen 
worden verlaagd door het alleen uit te voeren in een specifieke groep van patiënten 
of door het bepalen van de resistentie in alleen het reverse transcriptase gen.
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